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Background Thrombin is a powerful cardiovascular agonist and a vital link between
thrombosis and inflammation. In addition to its role in the coagulation cascade, it directly
activates platelets, inflammatory cells, endothelium and vascular smooth muscle. Protease-
activated receptor-1 (PAR-1) has been proposed as the principal thrombin receptor in man
although its actions in vivo have not been defined. The aim of this thesis was to determine
the direct vascular actions of PAR-1 agonism in the human venous and arterial circulations.
Objectives The effects of PAR-1 activation on dorsal hand vein diameter were measured by
the Aellig technique in healthy volunteers, compared with activation of the trypsin receptor
PAR-2, and further assessed in the presence or absence of norepinephrine, the glycoprotein
(GP)IIb/IIIa antagonist tirofiban, and endothelial denudation. In the arterial circulation,
forearm blood flow was measured by venous occlusion plethysmography. Intra-arterial
PAR-1 activating peptide was co-infused with tirofiban, and compared with PAR-2
activation and bradykinin infusion. Platelet-monocyte binding (a sensitive measure of
platelet activation) and tissue plasminogen activator release (t-PA) were measured
throughout. In subsequent studies, effects of inhibition of the endothelium-dependent
vasodilators nitric oxide (NO), prostacyclin and endothelium-derived hyperpolarisation
factor (EDHF) on PAR-1 activation were assessed, as well as comparing the effects of
PAR-1 activation in smokers and non-smokers.
Methods Activation of PAR-1 caused dose-dependent venoconstriction (P<0.001) that was
unaffected by norepinephrine or tirofiban co-infusion and endothelial denudation. In forearm
resistance vessels, arterial PAR-1 activation increased forearm blood flow (P<0.001), t-PA
release (P<0.001) and platelet-monocyte binding (PO.OOOl). Activation of PAR-2 caused
venous (P<0.001) and arterial (P<0.01) dilatation without t-PA release or platelet activation.
Although blockade of prostacyclin production had no effect, PAR-1 induced arterial
vasodilatation was attenuated by inhibition ofNO synthesis (PO.OOOl) and EDHF (PO.05),
and abolished by their combination (PO.Ol). Smokers had impaired PAR-1 mediated
vasodilatation and t-PA release.
Results We have, for the first time, demonstrated that PAR-1 agonism in vivo in man causes
arterial dilatation, venoconstriction, platelet activation and t-PA release that is mediated
through endothelium-dependent and independent pathways, and impaired in smokers. These
unique and contrasting effects are of major physiological relevance to the regulation and
resolution of intravascular thrombosis. These findings have implications for the development
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cAMP Cyclic adenosine monophosphate
cGMP Cyclic 3'5'-guanosine monophosphate
EDHF Endothelium-derived hyperpolarising factor
EET Epoxyeicosatrienoic acid
eNOS Endothelial nitric oxide synthase
FITC Fluorscein isothiocyanate
GP Glycoprotein
GPIs Glycoprotein Ilb/IIIa inhibitors
GTP Guanosine 5'-triphosphate
INR International Normalised Ratio
L-NMMA L-NG-monomethyl arginine citrate
LVDT Linear variable differential transducer
MAP kinase Mitogen-activated protein kinase
NO Nitric oxide






PKC Protein kinase C
PLCfi Phospholipase C beta
PPACK D-phenylalanyl-L-propyl-L-arginine chloromethylketone
SEM Standard error of the mean
Ser Serine




t-PA Tissue plasminogen activator
u-PA Urokinase plasminogen activator
Val Valine
vWF von Willebrand factor
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THROMBIN RECEPTORS, PLATELET ACTIVATION, VASCULAR
FUNCTION AND ENDOGENOUS FIBRINOLYSIS
1.1 THROMBIN
1.1.1 Thrombin in the coagulation cascade
Blood coagulation prevents blood loss and has been crucial to survival throughout
evolution. It is initiated by 'intrinsic' factors in the blood coming into contact with a
foreign surface, such as collagen or subendothelial matrix, or in response to
'extrinsic' factors released by injured tissues, such as tissue factor. These intrinsic
and extrinsic pathways of the coagulation cascade converge and both lead to
thrombin activation. Thrombin (factor Ha) is mainly generated on the surface of
platelets, from prothrombin synthesised in the liver. Thrombin plays an essential role
in coagulation through its protease activity, leading to the formation of fibrin from
fibrinogen, and generates the characteristic fibrin mesh of thrombus. Thrombus
formation is further enhanced by positive feedback loops causing activation of factor
V, VIII and X in the intrinsic pathway and factor VII in the extrinsic pathway. Factor
XIII is also activated by thrombin and stimulates cross-linking and stabilisation of
fibrin (Figure 1.1) [Patterson et al, 2001; Lane et al, 2005].
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* Heparin, low molecular weight
heparin and fondaparinux
augment antithrombin III mediated
inhibition of factors lla and Xa.
**Warfarin inhibits carboxylation






Figure 1.1 Schematic view of the coagulation cascade. TF - tissue factor.
1.1.2 Receptor mediated effects of thrombin: platelets and
endothelium
Apart from its central role in the coagulation cascade thrombin is one of the most
important physiological agonists in the cardiovascular system and thrombin is at the








Figure 1.2 Thrombin stimulates fibrin production through its enzymatic activity in the coagulation
cascade and causes cell activation through direct receptor mediated effects.
Thrombin causes platelet activation and aggregation, as well as activating
leukocytes, endothelial and vascular smooth muscle cells. Thrombin also stimulates
release of various cytokines and tissue-plasminogen activator (t-PA) [Patterson et al,
2001]. Thrombin is a vital link between thrombosis and inflammation, the key
factors in wound healing and vascular injury as well as in pathophysiology such as in
atherosclerosis and acute ischaemic events [Coughlin, 2005]. Identification of
thrombin receptors has therefore been an important step in cardiovascular research.
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1.2 PROTEASE-ACTIVATED RECEPTORS
1.2.1 Classification of protease-activated receptors
The apparent direct cellular effects of thrombin led to an extensive search for a
thrombin receptor and eventually the discovery of a thrombin receptor. Once
traditional ligand binding approaches proved fruitless, expression cloning methods
were employed to conduct an extensive search for its receptor and used to identify
functional human thrombin receptor cDNA [Rasmussen et al, 1991; Vu et al, 1991].
This led to the identification of G-protein coupled protease-activated receptors
(PARs) that are characterised by a unique mechanism of activation: proteolytic
cleavage unmasks a short peptide sequence that remains tethered and initiates
transmembrane signalling via the receptor [Vu et al, 1991; Gerszten et al, 1994],
Four different types of PARs have been identified: PAR-1, -3 and -4 are all activated
by thrombin. The type 1 receptor has been proposed as the principal thrombin
receptor in man [Coughlin, 2000; Coughlin, 2005] and is widely expressed in many
organ systems. Protease-activated receptor-1 is particularly important in human
platelets, endothelial cells and vascular smooth muscle. Protease-activated receptor-1
is a high-affinity thrombin receptor, whereas PAR-4 requires a higher concentration
of thrombin for activation of human platelets and PAR-4 does not appear to have
important function in human endothelial cells [O'Brien et al, 2000]. The expression
of PAR receptors differs between animals. In smaller animals PAR-4 is the main
platelet receptor with PAR-3 mainly being a co-factor for activation of PAR-4
[Nakanishi-Matsui et al, 2000],
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In contrast to PAR-1, -3 and -4, the PAR-2 receptor is activated by trypsin, tryptase
and to a lesser extent, by coagulation factors upstream of thrombin [Hollenberg and
Compton, 2002]. It appears to be of importance in inflammatory conditions that
induce endothelial PAR-2 expression and vasodilatation [Ballerio et al, 2006].
1.2.2 Par activation and par activating peptides
Protease-activated receptors are G-protein coupled receptors that use a unique
mechanism to convert proteolytic cleavage into a chain of diverse G-protein coupled
signalling pathways. The protease cleaves the extracellular, amino-terminal of the
receptor at a specific site that differs for each of the PARs, for thrombin the cleavage
site on PAR-1 is between the amino acids arginine (Arg)41 and serine (Ser)42, and
mutation of this cleavage site prevents thrombin-induced activation of the receptor
[Vu et al, 1991]. This proteolytic cleavage exposes a new extracellular N-terminus of
the receptor that remains tethered and binds to the body of the receptor to activate
transmembrane signalling (Figure 1.3).
N
Figure 1.3 PAR activation: proteolytic cleavage, mainly by thrombin, exposes a new extracellular
terminal of the receptor, that remains tethered and auto-activates the receptor [From Coughlin, 2000].
PAR-1 - protease-activated receptor-1.
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By mimicking the newly exposed tethered ligand of the receptor, fully active
synthetic peptides can be produced, that directly activate intact PARs without
requirement for proteolytic cleavage of the receptor. Establishing the
pharmacological structure of activating peptides for each of the PARs has opened
avenues to studying the mechanism of receptor activation, the downstream G-protein
coupled pathways and development of receptor antagonists. The development of
selective PAR-1 agonists enables us to study the physiological role of the PAR
receptors in vivo. In particular, the PAR-1 mediated effects of thrombin can be
studied in isolation from its wider effects in the coagulation cascade whereas, it
would not be possible to study the effects of thrombin itself in the human vasculature
due to risk of vascular occlusion.
The characteristics of the extracellular ligand and corresponding protease-activated
peptides have been studied in detail for each of the PARs [Hollenberg and Compton,
2002], The protease-activating peptides can be as short as six amino acids in length
and still retain full activity. For PAR-1, the endogenous tethered ligand domain is
S42FLLRNPNDKYEPF but the hexapeptide SFLLRN is a more potent agonist
[Scarborough et al, 1992] and has been widely used in studies of the PAR-1 receptor.
The endogenous sequence SFLLRN is also a weak agonist of PAR-2 receptor.
*
However, replacing Ser1 with threonine (Thr)1 generates TFLLRN which has similar
potency to SFLLRN but is a more selective PAR-1 agonist [Hollenberg et al, 1997;
Kawabata et al, 1999].
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Protease-activated receptor PAR-2 activating peptides, derived from the human
(SLIGKV) receptor sequences, can mimic the action of trypsin in selectively
activating the PAR-2 receptor [Kawabata et al, 2004] and other activating peptides
can be used to mimic the actions of thrombin on PAR-4. In contrast to PAR-1, PAR-
2, and PAR-4, synthetic peptides corresponding to the tethered ligand of PAR-3 do
not activate PAR-3. The reason for this is unknown. PAR-3 does not generate a
signal when expressed alone, without other PARs, and appears to be mainly cross-
activated via PAR-4 on mouse platelets but has little role in humans [Kahn et al,
1998],
1.2.3 Transmembrane signalling
Activation of PAR receptors leads to coupling to G-proteins at the plasma
membrane. Most of our understanding of thrombin-induced PARs signalling comes
from extensive studies of PAR-1. Protease-activated receptor-1 can activate at least
three distinctive Ga subunits: G12/13, Gq and G, to induce a wide array of downstream
effects (Figure 1.4) [Hung et al, 1992; Offermanns et al, 1994; Barr et al, 1997].
Activation of Gq causes activation of phospholipase CP, elevation of cytoplasmic
calcium and activation of protein kinase C with subsequent platelet degranulation
and platelet aggregation [Offermanns et al, 1997b]. These pathways also cause
stimulation of calcium regulated protein kinases and mitogen-activated protein
(MAP) kinases which play a critical role in cell proliferation and differentiation.
Stimulation ofG, inhibits adenylyl cyclase and reduces formation of cyclic adenosine
monophosphate (cAMP) and stimulation of Gi also causes stimulation of
phosphoinositide-3-kinase (PI3K), release of phosphatidylinositols and contributes to
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platelet degranulation. Activation of G12/13 induces platelet shape change via
activation of Rho kinases [Klages et al, 1999], cellular migration and vascular
genesis [Offermanns et al, 1997a]. These platelet activation mechanisms
subsequently cause platelet aggregation by expression of the platelet integrin
glycoprotein (GP)IIb/IIIa and GPIb and their cross-linking with von Willebrand
factor (vWF) and fibrinogen [Davi and Patrono, 2007]. It is likely that different
expression of these G-protein receptors explains how activation of the same receptor
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Figure 1.4 PAR-1 activation stimulates various G-protein coupled signalling pathways.
PAR-1 - protease-activated receptor-1; PLC p - phospholipase C beta; Caf+ - calcium ions; PKC -
protein kinase C; MAPK - mitogen-activated protein kinase; PI3K - phosphoinositide-3-kinase; Ki -
potassium ion channels; TK - tyrosine kinase.
Activation of PARs causes a transient signal, lasting a few minutes. Considering that













is turned off. Protease-activated receptors-1 are rapidly internalised by endocytosis
after activation [Trejo et al, 2000] and although a majority of the receptors undergo
lysosomal degradation, a proportion is subsequently recycled to the cell surface
[Shapiro et al, 1996]. A sustained signal would therefore require mobilisation of
intact receptors from intracellular stores or the synthesis of new receptors. In
endothelial cells and fibroblasts, prompt generation and mobilisation of PARs from
internal stores is important. Platelets, however, neither have the ability to synthesise
new receptors, nor have large intracellular stores, as thrombin causes irreversible
platelet aggregation and platelets only need to respond once.
1.2.4 Knockout mice and animal studies
Generation of genetically modified animals for PARs has been an important
contribution for our understanding of their physiological function, in particular in the
absence of widely available, selective antagonists. Knockout mice have been
generated for each of the PARs [Connolly et al, 1996; Damiano et al, 1999; Lindner
et al, 2000; Weiss et al, 2002]. These studies have demonstrated that approximately
half of PAR-1 deficient mice {PAR -/- mice) die from bleeding at embryonic stage,
whereas the surviving embryos appear to develop fairly normally to adult mice
without bleeding diathesis [Connolly et al, 1996], When endothelial development
only is driven forward in the PAR-1 deficient embryos (by an endothelium specific
promoter), the embryos develop normally suggesting that PAR-1 is required for
t
normal angiogenesis and haemostasis in the mouse embryo [Griffin et al, 2001], In
mice, platelets of PAR-1 deficient animals remain responsive to thrombin. This and
other studies demonstrated that PAR-1 receptors are not expressed or required for
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activation of platelets in most rodents and small animals, but were subsequently
found to express and be activated by PAR-4 and PAR-3. As PAR-1 is the most
important thrombin receptor in human platelets, this difference in PAR expression
markedly limits the use of small animals to further our understanding of PAR-1 in
the human cardiovascular system.
1.2.5 Physiological role of protease-activated receptors
Protease-activated receptors appear to be important in various organ systems. Their
physiological role has not been fully established and depends in part on different
expression of the various receptors between tissues.
PARs in the cardiovascular system
Given the imperative function of thrombin in the cardiovascular system, there has
been a great interest in studying the physiological and pathophysiological role of
PARs in the vasculature. The availability of specific PAR activating peptides has
enabled us to study the receptor mediated effects of thrombin in separation from
thrombin's effects in the coagulation cascade. Protease-activated receptors are
expressed by endothelial and vascular smooth muscle cells, as well as by circulating
blood cells. Extensive studies have been carried out in vitro, using vascular segments
to study vasomotor effects and ex vivo platelet studies. Platelet studies have
confirmed that PAR-1 and to a lesser extent PAR-4, but not PAR-2 or PAR-3, are the
principal thrombin receptors on human platelets. Vasomotor studies have in general
demonstrated that PAR-1, and to some extent PAR-2, appears to induce
endothelium-dependent vasorelaxation [Kawabata et al, 2004] In mice, PAR-1
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activation in vivo causes a transient hypotensive response, followed by a more
sustained period of increase in blood pressure, whereas PAR-2 activation causes
hypotension only [Cheung et al, 1998], Activation of PAR-2 stimulates endothelial
[Mirza et al, 1996] and vascular smooth muscle cell proliferation in cultures
[McNamara et al, 1993] and induces angiogenesis in rodents [Milia et al, 2002]. The
partial embryonic lethality caused by deletion of PAR-1 in knockout mice, is
probably largely due to impaired angiogenesis [Griffin et al, 2001], As mentioned
above, due to species heterogeneity in PAR-1 expression, most rodent studies are,
however, of limited relevance in humans. No previous studies have been done on the
effects of PAR-1 receptor activation in the human vasculature in vivo, but a previous
study looking at PAR-2 receptor activation has demonstrated that PAR-2 activation
causes venous and arterial dilatation in humans [Robin et al, 2003],
PARs in other organ systems
The role of protease-activated receptors has been investigated extensively in vitro
and in small animals and they have an important role in various tissues and organs.
In the nervous system PARs are widely expressed, in particular PAR-1. This is likely
to have implications for neuronal function, such as neurotransmission and pain, as
well as during trauma and inflammation when low level stimulation may have a
protective effect but high and prolonged stimulation may be detrimental [Vaughan et
al, 1995; Luo et al, 2007]. In the gastrointestinal and respiratory tract PAR-2 is
mainly involved in inflammatory conditions.
23
1.3 THROMBOSIS AND PLATELETS
1.3.1 Thrombosis: venous and arterial
Although blood coagulation prevents inappropriate haemorrhage and exsanguination
following tissue trauma or injury, intravascular thrombosis is a major cause of
morbidity and mortality. Arterial thrombosis causes tissue ischaemia including
myocardial and cerebral infarction, and is the leading cause of death in western
societies. Venous thrombosis can cause localised tissue oedema but is most serious
when it embolises to the lung where it may cause life-threatening pulmonary
thromboembolism.
Venous blood flow is slow and under low pressure. Thrombus formation is most
common in the calf veins and mainly consists of red blood cells in a mesh of fibrin;
so-called 'red thrombus'. Venous thrombosis is therefore readily prevented and
treated by inhibiting thrombin-induced fibrin formation. Consistent with Virchow's
triad, any condition that causes venous congestion (reduced flow), trauma (vessel
wall damage) or activation of the coagulation system (hypercoagulability) will
predispose to venous thrombosis. There are several well recognised risk factors
including major surgery, malignancy (especially adenocarcinoma), immobility,
*
genetic traits and oral contraceptives or hormone replacement therapy [Scottish
Intercollegiate Guidelines Network (SIGN), 2002], Most venous thrombi of the
calves go unnoticed and small emboli frequently get filtered from the circulation in
the lungs without causing symptoms. The risk of complications increases steeply if
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the thrombus extends more proximally and detachment may lead to symptomatic
pulmonary embolism. Venous thromboembolism prophylaxis, normally with low
doses of heparin, is indicated in immobilised and post-operative patients. Longer
treatment is indicated in those with confirmed proximal (above knee) deep vein
thrombosis and pulmonary embolism but the length of treatment varies between
3 months and indefinitely [Scottish Intercollegiate Guidelines Network
(SIGN), 1999; Hyers et al, 2001],
Arterial occlusion can be due to thrombosis in situ, such as with an acute coronary
syndrome, or due to thromboembolism, such as a stroke from aortic or cardiac
thrombus. Arterial thrombus tends to be caused by mechanical injury or plaque
rupture of atherosclerotic arteries. The thrombus is rich in platelets connected by
fibrin strands; so called 'white thrombus'. Agents that minimize either platelet
activation or thrombin deposition are therefore used for prevention and treatment of
arterial thrombus. In atrial fibrillation, cardiac thrombus forms because of atrial
blood stagnation and is not as platelet rich [Kamath et al, 2001]. This may in part
explain why aspirin is less effective in preventing stroke than warfarin in patients
with atrial fibrillation [Petersen et al, 1989].
1.3.2 Platelets
Platelets are an essential part of thrombus formation stopping haemorrhage after
vascular trauma. Platelet activation and aggregation is important in both the acute
and chronic pathophysiology of atherothrombotic diseases where, as well as forming
a haemostatic plug, they mediate inflammation. The discovery and extensive
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employment of antiplatelet agents has been imperative to the advances in treatment
and outcome of cardiovascular diseases such as myocardial infarction and stroke.
Platelets are produced by megakaryocytes and are anucleate cells. The initial
tethering of platelets to the site of vascular injury is mediated via the vWF receptor
complex GPlb/V/IX and subsequently strengthened through activation of integrins,
in particular GPIIb/IIIa and GPIa/IIa. Following the initial tethering of the platelets
further activation and augmentation of the response is mediated by several agonists,
in particular thrombin, adenosine diphosphate (ADP), thromboxane A2 and
epinephrine, through G-protein coupled receptors [Offermanns 2006; Davi and
Patrono, 2007], Platelet activation causes further release of these mediators, shape
change of the platelet cytoskeleton, release of platelet granules and expression of
membrane proteins on the platelet surface and hence powerful positive feedback
leading to platelet aggregation and formation of a platelet plug [Ruggeri, 2002].
Although physiologically necessary to ensure haemostasis at the site of vascular
injury, platelets can also be activated by damaged endothelium in diseased arteries
causing thrombotic events and tissue damage, in particular when release of
substances that prevent platelet activation such as nitric oxide (NO), is hampered.
1.4 ENDOGENOUS FIBRINOLYSIS
The endogenous fibrinolytic system is responsible for the dissolution of arterial
thrombi that are frequently found on the surface of atherosclerotic plaques at areas of
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endothelial denudation [Davies et al, 1988; Oliver et al, 2005], It is necessary for
maintenance of vessel patency and prevention of tissue ischaemia.
Endogenous fibrinolysis involves clot dissolution where cross-linked fibrin
undergoes hydrolytic cleavage by plasmin to generate fibrin degradation products.
Fibrinolysis is regulated by the pro-fibrinolytic factor, tissue plasminogen activator
(t-PA), and its endogenous inhibitor, plasminogen activator inhibitor type 1 (PAI-1).
1.4.1 Plasmin and plasminogen activators
Plasmin is a serine protease generated from plasminogen, a single chain glycoprotein
consisting of 791 amino acids, principally produced by the liver [Raum et al, 1980].
Plasmin is formed by enzymatic cleavage of plasminogen at Arg561-Valine (Val)562
by plasminogen activators. Plasminogen activators are therefore required to initiate
fibrinolysis. The two principal endogenous plasminogen activators are t-PA and
urokinase plasminogen activator (u-PA). Whereas t-PA is the main plasminogen
activator for intravascular fibrin degradation, u-PA appears more important for cell
migration [Binder et al, 2007],
As well as regulating fibrinolysis, plasminogen activators appear to have other
functions involving degradation of protein barriers, thereby facilitating cell migration
and contributing to various physiological and pathophysiological processes such as
embryogenesis, wound healing, angiogenesis and tumour growth and dissemination.
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1.4.2 Tissue plasminogen activator
Tissue plasminogen activator is a 527 amino acid glycoprotein, principally released
from the endothelium [van Zonneveld et al, 1986a]. Under normal conditions total
plasma t-PA concentration is around 70 pmol/L, and t-PA has a short half-life of
about 5 minutes due to rapid hepatic clearance [Chandler et al, 1997]. Further t-PA
can be rapidly released from small, dense endothelial storage vesicles
[Eijnden-Schrauwen et al, 1995; Emeis et al, 1997] in response to various stimuli
such as thrombin, bradykinin and substance P, as well as sympathetic stimuli such as
exercise [Chandler et al, 1995; Newby et al, 1997b; Brown et al, 1999],
Tissue plasminogen activator alone is a weak plasminogen activator, but once bound
to fibrin its catalytic activity rises 1000-fold due to conformational changes [van
Zonneveld et al, 1986b], The rapid mobilisation of t-PA from the endothelium is
crucial, with thrombus dissolution being much more effective if t-PA is incorporated
during, rather than after, thrombus formation [Fox et al, 1985]. Indeed, acute
stimulated t-PA release predicts the future risk of cardiovascular events [Robinson et
al, 2007],
1.4.3 Plasminogen activator inhibitor type i
Plasminogen activator inhbitor type 1 is the main t-PA inhibitor in man. It is a 379
amino acid glycoprotein that has a plasma concentration of around 500 pmol/L, and
is produced by several tissues, mainly endothelial cells and vascular smooth muscle
cells, but with a contribution from platelets and the liver [Simpson et al, 1991],
Plasminogen activator inhibitor type 1 is present in either an active or an inactive or
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latent form in the circulation [Levin, 1995], It is synthesised in the active form,
which is unstable, with a half-life of approximately 30 minutes, although stability is
enhanced by binding with vitronectin [Declerck et al, 1988; Seiffert et al, 1994]. The
active form is converted to the latent form, which has a longer half-life of around
4 hours.
Plasma PAI-1 appears to be largely derived from endothelial and smooth muscle
cells. Plasminogen activator inhibitor type 1 is also stored in high concentrations in
the a-granules of platelets. During thrombotic events, when there are high levels of
platelet activation, a large proportion of PAI-1 concentration can be derived from
platelets [Brogren et al, 2004]. Platelet PAI-1 is, however, much less active than
plasma PAI-1 derived from the endothelium (<5%), probably due to lack of the
stabilising effects of vitronectin.
By binding to t-PA and thereby preventing t-PA binding to fibrin, a t-PA-PAI
complex is formed which is eliminated from the circulation by the liver (Figure 1.5).
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Figure 1.5 From Oliver et al [2005],
1.5 VASCULAR FUNCTION
1.5.1 Vascular endothelium
The endothelium is a vital organ, and not merely an inert physical barrier between
blood and surrounding tissues. The endothelium is a single cell layer with a wide
array of biological functions interacting with platelets, leukocytes and vascular
smooth muscle cells to regulate vascular tone, haemostasis and fibrinolysis as well as
releasing inflammatory mediators.
Regulation ofvascular tone
The endothelium regulates blood flow by secretion of vasoactive compounds that
either cause relaxation or constriction of blood vessels. A number of
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endothelium-dependent agonists such as thrombin, bradykinin, acetylcholine and
substance P have been identified that can act through three different
mechanisms: NO-, prostacyclin- or endothelium-derived hyperpolarising
factor (EDHF)-dependent pathways. The relative importance of each of these
pathways differs between vascular beds and can be studied using pharmacological
tools and knockout mice [Scotland et al, 2005].
Nitric oxide
Nitric oxide is the principal endothelium-derived relaxing factor. In their pioneering
work, published in 1980 that subsequently led to their Nobel award, Furchgott and
Zawadski first described the fundamental role of intact endothelium for acetylcholine
mediated relaxation of blood vessels [Furchgott and Zawadski, 1980], They proposed
that the endothelium-dependent relaxation of arteries was mediated by an unstable
substance, endothelium-derived relaxing factor. Two separate groups, led by Ignarro
and Moncada, later simultaneously identified endothelium-derived relaxing factor as
NO [Ignarro et al, 1987; Palmer et al, 1987]. Nitric oxide is formed by oxidation of
L-arginine to L-citrulline by NO synthase in endothelial cells and platelets, or can be
derived from an exogenous source i.e. NO donor drugs such as sodium nitroprusside.
Nitric oxide diffuses into platelets and smooth muscle cells. The effects of NO are
predominantly mediated via stimulation of soluble guanylate cyclase which catalyses
synthesis of the secondary messenger cyclic 3'5'-guanosine monophosphate (cGMP)
from guanosine 5'-triphosphate (GTP) [Lucas et al, 2000]. Cyclic GMP reduces
platelet adhesion and aggregation via predominantly protein kinase C mediated
pathways [Hofmann et al, 1992] and suppresses the binding of GPIIb/IIIa integrins to
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fibrinogen as well as causing smooth muscle relaxation through reduction in
intracellular calcium.
Endothelial nitric oxide synthase (eNOS) is constitutively expressed in endothelial
cells, but up-regulated by various agonists including thrombin, bradykinin, substance
P and acetylcholine. Flow mediated autoregulatory mechanisms in response to shear
and mechanical stress, such as during ischaemia and hyperaemia, are also of
importance [Loscalzo and Vita, 1994],
Prostacyclin
Prostacyclin is the second major endothelium-derived vasodilator and the
predominant prostaglandin produced by endothelial cells. Prostacyclin is produced
by cyclooxygenase from arachidonic acid, which is produced from membrane
phospholipids by phospholipase A2 [Smith, 1992], Synthesis is stimulated by various
agonists such as thrombin, bradykinin and adenosine nucleotides and can be
inhibited by cyclooxygenase inhbitors. Prostacyclin has protective effects in the
cardiovascular system. As well as being a vasodilator, it inhibits platelet activation
and vascular smooth muscle cell proliferation. It also counteracts the prothrombotic
effects of thromboxane A2 released from platelets which causes vasoconstriction and
platelet activation [Alfranca et al, 2006],
Endothelium-derived hyperpolarisingfactor
Endothelium-derived hyperpolarising factor refers to an unknown compound
secreted by endothelial cells which leads to NO- and prostacyclin-independent
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vasodilation by relaxation of vascular smooth muscle. This observed increased
vasodilatation is inhibited by calcium-activated potassium channel blockers, and
therefore relies on hyperpolarisation of vascular smooth muscle. The two main
components of the EDHF-induced vasodilatation are the initial potassium channel-
dependent endothelial hyperpolarisation and subsequent relay of the electrical signal
through smooth muscle gap junctions. The exact chemical identity of EDHF remains
elusive and good selective antagonists are lacking. Although no single compound has
emerged as a universal EDHF, various substances may mediate endothelial
relaxation via hyperpolarisation; for instance arachidonic acid derivates
epoxyeicosatreionic acid (EET), hydrogen peroxide, potassium ions and C-type
natriuretic peptide [Griffith, 2004],
Vasoconstrictingfactors
Vascular tone is maintained by the balance between vasodilators and
vasoconstrictors. The best known vasoconstrictors are angiotensin II and
endothelin-1. Endothelin-1, the most potent vasoconstrictor [Levin, 1995], is
synthesised and released from the endothelium in response to hypoxia, shear stress
and ischaemia and binds to the endothelin receptor on vascular smooth muscle cells
leading to increased vascular tone. It augments the vasoconstrictor effects of
catecholamines, as well as contributing to maintainance of basal vascular resistance
[Davenport et al, 1990; Haynes et al, 1995]. Another well established and
investigated vasoconstrictor is angiotensin II, released through the renin-angiotensin-
aldosterone system: renin, released from the renal juxtaglomerular cells, converts
angiotensinogen to angiotensin I. Angiotensin I is then converted to angiotensin II by
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angiotensin-converting enzyme (ACE) which is mainly located on the surface of
endothelial cells in the lungs. G-protein coupled angiotensin receptors subsequently
cause increased blood pressure, vascular inflammation, production of aldosterone
and various other cardiovascular responses [Peach, 1977; Brasier et al, 2002].
1.6 ANTITHROMBOTIC TREATMENT
1.6.1 Anticoagulation
Anticoagulant therapy is used in the treatment and prevention of arterial and venous
thrombosis in patients with a range of conditions including atrial fibrillation,
mechanical prosthetic heart valves, deep venous thrombosis, acute coronary
syndromes and pulmonary embolism. Current parenteral and oral anticoagulant
therapies tend to act at multiple sites in the coagulation cascade and have significant
drawbacks that limit their use. Warfarin and heparin are the most commonly used
anticoagulant agents but have unpredictable pharmacokinetic and pharmacodynamic
actions, potentially serious side-effects, and important drug and food interactions.
They require regular repeated monitoring and dose adjustments. There is therefore a
need for more convenient, predictable and reliable anticoagulant therapies.
Warfarin
Warfarin blocks the hepatic y-carboxylation of the vitamin K-dependent clotting
factors II, VII, IX and X. The onset of anticoagulant activity is delayed in accordance
with the half-life of these factors: 2 to 3 days. Long-term anticoagulation with
warfarin is considered in patients with atrial fibrillation, prosthetic heart valves,
rheumatic heart disease, deep vein thrombosis or pulmonary embolism.
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Treatment with warfarin is complicated by the need to assess liver function at onset
and the continuous monitoring of anticoagulant control using the International
Normalised Ratio (INR) of the prothrombin time. Achieving the appropriate level of
anticoagulation is hindered by numerous and important drug-drug and drug-food
interactions. Warfarin has a narrow therapeutic window and the risk of bleeding
increases steeply with a small rise in INR. The risk of major haemorrhage (death,
hospitalisation, intracranial haemorrhage or requiring blood transfusion) with
warfarin is about 1-4% per year [Schulman, 2003], Warfarin also inhibits production
of the anticoagulant factors C and S. If their concentration falls dramatically, such as
with excessive loading doses, or in people with hereditary Protein C or S deficiency,
there is a temporary procoagulant state with the risk of small vessel thrombosis and
skin necrosis. Warfarin can also be teratogenic and should be avoided in pregnancy.
Heparin
Heparin inhibits factors Xa and Ha (thrombin) by enhancing the activity of
antithrombin III. Unfractionated heparin has largely been replaced by low molecular
weight heparin for some indications, such as unstable angina and deep vein
thrombosis, but remains a common anticoagulant in certain settings, such as in
patients with acute renal failure, due to its short half-life.
The use of heparin can have several limitations and side-effects. Plasma proteins can
bind to heparin and reduce its activity. Anticoagulation with unfractionated heparin
is often unpredictable and requires frequent monitoring and dose titration.
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Antithrombin III only works against free factor Xa and there is little activity against
clot bound factor Xa. Heparin can cause platelet activation and one of the most
serious non-haemorrhagic side-effects is heparin-induced thrombocytopenia.
Heparin-induced thrombocytopenia is much less common with low molecular weight
heparin and very unlikely with the new pentasaccharides [Amiral et al, 1997], such
as fondaparinux that act indirectly to decrease thrombin generation by factor Xa
inhibition.
Direct thrombin inhibitors
Direct thrombin inhibitors are a new class of anticoagulant therapy that act solely
through direct enzymatic inhibition of thrombin. These drugs can either be
administered orally or parenterally and inhibit both free and clot bound thrombin.
Direct thrombin inhibitors also have antiplatelet effects [Nylander and Mattsson,
2003] and may augment thrombolysis induced by fibrinolytic agents [Visconte et al,
2004],
Oral direct thrombin inhibitors are the first oral anticoagulant agents since the
introduction of warfarin over 60 years ago. There has been considerable interest
surrounding the clinical use of these drugs as they do not require monitoring of INR,
both for deep vein thrombosis prophylaxis after operations, and in patients with atrial
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fibrillation and after myocardial infarction. The first such drug, ximelagatran, was
however withdrawn, mainly due to concerns regarding adverse effects on liver
function. Deranged liver function tests, which are the most frequent side-effects (in
about 6-7% of patients), are in most instances reversed back to normal either
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spontaneously or after cessation of treatment. Evidence that ximelagatran could in
very rare cases induce severe liver injury did however lead the American Food and
Drug Administration to conclude that potential risk of side-effects might outweigh
the benefit and that further studies were required. Another drug, dabigatran has
subsequently been licensed for use in primary prevention of venous thromboembolic
events after hip or knee replacement. Dabigatran does not appear to affect liver
function as frequently and has now also been studied in patients with atrial
fibrillation [Connolly et al, 2009],
Bivalirudin is a parenteral peptidic agent that has shown particular promise as
anticoagulant treatment during percutaneous coronary intervention [Lincoff et al,
2003; Stone et al, 2007; Stone et al, 2008], Bivalirudin is a recombinant polypeptide
analogue of the carboxy-terminal of hirudin [Maraganore et al, 1990]. It is a direct
thrombin inhibitor given by intravenous infusion and forms a bivalent complex with
thrombin. The connection is slowly reversible due to proteolytic cleavage by
thrombin [Witting et al, 1992] and its half-life is short at about 25 minutes [Fox et al,
1993]. In addition to its anticoagulant effects bivalirudin, unlike unfractionated
heparin, causes additional inhibition of ADP-induced platelet aggregation in patients
pretreated with clopidogrel who are undergoing percutaneous coronary intervention
[Sibbing et al, 2008].
The effects of prolonged direct thrombin inhibition are unknown. Thrombin not only
acts in the coagulation system but has a widespread physiological role in cell
signalling, largely through activation of protease-activated receptors. Studies on
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small animals have suggested that thrombin inhibition might reduce tumour invasion
and metastases, and be beneficial in inflammatory conditions [Ossovskaya and
Bunnett, 2004], Long-term inhibition may furthermore cause up-regulation of the
receptors and a rebound effect when thrombin receptor antagonists are withdrawn.
We do however not have clinical studies on the long-term use of these medications in
humans and it remains to be established what the balance will be between these
potential benefits and possible adverse effects.
1.6.2 Antiplatelet treatment
Acute atherothrombotic events such as myocardial infarction and stroke are the most
common causes of death and morbidity in the western world. Antiplatelet agents are
essential in the treatment of all cardiovascular diseases and have been a key element
in advances made in this field in recent decades. The goal of antiplatelet treatment is
to prevent platelet aggregation with minimal increase in the risk of bleeding.
Aspirin
Aspirin remains the most ubiquitously used and important antiplatelet agent and is
established in the treatment of coronary, cerebrovascular and peripheral artery
disease. Aspirin causes irreversible inhibition of platelet cyclooxygenase 1
(prostaglandin G/H synthase), suppressing the conversion of arachidonic acid to
thromboxane A2 [Patrono, 1994].
The acute and chronic use of aspirin in patients with atherothrombotic diseases has
been extensively studied and consistently proven to be of great benefit in most
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groups. The Antithrombotic Trialists' Collaboration meta-analysis [2002] established
that aspirin treatment in patients with high risk of vascular disease reduces the
incidence of death, myocardial infarction and stroke by 25%.
Clopidogrel
Aspirin alone is in many instances not sufficient to prevent platelet aggregation and
the use of adjunctive antiplatelet treatment in addition to aspirin is increasingly
common, in particular in patients at high risk of vascular events. Clopidogrel, a
thienopyridine derivative, acts by disrupting ADP mediated platelet activation by
binding to a platelet surface receptor P2Y12. Combination therapy of aspirin and
clopidogrel has been shown to be valuable in patients with acute coronary syndromes
and in patients undergoing percutaneous coronary intervention [Yusuf et al, 2001;
Sabatine et al, 2005], Long-term dual antiplatelet treatment with aspirin and
clopidogrel in patients at high risk of atherothrombotic events does not have major
benefits and is associated with increased risk of bleeding [Bhatt et al, 2006],
Glycoprotein Ilb/IIIa inhibitors
All stimulants of platelets ultimately cause platelet aggregation via activation of the
GPIIb/IIIa integrin complex and the subsequent bridging between platelets is further
facilitated by fibrinogen and vWF. Glycoprotein Ilb/IIIa inhibitors (GPIs) would
therefore be expected to be the ultimate platelet antagonists. Glycoprotein Ilb/IIIa
inhibitors such as abciximab and tirofiban have been shown to be very efficient
inhibitors of platelet aggregation when given intravenously in high risk patients
undergoing percutaneous coronary intervention [Valgimigli et al, 2004;
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Kastrati et al, 2006], Results of trials of oral GPIs given for longer periods did
however show adverse effects which may be due to lack of inhibition of platelet
leucocyte binding and platelet microaggregation or possible pro-inflammatory effects
[Storey et al, 1998; Nannizzi-Alaimo et al, 2003; Zhao et al, 2003],
Emerging antiplatelet agents
Despite combined antiplatelet treatment with currently available agents, platelet
inhibition remains incomplete and acute thrombotic events continue to occur. It is
therefore not surprising that this an active field for research and development of new
therapeutic tools. Prasugrel and ticagrelor are emerging drugs that inhibit ADP-
induced platelet activation [Jernberg et al, 2006; Wallentin et al, 2009], and
thrombin-induced platelet aggregation may in the future be inhibited with the
development of thrombin receptor antagonists (see below).
1.7 CLINICAL RISK FACTORS ASSOCIATED WITH
ATHEROTHROMBOSIS
Cardiovascular diseases are becoming a leading cause of death worldwide, already
being the most common cause of death in developed countries [Yusuf et al, 2004;
Teo et al, 2006], Large epidemiological studies, pioneered by the Framingham heart
study, have helped to establish the most important clinical risk factors for
atherothrombosis and this has had radical impact on our understanding, prevention
and treatment of atherothrombotic diseases. Smoking, hypertension, hyperlipidaemia
and diabetes are all well characterised clinical risk factors, but others such as lack of
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exercise, obesity and depression also to play a role. Markers of inflammation such as
highly sensitive c-reactive protein test can also be of value in predicting
cardiovascular risk [Danesh et al, 2004],
1.7.1 Smokers
Smoking tobacco remains one of the most important and consistent modifiable risk
factors for myocardial infarction and fatal coronary artery disease [Ambrose and
Barua, 2004]. The INTERHEART study revealed that smoking tobacco increases the
risk of non-fatal myocardial infarction by up to 7-fold [Teo et al, 2006]. The
pathophysiological mechanisms underlying this association are likely to be a
combination of accelerated atherosclerosis [Zieske et al, 2005] and a propensity to
acute coronary thrombosis [Burke et al, 1997; Ambrose and Barua, 2004). Function
of both circulating blood cells and endothelial cells is affected in smokers. Smokers
have increased levels of platelet activation as measured by levels of platelet-moncyte
binding [Harding et al, 2004]. Endothelium-dependent vasodilatation in both the
peripheral and coronary circulation is impaired in patients with atherosclerosis
[Ludmer et al, 1986], Even subjects who do not have clinical evidence of
cardiovascular diseases, but who have clinical risk factors such as smoking, have
impaired endothelium-dependent vasodilatation and t-PA release in the peripheral
and coronary circulations [Celermejer et al, 1996; Newby et al, 1999; Newby et al,
2001; Takashima et al, 2007] and this has predictive value for future cardiovascular
events [Widlansky et al, 2003],
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1.8 PROTEASE-ACTIVATED RECEPTORS IN DISEASE:
PATHOPHYSIOLOGY AND THERAPEUTIC TARGETS
1.8.1 Pathophysiological role of pars
Protease-activated receptors are involved in the regulation of many physiological
processes such as inflammation, coagulation, angiogenesis and neurotransmission.
Their contribution to various diseases and possible therapeutic modulation is
therefore intriguing. Inhibition of PAR-1 may in particular have beneficial
antiplatelet effects [Derian et al, 2003] but further understanding of the effects of
PAR-1 agonism and antagonism is required. Research and understanding of the role
of PAR receptors in disease is however not straightforward. Expression of PARs
differs between species and tissue types and is affected by disease processes such as
inflammation and atherosclerosis. In the cardiovascular system, as well as being one
of the principal receptors for platelet activation and aggregation, PARs contribute to
vascular inflammation and restenosis [Andrade-Gordon et al, 2001].
PAR-1 and -2 are expressed and up-regulated in various tumour cells. Cancer
metastasis relies on cell motility, degradation of basement membrane and stromal
tissue and tumour angiogenesis. There is evidence that PAR-1 expression on cancer
cells correlates with their invasiveness and metastatic potential [Even-Ram et al,
*
1998; Henrikson et al, 1999; Kaushal et al, 2006], Protease-activated receptor-1
antagonists may therefore be useful as adjuvant treatment for some types of cancer.
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1.8.2 Par-i antagonists
Selective inhibition of PAR-1 reduces platelet activation and aggregation without
affecting the enzymatic activation of fibrinogen in the coagulation cascade. Protease-
activated receptor-1 antagonists have been used as a research tool for in vitro studies
and their therapeutic role as antiplatelet agents is currently ofmajor clinical interest.
Numerous PAR-1 antagonists (thrombin receptor antagonists) have been developed
or are in development [Chackalamannil et al, 2003; Maryanoff et al, 2003;
Nantermet et al, 2002; Seiler and Bernatowicz, 2003; Selnick et al, 2003] including
the indazole based peptide mimetic RWJ-58259 (aS-N-[(lS)-3-amino-l-
[[(phenylmethyl)-amino]carbonyl]propyl]-alpha-[[[[[l-(2,6-dichlorophenyl) methyl]-
3-(l -pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-
difluorobenzenepropanamide) [Andrade-Gordon et al, 2001; Damiano et al, 2003;
Derian et al, 2003; Zhang et al, 2003] and a himbacine-derived thrombin receptor
antagonist [Xia et al, 2007],
Data from a phase II clinical trial (see Chapter 7), where the use of the oral TRA
SCH 530348 was compared with placebo in patients undergoing non-emergency
percutaneous coronary intervention, in addition to other standard antiplatelet and
antithrombotic treatment, have indicated that the use of thrombin receptor
antagonists is safe and feasible [Becker et al, 2009].
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1.9 HYPOTHESIS
Thrombin is one of the most important agonists in the cardiovascular system.
Protease-activated receptors, in particular PAR-1, have been proposed as the
principal thrombin receptors and PAR-1 antagonists are in clinical development as
antiplatelet agents, but no data are available on the effects on PAR-1 activation in
vivo in man.
In a series of clinical studies, the following hypotheses will be addressed:
1. PAR-1 activation causes concentration-dependent platelet aggregation and
activation in vitro, and that PAR-1 induced platelet aggregation can be inhibited
by specific PAR-1 antagonists.
2. PAR-1 activation causes venous dilatation in vivo in man.
3. PAR-1 activation induces arterial dilatation, platelet activation and acute release
of endothelium dependent factors such as t-PA, in vivo in man.
4. PAR-1 mediated vasodilatation is endothelium-dependent, through nitric oxide,
prostacyclin and endothelium-derived hyperpolarising factor release.
5. The effects of PAR-1 activation are altered in subjects with impaired endothelial
function such as in smokers.
Currently available data stems from in vitro and animal studies but human data are
lacking. After initial pilot studies looking at the effects of PAR activation on human
platelet activation and aggregation in vitro, we intend to assess for the first time, the
effects of PAR-1 activation in the venous and arterial circulation in vivo in man. Our
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aim is to assess the effects of activation of this thrombin receptor on platelet
function, release of endothelium-dependent factors and venous and arterial
vasomotor function.
1.10 AIMS
The aims of the thesis were:
In platelets from healthy volunteers:
• To assess the effects of stimulation of PARs on human platelet activation as
measured by levels of platelet-monocyte binding and on platelet aggregation.
• To assess the inhibitory effects of a specific PAR-1 antagonist, RWJ-58259,
on platelet aggregation induced by the PAR-1 activating peptide SFLLRN,
thrombin and by the thromboxane A2 agonist U46619.
• To assess the effects of the glycoprotein Ilb/IIIa inhibitor tirofiban on
SFLLRN-induced platelet activation and aggregation.
In the venous circulation of healthy volunteers:
• To compare the effects of infusion of the PAR-1 activating peptide SFLLRN
to infusion of the PAR-2 activating peptide SLIGKV in the dorsal hand vein.
• To assess the effects of SFLLRN infusion in the dorsal hand vein in the
presence and absence of norepinephrine and tirofiban.
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In the arterial circulation of healthy volunteers:
• To compare the effects of intra-arterial infusion of the PAR-1 activating
peptide SFLLRN with the PAR-2 activating peptide SLIGKV and the
endothelium-dependent vasodilator bradykinin on vasomotor function.
• To assess the effects of intra-arterial PAR-1 activation on release of t-PA,
PAI-1 and vWF.
• To assess the effects of intra-arterial PAR-1 activation on platelet activation
as measured by levels of platelet-monocyte binding.
To assess the role of endothelial function on the effects of PAR-1 activation in
healthy volunteers:
• In the dorsal hand vein, to assess the effects of the PAR-1 activating peptide
before and after endothelial denudation.
• In the forearm, assess the importance of endothelium-dependent pathways on
PAR-1 induced vasomotor responses.
In smokers:
• To compare PAR-1 mediated vasomotor responses, and t-PA and PAI-1





ASSESSMENT OF THE EFFECTS OF PROTEASE-ACTIVATED
RECEPTOR STIMULATION ON PLATELETS, VASCULAR FUNCTION
AND RELEASE OF ENDOTHELIUM-DERIVED FACTORS
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2.1 INTRODUCTION
Cardiovascular events such as myocardial infarction and stroke are the result of a
complex interaction between the endothelium, vascular smooth muscle, platelets,
inflammatory cells and the coagulation cascade. Thrombin is a powerful
physiological stimulator of inflammation and thrombosis and PARs, in particular
PAR-1, are believed to be the principal thrombin receptors in man. Protease-
activated receptors are widely expressed in humans in most tissues including the
cardiovascular, respiratory and nervous systems and the gastrointestinal tract
[Ossovskaya and Bunnett, 2004], Previous studies of PAR-1 receptors have been
carried out in vitro or in small animals but their role has not been previously studied
in vivo man.
When studying a widely expressed receptor, such as PARs, systemic administration
of a receptor agonist could cause concomitant effects in other organs such as the
nervous system. This could potentially stimulate confounding neurohormonal
reflexes, and vascular responses could thus not be solely attributed to the effects of
direct vascular receptor stimulation [Webb, 1995]. Venous and arterial responses
can, however, be studied directly without systemic influences, by assessing the
effects of a localised infusion into the venous or arterial circulation with the Aellig




By using the Aellig dorsal hand vein technique [Aellig, 1981], the direct effects of a
locally active, subsystemic dose of infused drugs can be assessed in the venous
circulation without systemic influences. As the doses required of the infused drugs
are very small, and get rapidly diluted downstream from the dorsal hand vein, this is
an excellent method to study drugs for the first time in man. Furthermore, dorsal
hand veins are representative of the physiological regulation of central venous
capacitance and cardiac preload, as cutaneous limb veins participate in sympathetic
venomotor reflexes, unlike skeletal muscle veins [Benjamin et al, 1995].
2.1.2 Arterial studies
By using venous occlusion plethysmography, vascular responses can be directly
assessed in vivo in response to unilateral brachial artery infusion of drugs at a
subsystemic, locally active dose, where the infused arm is compared with the non-
infused arm [Benjamin et al, 1995; Webb, 1995], This method has been widely used
and tested by our group and others. It has proven to be an excellent tool to assess
vascular function and responses to various endogenous and exogenous factors in
healthy subjects and patients with atherothrombotic diseases [Haynes et al, 1995;
Newby et al, 1997a; Verhaar et al, 1998; Hrafnkelsdottir et al, 2004], Furthermore,
the antecubital fossae veins can be cannulated enabling intermittent blood sampling
and measurements of endothelium released factors and inflammatory parameters.
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2.2 STUDY SUBJECTS AND CONDITIONS
2.2.1 Study subjects
Study volunteers were healthy males and females, aged 20-38 years, who had not
been taking any regular medications, including anti-inflammatory medications, over
the counter medications, herbal supplements or vitamins. They did not have
clinically significant co-existing conditions including hypertension, hyperlipidaemia,
diabetes mellitus, asthma and coagulopathy, and had not suffered a recent infective
or inflammatory condition. Study volunteers were not involved in other clinical trials
at the time of the study.
2.2.2 Ethics committee approval and informed consent
Each study was approved by the Lothian Research Ethics Committee, and conducted
in accordance with the Declaration of Helsinki (1996) of the World Medical
Association, and with the written informed consent of all volunteers.
2.2.3 Study conditions and preparation
All studies were carried out in a quiet, temperature controlled room (22-24°C).
Participants were semi-recumbent (venous studies) or supine (arterial studies) and
had abstained from alcohol for 24 hours, and from food and caffeine-containing
*
drinks for at least 4 hours prior to the study.
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2.3 DRUGS AND MATERIALS
For preliminary in vitro platelet studies, research grade PAR agonists were used.
Protease-activated receptor-1 agonist SFLLRN, PAR-2 agonist SLIGKV PAR-4
agonist GYPGQV and GPRP (to prevent thrombin-induced fibrin polymerisation in
platelet rich plasma) were custom synthesised by Auspep, Parkville Victoria,
Australia. RWJ-58259 was custom synthesised and molecular structure verified by
mass spectral analysis and high performance liquid chromatography by American
Peptide, Sunnyvale, California, USA. Lepirudin was obtained from Schering,
Burgess Hill, UK. CD42a-fluorscein isothiocyanate (FITC), and control IgGl-FITC
and CD14-phycoerythrin (PE) fluorochrome labelled monoclonal antibodies were
obtained from Serotec Ltd, Oxford, UK and Dako UK Ltd, Buckinghamshire, UK,
respectively. FACSLyse solution was from Becton Dickinson (BD), Oxford, UK. All
other salts and reagents for in vitro studies were from Sigma, Gillingham, UK.
Clinical grade compounds were used for all intravenous and intra-arterial infusions.
Custom synthesised clinical grade SFLLRN and SLIGKV, as well as bradykinin and
L-NG-monomethyl arginine citrate (L-NMMA) and tetraethylammonium (TEA) were
purchased from Clinalfa, Laufelfingen, Switzerland. Acetylcholine was from
Novartis Pharmaceuticals UK Ltd, Frimley, UK, sodium nitroprusside (SNP) from
David Bull Laboratories, Faulding, UK, norepinephrine from Abbott Laboratories,
Maidenhead, UK, and tirofiban from Merck, Sharp and Dohme, Hoddesdon, UK.
2.4 PLATELET STUDIES
2.4.1 Platelet aggregometry
Blood was sampled with a 19-gauge needle from the antecubital fossa into a 50 mL
syringe, transferred into tubes containing 3.8% citrate and centrifuged at 130 g for
20 minutes at room temperature to obtain platelet rich plasma. Blood was centrifuged
at 1200 g for 10 minutes to obtain platelet poor plasma for reference samples.
Platelet aggregation was measured at 37°C using standard optical platelet
aggregometry [Sogo et al, 2000a; Crane et al, 2005; GuQmundsdottir et al, 2005].
Platelet rich plasma and washed platelet samples were equilibrated at 37°C and
stirred continuously. Aggregation was monitored in a four channel aggregometer
(Chronolog 470 VS, Labmedics, Stockport, UK) linked to a MacLab 4s analogue-
digital converter and Chart software (AD instruments, Sussex, UK) or PAP-4D,
(Biodata Corporation, USA) linked to PC interface software (Platelet aggregation
profiler® version 2.3, Biodata Corporation, USA). Aggregation was monitored for
5 minutes after addition of agonist alone or for 10 minutes after addition of agonist in
the presence of antagonist.
Preparation ofwashedplatelets
Washed platelets were prepared by centrifuging platelet rich plasma at 1200 g for
10 minutes in the presence of prostacyclin (300 ng/mL) and resuspending the platelet
pellet in Hepes-Tyrodes buffer (134 mM NaCl, 12 mMNaHCOs, 2.9 mM KC1, 0.34
mM Na2HPC>4, 1 mM MgCl2, 10 mM Hepes, 5 mM glucose; pH adjusted to 7.4),
again with prostacyclin. This was centrifuged at 1200 g for 10 minutes and
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resuspended in Tyrodes buffer solution with 1 mM Ca++ added. Hepes-Tyrodes
buffer solution was used as reference control for washed platelets.
Preparation ofRWJ-58259
Because of its highly lipophilic structure (logP of 6.1; Figure 2.1) [Damiano et al,
2003], the lyophilised powder of the PAR-1 antagonist RWJ-58259 [Damiano et al,
2003] was dissolved in DMSO to produce a 25 mM solution. Serial dilutions in 5%
dextrose were used to obtain a 0.5 and 1 mM stock of RWJ-58259. The final
concentration of DMSO in the platelet rich plasma/washed platelets was <0.5%.
Figure 2.1 Structure of RWJ-58259.
Agonists
Preliminary in vitro platelet studies were carried out to construct concentration-
response curves to define the concentration of the PAR-1 agonist SFLLRN that
caused platelet activation and aggregation. SFLLRN (Auspep, Australia) was
compared with thrombin (1 mM GPRP was added prior to thrombin to prevent fibrin
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polymerisation in platelet rich plasma) and the thromboxane A2 agonist U46619
(Sigma, UK) in both platelet rich plasma and washed platelets [Crane et al, 2005].
RWJ-58259
To assess the specificity of the PAR-1 activating peptide, both SFLLRN, thrombin
and U46619-induced platelet aggregation were assessed in the presence and absence
of the PAR-1 antagonist, RWJ-58259 (aS-N-[(lS)-3-amino-l-[[(phenylmethyl)-
amino]carbonyl]propyl] -alpha- [ [ [[[ 1 -(2,6-dichlorophenyl)methyl]-3 -(1 -
pyrrolidinylmethyl)-lH-indazol-6-yl]amino]carbonyl]amino]-3,4-
difluorobenzenepropanamide; American Peptide Company, USA) in washed
platelets. Washed platelets were incubated with the antagonist for 2 minutes prior to
addition of agonist (at EC50-70, EC100 and supramaximal concentrations: thrombin
0.2, 0.3 and 1.0 U/mL; SFLLRN 1.8, 3.0 and 10.0 pM; and U46619 6.0 and 12 pM)
and concentration response curves obtained.
Lepirudin
SFLLRN and thrombin-induced platelet aggregation was also assessed in the
presence of the direct thrombin inhibitor, lepirudin (0.1 and 1.0 mg/mL; Schering,
UK), a recombinant hirudin analogue [Gosselin et al, 2004].
Tirofiban
We chose the concentration of SFLLRN that caused near maximal platelet
aggregation and assumed that the vascular and platelet PAR-1 receptor sensitivities
were equivalent. Flowever, before progressing to in vivo infusions, we defined the
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dose of tirofiban that would completely inhibit platelet aggregation using the clinical
grade preparation of SFLLRN. Platelet rich plasma was incubated for 5 minutes in
the presence or absence of tirofiban (Merck, Sharp and Dohme, UK) at 50 ng/mL.
Platelet aggregation was measured after the administration of 0.06-12 M of the
clinical grade PAR-1 activating peptide SFLLRN (Clinalfa, Switzerland).
2.4.2 Platelet-monocyte binding
Five millilitres of venous blood were collected through a 19-gauge needle and
transferred carefully into a tube containing the direct thrombin inhibitor,
D-phenylalanyl-L-propyl-L-arginine chloromethylketone (PPACK). Five minutes
after sampling, 60 pL of whole blood was incubated with monoclonal antibodies
directly conjugated to fluorochromes for 20 minutes: FITC-conjugated IgGl, and
PE-conjugated CD14 to label monocytes and FITC-conjugated CD42a with CD 14-
PE to label platelet-monocyte aggregates. The samples were then fixed with 500 pL
FACSLyse solution (Becton Dickinson). Samples were run through a Beckman-
Coulter XL2 flowcytometer. Monocytes and platelets were identified by gating for
CD14 and CD42a positive cells respectively. Platelet-monocyte aggregates were
defined as monocytes positive for CD42a. At least 3000 cells will be measured by
flowcytometry and analyses performed using EXPO 32 software (Beckman-Coulter)
software [Sarma et al, 2002].
Preliminary in vitro platelet studies were carried out to construct concentration-
response curves to define the concentration of the PAR-1 agonist SFLLRN that
caused platelet activation as measured by levels of platelet-monocyte binding. Blood
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was collected into PPACK tubes with or without tirofiban (50 ng/mL). The PAR-1
agonist SFLLRN (0.06-6 pM) was added and whole blood incubated with
monoclonal antibodies labelled with fluorochormes.
For in vivo studies of platelet-monocyte binding, whole blood was sampled
simultaneously from the infused and non-infused arms at baseline and during
infusion of study drugs, but no other agonists added and samples were processed as
above.
2.5 DORSAL HAND VEIN STUDIES
2.5.1 Dorsal hand vein infusion andmeasurement
A 23-gauge butterfly needle was sited in a dorsal hand vein, attached to a 16-gauge
epidural catheter (Smiths Medical International, Watford, UK) and total infusion rate
kept constant at 0.25 mL/min. If the subject returned for more than one study the
same hand vein was used in all studies. The hand was supported above the level of
the heart and an upper arm cuff inflated to 40 mmHg to obstruct venous return
(Figure 2.2). The internal diameter of the dorsal hand vein was measured by the
Aellig technique [Aellig, 1981], In brief, a magnetised lightweight rod rested on the
summit of the infused vein ~1 cm downstream from the tip of the infusion needle.
*•
The rod passes through a core of a linear variable differential transformer (LVDT),
supported above the hand by a small tripod. Changes in diameter of the vein cause
vertical displacement of the rod, leading to a linear change in the voltage generated
by the LVDT. This enables calculation of absolute changes in vein size.
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Figure 2.2 Aellig dorsal hand vein technique.
2.5.2 Effect of par activation on venous tone
Because dorsal hand veins do not have resting tone, norepinephrine (1-128 ng/min)
was used to induce and maintain a 50-70% reduction in vein diameter throughout the
study to allow detection of either venodilatation or venoconstriction. This was
followed by co-infusion of the PAR-1 activating peptide SFLLRN (0.05-5 nmol/min)
or the PAR-2 activating peptide SLIGKV (Clinalfa, Switzerland; 1.6-160 nmol/min).
2.5.3 Effect of glycoprotein iib/iiia receptor antagonism
The effects of SFLLRN (0.05-15 nmol/min) in the presence and absence of the
GPIIb/IIIa inhibitor tirofiban (250 ng/min), and norepinephrine (1-128 ng/min) were
assessed to determine the importance of platelet aggregation on PAR-1 mediated
alterations of venous tone. The doses of tirofiban and SFLLRN were chosen to
achieve end-organ concentrations equivalent to those with efficacy in in vitro studies
and assumed a dorsal hand vein flow of 5 mL/min.
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2.5.4 Effect of endothelial denudation
The effects of SFLLRN were assessed before and after localised endothelial
denudation. First we established the presence of functional endothelium. As dorsal
hand veins do not have resting tone, norepinephrine (1-128 ng/min) was used to
induce 70% reduction in vein diameter. Once stable venoconstriction was obtained,
acetylcholine (1 nmol/min; Novartis Pharmaceuticals UK Ltd, Frimley, UK) was co-
infused with norepinephrine for 8 minutes to demonstrate endothelium-dependent
venodilatation and an intact functional endothelium. Following a 20-minute saline
infusion, the PAR-1 activating peptide, SFLLRN (0.05-15 nmol/min; Clinalfa,
Switzerland), was administered intravenously before a final 20-minute saline
washout infusion. At the end of the visit, the endothelium of the venous segment was
denuded as previously described [Collier and Vallance 1989, Sogo et al, 2000b]. In
brief, a second 23-gauge butterfly needle was sited 3-4 cm downstream from the tip
of the infusion needle, and this segment of the vein isolated by the use of occlusion
wedges. Distilled water was infused through the venous segment at a rate of
5 mL/min for 15 minutes, thereby causing endothelial denudation that persists for at
least 2 days [Sogo et al, 2000b]. Aspirin (300 mg orally), was given 30 minutes prior
to start of the first study, and on each of the two subsequent days to prevent venous
thrombosis. On the second day following denudation, subjects re-attended and the
first protocol was repeated using the same venous segment. In the absence of
functional endothelium, acetylcholine co-infused with norepinephrine causes
venoconstriction.
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2.6 FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY
2.6.1 Brachial artery cannulation
The brachial artery of the non-dominant arm was cannulated with a 27-standard wire
gauge steel needle (Cooper's Needle Works Ltd, Birmingham, UK) after infiltration
of local anaesthesia with 1% lignocaine, and attached to a 16-gauge Portex epidural
catheter (Smiths Medical International, Watford, UK). The total rate of infusion was
kept constant throughout all studies at 1 mL/min (Figure 2.3).
Figure 2.3 Brachial artery infusion.
2.6.2 Forearm blood flow
Forearm blood flow was measured in the infused and non-infused arms by venous
occlusion plethysmography (Figure 2.4) using mercury-in-silastic strain gauges
applied to the widest part of the forearm [Newby et al, 1999; Witherow et al, 2002].
During measurements the hands were excluded from the circulation by rapid
inflation of the wrist cuffs to 200 mmHg for 3 minutes at a time. Upper arm cuffs
were inflated intermittently to 40 mmFlg to achieve venous occlusion and obtain
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plethysmography recordings (Figure 2.5). Supine heart rate and blood pressure were
monitored at intervals throughout each study using a semi-automated non-invasive
oscillometry sphygmomanometer. Blood pressure was measured immediately after
forearm blood flow measurements to avoid effects of venous congestion caused by
blood pressure measurement on forearm blood flow.






Figure 2.5 Forearm venous plethysmography recordings.
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2.6.3 GPIIb/IIIa inhibition
Tirofiban (1.25 pg/min) was infused prior to and during PAR-1 activation to inhibit
in vivo platelet aggregation and prevent potential thrombosis. The doses of tirofiban
and SFLLRN were chosen to achieve end-organ concentrations equivalent to those
with efficacy in in vitro studies and assumed a brachial artery blood flow of
25 mL/min.
2.6.4 Par activation
Forearm blood flow was measured by venous occlusion plethysmography in
response to brachial artery infusion of PAR-1 activating peptide SFLLRN (5-
50 nmol/min) with tirofiban (1.25 pg/min) and PAR-2 activating peptide SLIGKV
(160-800 nmol/min) in eight healthy volunteers and compared with the effects of the
endothelium-dependent vasodilator bradykinin.
2.6.5 Inhibition of nitric oxide and prostacyclin synthesis
Forearm blood flow was measured by venous occlusion plethysmography in
response to brachial artery infusion of SFLLRN (PAR-1 agonist; 5-50 nmol/min)
with tirofiban (1.25 pg/min) in eight healthy volunteers on four visits using a
randomised controlled cross-over study employing a two-by-two factorial design:
with and without aspirin (600 mg orally; to inhibit prostacyclin synthesis) and the
'nitric oxide clamp'.
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The 'nitric oxide clamp' was used to determine the contribution of NO in PAR-1
mediated vascular effects. Following baseline intra-arterial tirofiban infusion, the
NO synthase inhibitor, L-NMMA (8 pmol/min), was co-infused. To compensate for
L-NMMA induced basal vasoconstriction, forearm blood flow was returned to
baseline using a titrated dose of exogenous NO in the form of intra-brachial sodium
nitroprusside (90-900 ng/min). This dose of sodium nitroprusside was co-infused
with L-NMMA and continued throughout the study. This arrangement allows a
constant 'clamped' delivery of exogenous NO whilst endogenous NO synthase
activity is inhibited.
2.7 BLOOD SAMPLING AND ASSAYS
Seventeen-gauge venous cannulae were inserted into left and right antecubital fossae.
Blood samples were drawn simultaneously from each arm at baseline. Blood samples
were also drawn before and after intra-arterial drug infusion. Blood was collected
into acidified buffered citrate (Stabilyte, Biopool International, UK; for t-PA assays)
and into citrate (Becton and Dickinson Vacutainer, BD UK Ltd, UK; for PAI-1,
(3-thromboglobulin and vWF assays). Samples were kept on ice before centrifugation
at 2000 g for 30 minutes at 4°C. Platelet-free plasma was decanted and stored at
-80°C before assay. Plasma t-PA antigen and activity (t-PA Combi Actibind Elisa
*
Kit; Technoclone, Austria), PAI-1 antigen and activity (Elitest-PAI-1 Antigen and
Zymutest PAI-1 Activity; Hyphen Biomed, France), P-thromboglobulin
(Asserachrom Btg, Diagnostica Stago, France) and vWF (Dako, Glostrup, Denmark)
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concentrations were determined by enzyme-linked immunosorbant assays. Full blood
count was measured at baseline and at the end of the studies.
2.8 DATA ANALYSIS AND STATISTICS
Dorsal hand venous [Haynes et al, 1995] and forearm plethysmographic [Newby et
al, 1997a] data were analysed as described previously. Recordings for the first
60 seconds after wrist cuff inflation were not used because of variability in blood
flow and reflex vasoconstriction this causes. In general the last five linear
plethysmographic recordings in each 3-minute measurement period were used.
Variables are reported as mean±standard error of the mean (SEM) and analysed
using repeated measures, one- and two-way analysis of variance (ANOVA) with
post-hoc Bonferroni corrections and two-tailed Students /-test as appropriate.
Statistical analysis was performed with GraphPad Prism (Graph Pad Software) and
statistical significance taken at the 5% level (P<0.05).
2.8.1 Net release of endothelium-derived factors
The estimated net release of t-PA, PAI-1 and P-thromboglobulin antigen and activity
was defined as the product of the infused forearm plasma flow (based on the mean
haematocrit (Hct) and the infused forearm blood flow (FBF)) and the concentration
difference between the infused ([t-PA]jnf) and non-infused ([t-PA]non_inf) arms
[Newby et al, 1997b] according to the formula:
Estimated net t-PA release = FBF x (1-Hct) x ([t-PA]inf- [t-PA]n0n-inf)
CHAPTER 3
THE EFFECTS OF PROTEASE-ACTIVATED RECEPTOR
STIMULATION AND INHIBITION ON
PLATELET AGGREGATION AND ACTIVATION
3.1 SUMMARY
Inhibition of platelet activation has been central to advances in cardiovascular
medicine over the last decades. Thrombin is one of the most important physiological
stimulator of platelet activation. Protease-activated receptor-1 has been proposed as
the principal thrombin receptor on human platelets and PAR-1 antagonists are in
development as antiplatelet agents. The aims of this study were to study the effects of
the PAR-1 activating peptide SFLLRN on platelet activation and aggregation and
compare it with the effects of thrombin and the thromboxane A2 agonist U46619. We
have also assessed the inhibitory effects of the PAR-1 antagonist RWJ-58259 (aS-N-
[(lS)-3-amino-l-[[(phenylmethyl)-amino]carbonyl]propyl]-alpha-[[[[[l-(2,6-
dichlorophenyl)methyl]-3-(l-pyrrolidinylmethyl)-lH-indazol-6-yl]amino]carbonyl]
amino]-3,4-difluorobenzenepropanamide), the direct thrombin inhibitor lepirudin,
and those of the GPIIb/IIIa inhibitor tirofiban.
Thrombin, SFLLRN and U46619 caused concentration-dependent platelet
aggregation (n=8). RWJ-58259 fully inhibited SFLLRN- (1.8 and 3 pM) induced
aggregation (n=8, PO.OOOl; one-way ANOVA; IC5o=2.1 pM). Thrombin (0.2-
1 U/mL, EC70-EC100) mediated aggregation was only partially (up to 50%) inhibited
by RWJ-58259 (n=8, P<0.01), but completely abolished by lepirudin (0.1-1 pg/mL;
n=6, PO.OOl). Tirofiban completely inhibited SFLLRN-(P<0.001; two-way
ANOVA) induced platelet aggregation without affecting platelet activation (P=NS)
as measured by levels of platelet-monocyte binding. We have, in preparation for
subsequent in vivo studies, carried out this series of in vitro platelet studies and
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demonstrated that the PAR-1 agonist SFLLRN causes concentration-dependent
platelet activation and aggregation that can be selectively inhibited with the PAR-1
antagonist RWJ-58259. Thrombin-induced platelet aggregation is fully inhibited by
the direct thrombin inhibitor lepirudin but only partially by RWJ-58259. We have
furthermore demonstrated that PAR-1 induced platelet aggregation, but not platelet
activation is inhibited by the GPIIb/IIIa inhibitor tirofiban.
3.2 INTRODUCTION
Inhibition of platelet activation has been pivotal to advances in cardiovascular
medicine, primarily by inhibiting ADP and thromboxane A2 mediated platelet
activation. In spite of thrombin being recognised as one of the principal mediators of
platelet activation, the identity of the thrombin receptor remained elusive until
recently, and direct pharmacological inhibition was therefore previously not feasible.
Thrombin mediates thrombus formation through its central role in the coagulation
cascade as well as having direct inflammatory and atherogenic effects. It is produced
by the proteolytic activation of prothrombin through the final common pathway of
the coagulation cascade, where it causes fibrin generation and cross-linking that
underpins the basic structure of thrombus. In addition to its critical enzymatic role in
blood coagulation, thrombin is one of the most important physiological stimulator of
platelets, endothelial cells, vascular smooth muscle cells and leukocytes [Patterson et
al, 2001]. An extensive search for a thrombin receptor led to the discovery of a group
of G-protein coupled receptors termed protease-activated receptors
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[Rasmussen et al, 1991; Vu et al, 1991] that mediate the cell signalling effects of
thrombin [Coughlin, 2005]. Protease-activated receptors share a unique mechanism
of activation where proteolytic cleavage of the receptor exposes a ligand that remains
tethered and activates the receptor. To date, four different PARs have been identified,
PAR-1, -3 and -4 are all activated by thrombin, whereas PAR-2 is mainly activated
by trypsin [Hollenberg and Compton, 2002],
PAR-activating peptides (PAR-APs) have been designed to correspond to the
tethered ligands of PARs and act as selective agonists [Hollenberg, 2000], This
makes it possible to study PAR mediated effects of thrombin in isolation from its
enzymatic effects on fibrinogen and the coagulation cascade. Human platelets
express both PAR-1 and PAR-4 [Chung et al, 2002), but not PAR-2 or PAR-3
[Ossovskaya and Bunnett, 2004], and thrombin mediates platelet activation in
humans principally via PAR-1, as well as via PAR-4 and GPIb [Kahn et al, 1999;
Lova et al, 2004]. Selective inhibition of PAR-1 could therefore have a therapeutic
role by reducing platelet activation and aggregation without affecting the enzymatic
activation of fibrinogen.
Numerous PAR-1 antagonists have been developed [Nantermet et al, 2002;
Chackalamannil et al, 2003; Maryanoff et al, 2003; Seiler and Bernatowicz, 2003;




yl]amino]carbonyl] amino]-3,4-difluorobenzenepropanamide) [Andrade-Gordon et
al, 2001; Damiano et al, 2003; Derian et al, 2003a; Zhang et al, 2003].
The aims of this study were to assess the effects of PAR-1 and thrombin-induced
platelet activation and aggregation in vitro, as well as the inhibitory effects of the
specific PAR-1 antagonist RWJ-58259, the GPIIb/IIIa inhibitor tirofiban and the
direct thrombin inhibitor lepirudin.
3.3 METHODS
3.3.1 Subjects
Peripheral venous blood was drawn from healthy, non-smoking male and female
volunteers (n=50). Participants had not been taking any regular medications, and did
not have clinically significant co-existing conditions including hypertension,
hyperlipidemia, diabetes mellitus, asthma and coagulopathy, and had not suffered a
recent infective or inflammatory condition. The study was approved by the Lothian
Research Ethics Committee, and conducted in accordance with the Declaration of
Helsinki and with the written informed consent of all volunteers.
3.3.2 Materials
*
Research grade PAR-1 agonist and GPRP were custom synthesised by Auspep,
Australia. Clinical grade SFLLRN and SLIGKV were custom synthesised by
Clinalfa, Switzerland. RWJ-58259 was custom synthesised and molecular structure
verified by mass spectral analysis and high performance liquid chromatography by
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American Peptide, USA. Lepirudin was obtained from Pharmion, UK. Tirofiban was
obtained from Merck, Sharp and Dohme, UK. CD42a-FITC and control IgGl-FITC,
and CD14-PE fluorochrome labelled monoclonal antibodies were obtained from
Serotec Ltd, Oxford, UK and Dako UK Ltd, Buckinghamshire, UK, respectively.
FACSLyse solution was from Becton Dickinson, Oxford, UK. All other salts and
reagents were from Sigma, Gillingham, UK.
Preparation ofRWJ-58259
Because of its highly lipophilic structure (logP of 6.1) [Damiano et al, 2003], the
lyophilised powder of RWJ-58259 was dissolved in DMSO to produce a 25 mM
solution. Serial dilutions in 5% dextrose were used to obtain a 0.5 and 1 mM stock of




Blood was collected from the antecubital fossa using a 19-gauge butterfly needle into
a 50 mL syringe and transferred into tubes containing 3.8% sodium citrate. The
blood was centrifuged at 130 g for 20 minutes at room temperature to obtain platelet
rich plasma and washed platelets as previously described [Crane et al, 2005], Platelet
counts were adjusted to 200-3 50 x 109/L. Platelet rich plasma was used within
2 hours of sampling. Blood was centrifuged at 1200 g for 10 minutes to obtain
platelet poor plasma for reference samples.
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Washed platelets were prepared by centrifuging platelet rich plasma at 1200 g for
10 minutes in the presence of prostacyclin (300 ng/mL) and resuspending the platelet
pellet in Hepes-Tyrodes buffer (134 mM NaCl, 12 mM NaHC03, 2.9 mM KC1, 0.34
mM Na2HP04, 1 mM MgCl2, 10 mM Hepes, 5 mM glucose; pH adjusted to 7.4),
again with prostacyclin. This was centrifuged at 1200 g for 10 minutes and
resuspended in Tyrodes buffer solution with 1 mM Ca++ added. Hepes-Tyrodes
buffer solution was used as reference control for washed platelets.
Platelet aggregometry
Platelet aggregation was measured using standard optical platelet aggregometry
[Sogo et al, 2000; Gudmundsdottir et al, 2005], Platelet rich plasma and washed
platelet samples were equilibrated at 37°C and stirred continuously. Aggregation was
monitored in a four channel aggregometer (Chronolog 470 VS, Labmedics,
Stockport, UK) linked to a MacLab 4s analogue-digital converter and Chart software
(AD instruments, Sussex, UK) or PAP-4D, Biodata Corporation, USA) linked to PC
interface software (Platelet aggregation profiler® version 2.3, Biodata Corporation;
USA). Aggregation was monitored for 5 minutes after addition of agonist alone or
for 10 minutes after addition of agonist in the presence of antagonist.
Agonists
Concentration response curves were obtained in platelet rich plasma and washed
platelets for thrombin (1 mM GPRP was added prior to thrombin to prevent fibrin
polymerisation in platelet rich plasma), the PAR-1 agonist SFLLRN, the
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thromboxane A2 agonist U46619, as well as confirming that the PAR-2 agonist
SLIGKV does not cause platelet aggregation.
PAR-1 antagonist, RWJ-58259
To assess response to the selective PAR-1 antagonist RWJ-58259, washed platelets
were incubated with the antagonist for 2 minutes prior to addition of agonist
(at EC50-70, EC100 and supramaximal concentrations: thrombin 0.2, 0.3 and 1.0 U/mL;
SFLLRN 1.8, 3.0 and 10.0 pM; and U46619 6.0 and 12 pM) and concentration
response curves obtained.
Direct thrombin inhibitor, lepirudin
The effect of thrombin on platelet aggregation was tested in the presence of the direct
thrombin inhibitor lepirudin, a recombinant hirudin analogue. Lepirudin (0.1 or
1 pg/mL [Gosselin et al, 2004] was added, with either 0.2 U/mL or 0.3 U/mL of
thrombin.
Glycoprotein Ilb/IIIa inhibitor, tirofiban
Before progressing to studies with SFLLRN infusions in vivo, we defined the dose of
the GPIIb/IIIa inhibitor tirofiban that would completely inhibit platelet aggregation
using the clinical grade preparation of SFLLRN. Platelet rich plasma was incubated
for 5 minutes in the presence or absence of tirofiban at 50 ng/mL (Dickfeld et al,




Five millilitres of venous blood were collected through a 19-gauge needle and
transferred into a tube containing the direct thrombin inhibitor, PPACK. For in vitro
studies, blood was collected into two PPACK tubes with or without tirofiban
(50 ng/mL) and incubated with clinical grade SFLLRN (0.06-6 pM). Five minutes
after sampling, 60 pL of whole blood was incubated with monoclonal antibodies
labelled with fluorochromes (IgGl-FITC and CD14-PE to label monocytes and
CD14-PE/CD42a-FITC to label platelet-monocyte aggregates) for 20 minutes before
the addition of 500 pL FACSLyse solution (Becton Dickinson). Samples were run
through a Beckman-Coulter XL2 flowcytometer, and data analysis was performed
using EXP032 (Beckman-Coulter) software [Sarma et al, 2002].
3.3.5 Statistical analysis
All results are expressed as a percentage of theoretical maximum platelet
aggregation. Results were analysed using GraphPad Prism software and expressed as
the mean±SEM. Analysis of variance was used to assess difference between groups.




Platelet aggregation to agonists
Thrombin, SFLLRN and U46619 caused concentration-dependent platelet
aggregation (EC5o=1.26 pM for SFLLRN, 0.25 U/mL for thrombin, and 0.78 pM for
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Effects ofPAR-1 antagonism
Protease-activated receptor-1 antagonism with RWJ-58259 caused a concentration-
dependent reduction in aggregation and was able to inhibit completely platelet
aggregation induced by 1.8 x 10"6 and 3 x 10"6 M SFLLRN (ICso=2.1 pM; n=8,
PO.OOl; one-way ANOVA; Figure 3.2A), see sample platelet aggregometry tracing
(Figure 3.3). In contrast, RWJ-58259 only partially inhibited thrombin-induced
platelet aggregation (n=8, P=0.003 for 0.2 U/mL thrombin; one-way ANOVA;
Figure 3.2B) and had no effect on platelet aggregation induced by the thromboxane
A2 agonist U46619 (n=8, P=NS; Figure 3.2C). Increasing the concentration ofRWJ-
58259 and thrombin did not affect the extent of the inhibition of platelet aggregation
(P=NS).
Figure 3.3. Sample platelet aggregometry tracing.
Direct thrombin inhibition
Lepirudin (1.0 and 0.1 mg/mL) completely inhibited thrombin (0.2 and 0.3 U/mL)
mediated platelet aggregation (from 68±14% and 91±5% respectively to 0%, n=6,
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PO.OOl; ANOVA) without affecting SFLLRN mediated platelet aggregation (n=6,
P=NS).
Glycoprotein Ilb/IIIa inhibition
The clinical grade SFLLRN also caused a dose-dependent increase in platelet
aggregation (ECso=0.66 pM) that was inhibited by tirofiban (Figure 3.4A; n=6,
PO.OOl; two-way ANOVA).
Figure 3.4 PAR-1 activating peptide (SFLLRN) induced (A) platelet aggregation and (B) platelet-
monocyte binding in the presence (A) or absence (□) of tirofiban (50 ng/mL). Mean±SEM. (A)
P<0.0001; two-way ANOVA, versus tirofiban (B) P=NS; two-way ANOVA, versus tirofiban.
PAR-1 - protease-activated receptor-1; SEM - standard error of the mean; NS - non-significant;
ANOVA - analysis of variance.
3.4.2 Platelet-monocyte binding
Protease-activated receptor-1 activation with clinical grade SFLLRN caused a dose-
dependent increase in whole blood platelet-monocyte binding (EC5o=0.23 pM), that
in contrast to platelet aggregation, was not affected by tirofiban (Figure 3.4B; n=6,
P=NS; two-way ANOVA).
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As anticipated, PAR-2 activation with SLIGKV induced neither platelet aggregation
nor platelet-monocyte binding (n>3; data not shown) at concentrations up to 3 mM.
3.5 DISCUSSION
Inhibition of platelet activation has been of major benefit in the prevention and
treatment of cardiovascular diseases. Thrombin is one of the most potent
physiological stimulants of platelet activation that appears to be mediated largely
through the PAR-1 receptor although significant contributions are also provided by
PAR-4 and GPIb receptors. To date, strategies to reduce the action of thrombin have
focused on direct inhibition of its enzymatic activity. Recently, PAR-1 antagonists
have been developed as potential antiplatelet agents [Chackalamannil et al, 2008]
that do not affect the coagulation cascade. It is therefore important to define the in
vitro and in vivo effects of PAR-1 agonism in man. As anticipated, we have
demonstrated that PAR-1, but not PAR-2, agonism caused concentration-dependent
platelet activation and aggregation. Moreover, in the presence of complete inhibition
of platelet aggregation with the GPIIb/IIIa receptor antagonist tirofiban, PAR-1
agonism continued to induce platelet activation as measured by platelet-monocyte
binding both in vitro and in vivo. This is consistent with previous findings that whilst
GPIIb/IIIa receptor antagonism inhibits platelet aggregation, it does not affect
platelet activation or platelet-monocyte binding [Sarma et al, 2002],
We have confirmed that the effects of the PAR-1 activating peptide SFLLRN are
fully and selectively inhibited by the PAR-1 antagonist RWJ-58259. Whereas PAR-1
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antagonism only partially inhibited the actions of thrombin, the direct thrombin
inhibitor lepirudin abolished thrombin-induced platelet aggregation, consistent with
its anticipated pharmacological effects.
The IC50 concentration of RWJ-58259 for PAR-1 agonist mediated platelet
aggregation is similar to that reported by Damiano et al [2003], indicating the
validity and efficacy of our preparation of this compound. Thrombin mediated
aggregation was however only partly inhibited by RWJ-58259 and this was not
augmented with increasing concentrations of the antagonist nor reduced by
increasing concentrations of thrombin. This suggests that thrombin-induced platelet
aggregation is, in part, mediated by non-PAR-1 mediated pathways.
Specific PAR-1 antagonists represent a potentially important novel and efficacious
antithrombotic therapy in patients with cardiovascular diseases. Previous studies
[Damiano et al, 2003; Derian et al, 2003a; Zhang et al, 2003] have indicated that
RWJ-58259 is a potent inhibitor of both PAR-1 agonist and thrombin mediated
platelet aggregation. However, there is limited specific information about the nature
and extent of inhibition of thrombin mediated platelet aggregation by RWJ-58259
[Damiano et al, 2003; Derian et al, 2003a; Zhang et al, 2003]. A partial inhibitory
effect on thrombin-induced platelet aggregation does not appear to be limited to
RWJ-58259 with other PAR-1 antagonists including BMS-200261 [Bernatowicz et
al, 1996] and SCH79797 [Ahn et al, 2000] demonstrating partial inhibitory actions
on thrombin-induced aggregation [Chackalamannil et al, 2003],
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Taken together, the findings with lepirudin and RWJ-58259, suggest the presence of
an alternative platelet receptor for thrombin. PAR-4 receptors are present on human
platelets and platelet aggregation can be induced with high concentrations (1 mM) of
the human PAR-4 agonists GYPGQV [Andersen et al, 1999; Soslau et al, 2001]. In
our studies, the PAR-4 agonist GYPGKV did not induce human platelet aggregation
at concentrations up to 3 mM and PAR-4 activation is, in our opinion, unlikely to
solely account for the PAR-1 independent platelet aggregation induced by thrombin.
Other known PARs, PAR-2 and PAR-3 receptors are not expressed on human
platelets [Ossovskaya and Bunnett, 2004], A potential candidate is the GPIb receptor
which is present on human platelets and can be activated by thrombin [Soslau et al,
2001],
In conclusion, we have demonstrated that the PAR-1 agonist SFLLRN causes
concentration-dependent platelet activation and aggregation that can be selectively
inhibited with the PAR-1 antagonist RWJ-58259. Thrombin-induced platelet
aggregation is fully inhibited by the direct thrombin inhibitor lepirudin but only
partially by RWJ-58259. We have furthermore demonstrated, in preparation for
subsequent in vivo studies, that PAR-1 induced platelet aggregation, but not platelet
activation can be inhibited by the glycoprotein Ilb/IIIa inhibitor tirofiban.
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CHAPTER 4
DIRECT VASCULAR EFFECTS OF
PROTEASE-ACTIVATED RECEPTOR-1 AGONISM
IN VIVO IN HUMANS
Gudmundsdottir IJ, Megson L, Kell JS,
Ludlam CA, Fox KAAA, Webb DJ, Newby DE.
Direct vascular effects of protease-activated receptor type 1
agonism in vivo in humans.
Circulation 2006;114:1625-1632.
4.1 SUMMARY
Protease-activated receptor-1 has been proposed as the principal thrombin receptor in
man although its actions in vivo have not been defined. The aim of the study was to
determine the direct vascular actions of PAR-1 agonism in man. Dorsal hand vein
diameter was measured by the Aellig technique in fourteen healthy volunteers during
local intravenous SFLLRN (PAR-1 agonist; 0.05-15 nmol/min) and SLIGKV (PAR-
2 agonist; 1.6-160 nmol/min) infusions. The venous effects of SFLLRN were further
assessed in the presence or absence of norepinephrine or the GPIIb/IIIa antagonist
tirofiban in the arterial circulation. Forearm blood flow was measured by venous
occlusion plethysmography in sixteen volunteers during infusion of SFLLRN (1-50
nmol/min), SLIGKV (160-800 nmol/min) and the endothelium-dependent
vasodilator, bradykinin (100-1000 pmol/min). Platelet-monocyte binding (a sensitive
measure of platelet activation), t-PA, PAI-1 and vWF concentrations were measured
at intervals throughout the study.
Protease-activated receptor-1 activation with SFLLRN caused dose-dependent
venoconstriction (P<0.001) that was unaffected by norepinephrine or tirofiban co-
infusion. In forearm resistance vessels, SFLLRN increased forearm blood flow
(P0.001), t-PA release (P<0.001) and platelet-monocyte binding (PO.OOOl)
without affecting plasma PAI-1 or vWF concentrations. Protease-activated receptor-2
activation with SLIGKV caused venous (PO.OOl) and arterial (PO.Ol) dilatation
without t-PA release.
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We have, for the first time, demonstrated that PAR-1 agonism causes platelet
activation, venous constriction, arterial dilatation and t-PA release in vivo in man.
These unique and contrasting effects provide important insights into the
physiological and pathophysiological role of thrombin in the human venous and
arterial circulations.
4.2 INTRODUCTION
Thrombin is a powerful physiological stimulant in the cardiovascular system. Apart
from its central enzymatic role in the coagulation cascade, it directly activates
platelets, leukocytes, and vascular smooth muscle and endothelial cells [Patterson et
al, 2001], Thrombin is therefore a vital link between thrombosis, cellular activation
and inflammation; key pathogenic factors in atherothrombotic disorders.
Given the apparent direct cellular effects of thrombin expression, cloning methods
[Rasmussen et al, 1991; Vu et al, 1991] were employed to conduct an extensive
search for its receptor. This led to the identification of G-protein coupled PARs that
are characterised by a unique mechanism of activation whereby proteolytic cleavage
unmasks a short peptide sequence that remains tethered and activates the receptor
[Vu, 1991; Swift et al, 2006]. Four different types of PARs have been identified:
PAR-1, -3 and -4 are all activated by thrombin. The type 1 receptor has been
proposed as the principal thrombin receptor in man [Coughlin 2000; Coughlin,
2005]. In contrast, the PAR-2 receptor is activated by trypsin, tryptase and to a lesser
extent by coagulation factors upstream of thrombin [Hollenberg and Compton,
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2002]. It appears to be of importance in inflammatory conditions that induce
endothelial PAR-2 expression and vasodilatation.
Protease-activated receptor-1 agonism has been extensively studied in vitro and is
associated with platelet activation and aggregation [Chung et al, 2002],
vasodilatation [Kawabata et al, 2004] and angiogenesis [Griffin et al, 2001],
Although studies in small animals suggest that PAR-1 and PAR-2 agonism induces
vasodilatation [Damiano et al, 1996; Cheung et al, 1998], there is significant species
heterogeneity and rodent models are of limited relevance to man [Kinlough-
Rathbone et al, 1993], Exploring the role of PAR-1 receptors in the human
vasculature would deepen our understanding of the physiological role of thrombin
and be of interest in the development of new therapeutic strategies, such as PAR-1
receptor antagonists [Damiano et al, 2003; Chackalamannil et al, 2005] and direct
thrombin inhibitors [Ebrahimi et al, 2005; Serruys et al, 2006].
The aims of the present study were therefore to determine for the first time, the direct
in vivo vascular effects of PAR-1 agonism in the human vasculature. Specifically, we
wished to assess the direct role of PAR-1 activation on venous and arterial tone,
platelet activation and the release of endothelium-derived factors in vivo in man and




Thirty healthy non-smokers (aged 21-32 years) were recruited into the study (Table
4.1). Participants had not been taking any regular medications, over the counter
medications, herbal supplements or vitamins. They did not have clinically significant
co-existing conditions including hypertension, hyperlipidaemia, diabetes mellitus,
asthma and coagulopathy, and had not suffered a recent infective or inflammatory
condition. The study was approved by the Lothian Research Ethics Committee, and
conducted in accordance with the Declaration of Helsinki and with the written
informed consent of all volunteers.
TABLE 4.1 Baseline characteristics of study volunteers. Mean± SEM





White Cell Count (x 109/L) 4.98±0.37
Platelet Count (x 109/L) 213±11
SEM - standard error of the mean.
All studies were carried out in a quiet, temperature controlled room (22-24°C).
Participants were semi-recumbent (venous studies) or supine (arterial studies) and
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had abstained from alcohol for 24 hours, and from food and caffeine-containing
drinks for at least 4 hours prior to the study.
4.3.2 Drugs
SFLLRN, SLIGKV, bradykinin (Clinalfa, Laufelfingen, Switzerland),
norepinephrine and tirofiban were all administered following dissolution in 0.9%
saline. All solutions were freshly prepared on the day of the study.
4.3.3 Venous studies
A 23-gauge butterfly needle was sited in a dorsal hand vein in the direction of flow
and total infusion rate kept constant at 0.25 mL/min in all studies. The hand was
supported above the level of the heart and an upper arm cuff inflated to 40 rnmHg to
obstruct venous return. The internal diameter of the dorsal hand vein was measured
by the Aellig technique [Aellig, 1981]. A magnetised lightweight rod rested on the
summit of the infused vein approximately 1 cm downstream from the tip of the
infusion needle. The rod passes through a core of a LVDT, supported above the hand
by a small tripod. Changes in diameter of the vein cause vertical displacement of the
rod, leading to a linear change in the voltage generated by the LVDT. This enables
calculation of absolute changes in vein size.
Protocol 1: Effect on venous tone
Because dorsal hand veins do not have resting tone, norepinephrine (1-128 ng/min)
was used to induce and maintain a 50-70% reduction in vein diameter throughout the
study to allow detection of either venodilatation or venoconstriction. This was
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followed by co-infusion of the PAR-1 activating peptide SFLLRN (0.05-5 nmol/min)
or the PAR-2 activating peptide SLIGKV (1.6-160 nmol/min).
Protocol 2: Effect ofglycoprotein Ilb/IIIa receptor antagonism
The effects of SFLLRN (0.05-15 nmol/min) in the presence and absence of the
GPIIb/IIIa inhibitor, tirofiban (250 ng/min), and norepinephrine (1-128 ng/min) were
assessed to determine the importance of platelet aggregation on PAR-1 mediated
alterations of venous tone. The doses of tirofiban and SFLLRN were chosen to
achieve end-organ concentrations equivalent to those with efficacy in in vitro studies
(Chapter 3) and assumed a dorsal hand vein flow of 5 mL/min.
4.3.4 Arterial studies
All subjects underwent brachial artery cannulation with a 27-standard wire gauge
steel needle under controlled conditions. Intra-arterial infusion rate was kept constant
at 1 mL/min throughout all studies. Forearm blood flow was measured in the infused
and non-infused arms by venous occlusion plethysmography using mercury-in-
silastic strain gauges as described previously [Newby et al, 1997a; Newby et al,
1999]. Supine heart rate and blood pressure were monitored at intervals throughout
each study using a semi-automated non-invasive oscillometric sphygmomanometer.
Tirofiban (1.25 pg/min) was co-infused during PAR-1 activation to inhibit in vivo
*
potential platelet aggregation. The doses of tirofiban and SFLLRN were chosen to
achieve end-organ concentrations equivalent to those with efficacy in in vitro studies
using the clinical grade preparation of SFLLRN and the dose of tirofiban that
completely inhibited platelet aggregation in vitro (Chapter 3) and assumed a brachial
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artery blood flow of 25 mL/min. Pilot studies were also carried out starting with
much lower intra-arterial doses (0.05 nmol/min) that produced no vascular effects.
Blood sampling
Seventeen-gauge venous cannulae were inserted bilaterally into the antecubital
fossae. Blood samples were drawn simultaneously from each arm during infusion of
saline, tirofiban and each dose of the PAR activating peptides and bradykinin. They
were collected into acidified buffered citrate (Stabilyte, Biopool International, UK;
fort-PA assays) and into citrate (Becton Dickinson Vacutainer, BD UK Ltd, UK; for
PAI-1 and vWF assays). Samples were kept on ice before centrifugation at 2000 g for
30 minutes at 4°C. Platelet-free plasma was decanted and stored at -80°C before
assay. Plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit;
Technoclone, Austria) and PAI-1 antigen and activity (Elitest-PAI-1 Antigen and
Zymutest PAI-1 Activity; Hyphen Biomed, France) concentrations were determined
by enzyme-linked immunosorbant assays. Full blood count was measured at baseline
and at the end of the study.
Platelet-monocyte binding
Blood was also collected from each arm for determination of levels of platelet-
monocyte binding in vivo; at baseline, the highest dose of SFLLRN, during saline
washout and at the highest dose of bradykinin. Five millilitres of venous blood were
collected and transferred into a tube containing the direct thrombin inhibitor,
PPACK. Five minutes after sampling, blood was incubated with appropriate
monoclonal antibodies labelled with fluorochromes for 20 minutes and platelet-
87
monocyte aggregates measured as described previously in Chapter 3 [Harding et al,
2004],
Protocol 3: PAR-1 activation
Following a 20-minute baseline saline infusion, tirofiban (1.25 pg/min) was infused
throughout the study. Thirty minutes from the commencement of the tirofiban
infusion, the PAR-1 activating peptide SFLLRN was co-infused at 5, 15 and
50 nmol/min for 8 minutes at each dose separated by 6-minute saline washout
infusions. This was followed by a 30-minute washout period before co-infusion of
bradykinin (an endothelium-dependent vasodilator that releases t-PA; Clinalfa,
Switzerland) at 100, 300, and 1000 pmol/min [Witherow et al, 2002] for 8 minutes at
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Figure 4.1 Schematic view of study Protocol 3.
Protocol 4: PAR-2 activation
Following a 20-minute baseline saline infusion, the PAR-2 activating peptide
SLIGKV was infused at 160, 360 and 800 nmol/min for 8 minutes at each dose
separated by 6-minute saline washout infusions, and followed by a 30 minute saline
infusion before infusing bradykinin at 100, 300 and 1000 pmol/min [Witherow et al,
2002] for 8 minutes at each dose.
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4.3.5 Data analysis and statistics
Dorsal hand venous [Haynes et al, 1995] and forearm plethysmographic [Newby et
al, 1997a] data were analysed as described previously. Variables are reported as
means±SEM and analysed using repeated measures one- or two-way ANOVA with
post-hoc Bonferroni corrections and two-tailed Students /-test as appropriate.
Statistical analysis was performed with GraphPad Prism (Graph Pad Software) and
statistical significance taken at P<0.05.
4.4 RESULTS
4.4.1 In vivo effects of par agonism on dorsal hand veins
After venoconstriction (50-70%) was induced and maintained with norepinephrine,
SFLLRN and SLIKGV caused dose-dependent venoconstriction (n=8, PO.OOl; one¬
way ANOVA) and venodilatation (n=6, PO.OOl; one-way ANOVA) respectively. In
the absence of norepinephrine, SFLLRN caused a dose-dependent venoconstriction
(PO.OOl; one-way ANOVA) that was able to induce complete constriction of the
venous segment. This was not mediated by platelet aggregation since co-infusion of
tirofiban had no effect on SFLLRN-induced venoconstriction (Figure 4.2). SFLLRN
was well tolerated by all subjects with no adverse effects. Vein patency was
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Figure 4.2 The PAR-1 activating peptide SFLLRN causes concentration-dependent venoconstriction
(■, n=6-8, P<0.001; one-way ANOVA) that is unaffected by norepinephrine (A and B) or tirofiban (C
and D) infusion, whereas the PAR-2 activating peptide SLIGKV (E) induces venodilatation (□, n=6,
P<0.001; one-way ANOVA). Mean±SEM. *P<0.05, **P<0.01, ***P<0.001.
PAR - protease-activated receptor; ANOVA - analysis of variance; SEM - standard error of the mean.
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4.4.2 In vivo effects of par agonism on forearm resistance vessel tone
There was no change in heart rate, blood pressure or non-infused forearm blood flow
throughout either study. Intra-arterial tirofiban had no effect on resting forearm blood
flow (P=NS). Both PAR-1 activation with SFLLRN and PAR-2 activation with
SLIGKV caused dose-dependent vasodilatation (Figure 4.3A and 4.3C; n=8,
PO.OOl and PO.Ol respectively; one-way ANOVA) with a rapid onset and offset of
action. As anticipated, bradykinin increased forearm blood flow (Figure 4.3B;
PO.OOl; one-way ANOVA) and was unaffected by tirofiban co-infusion
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Figure 4.3 Forearm vasodilatation induced by the PAR-1 activating peptide SFLLRN (A; ■. n=8,
P<0.001; one-way ANOVA), the PAR-2 activating peptide SLIGKV (C; □, n=8, PO.Ol; one-way
ANOVA), and bradykinin (B;* and D;o, n=8, PO.OOl; one-way ANOVA). Mean±SEM. *PO.05,
**PO.01, ***P0.001.
PAR - protease-activated receptor; ANOVA - analysis of variance.
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4.4.3 In vivo effects of par agonism on endothelium-derived factors
Plasma t-PA antigen and activity concentrations increased in a dose-dependent
manner during SFLLRN and bradykinin, but not SLIKGV infusion (Figure 4.4;
PO.OOl for all). Plasma PAI-1 antigen and activity, and vWF concentrations were
unaffected by all infusions (P=NS for all; Table 4.2). Although there was an apparent
rise in plasma PAI-1 antigen concentration at 50 nmol/min of SFLLRN, this did not
achieve statistical significance (P=0.08, paired t-test versus baseline) and was not
associated with increases in PAI-1 activity or vWF. There were no differences in
peripheral blood haematocrit (0.416±0.006 versus 0.426±0.008) or platelet counts
(213±16 x 109 versus 216±15 x 109 /L) at baseline and the end of the study. The
PAR-2 activating peptide, SLIKGV had no effect on plasma t-PA concentrations
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Figure 4.4 Plasma t-PA antigen (solid lines) and activity (dashed lines) during infusion of the PAR-1
activating peptide SFLLRN (■) and bradykinin (•). Mean±SEM.
t-PA - tissue plasminogen activator; PAR-1 - protease-activated receptor-i; SEM - standard error of
the mean.
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TABLE4.2PlasmaI-1(plasminogenctivatorinhibitortyp1)ntigedctivity,vonWille r dF (vWF)antigenconcentrationsithnfusedn n- fusedrmsd i gbr chialr ryi iofSFLLRN bradykinin(n=8forall).Mean±SEMst darderrorfthem an) Baseline Tirofiban SFLLRN 5nmol/min 15nmol/min 50nmol/min Washout Bradykinin 100pmol/min 300pmol/min 1000pmol/minPAI-1Antigen(ng/mL) InfusedNon-Infused ArmPAI-1Activity(U/mL) InfusedNon-Infused Arm
vWFAntigen(ng/mL) InfusedNon-Infused Armr
27.3±5.5 25.6±5.5 23.0±4.7 24.3±4.5 33.8±6.8 22.9±4.2 19.6±3.7 19.5±4.4 19.5±3.2
27.7±5.6 24.5±4.4 24.9±4.4 23.8±4.4 26.9±5.3 23.1±3.6 21.3±3.9 19.5±4.9 19.1±2.9
0.58±0.14 0.40±0.09 0.44±0.12 0.41±0.10 0.37±0.09 0.32±0.08 0.27±0.07 0.25±0.06 0.16±0.03
0.51±0.13 0.43±0.12 0.47±0.11 0.41±0.11 0.42±0.09 0.33±0.08 0.35±0.09 0.26±0.07 0.25±0.05
0.72±0.08 0.69±0.04 0.62±0.06 0.67±0.06 0.73±0.08 0.67±0.09 0.80±0.08 0.73±0.08 0.76±0.07
0.72±0.07 0.62±0.08 0.67±0.08 0.74±0.10 0.76±0.08 0.74±0.09 0.64±0.09 0.70±0.07 0.67±0.07
4.4.4 In vivo effects of par agonism on platelet activation
In keeping with results of previous in vitro studies, SFLLRN increased in vivo
platelet-monocyte binding (from 16±5% to peak of 74±5%; Figure 4.5; PO.OOOl;




50 nmol/min 1000 pmol/min
Figure 4.5 Platelet-monocyte binding during the infusion of the PAR-1 agonist SFLLRN in the
infused (open bars) and non-infused (grey bars) arms. Mean±SEM.
PAR-1 - protease-activated receptor-1; SEM - standard error of the mean.
4.5 DISCUSSION
In a series of clinical studies we have, for the first time, described the direct vascular
effects of PAR-1 agonism and established the induction of in vivo platelet activation,
venoconstriction, vasodilatation and t-PA release as well as confirming the
vasodilatory effects of PAR-2 agonism. These unique and contrasting effects of
PAR-1 activation provide important insights into the physiological and
pathophysiological role of thrombin in the venous and arterial circulations ofman.
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4.5.1 VASCULAR EFFECTS OF PAR ACTIVATING PEPTIDES
Protease-activated receptor-1 appears to be the principal receptor responsible for the
vascular actions of thrombin and includes the regulation of vasomotion, platelet
aggregation, inflammation and angiogenesis. Investigation of the in vivo vascular
effects of thrombin itself presents challenges because of the direct activation of the
coagulation cascade and platelets that may result in intravascular thrombosis. We
have here, chosen to use PAR activating peptides that cause direct cellular
stimulation without enzymatic activation of the coagulation cascade.
The direct vascular effects of PAR-1 receptor agonism have not been previously
reported in man. Our study protocol was vigilant to minimise any potential
prothrombotic effects associated with PAR-1 induced platelet aggregation. We
defined the in vitro concentrations of GPIIb/IIIa receptor antagonism that would
permit the direct in vivo intravascular infusion of PAR-1 activating peptide without
inducing platelet aggregation and potential thrombosis. This appears to have been
successfully achieved given the absence of significant adverse clinical side-effects or
thrombosis.
Venous effects ofPAR activating peptides
Thrombin, and the PAR-1 agonist SFLLRN, have previously been shown to cause
endothelium- and NO-dependent venous and arterial dilatation in canine and porcine
ring segments [Ku and Zaleski, 1993; Tesfamariam et al, 1993]. Although
confirming previous observations of PAR-2 mediated venodilatation [Robin et al,
2003], we have rather unexpectedly described a dose-dependent venoconstriction
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with PAR-1 activation. This may be mediated by platelet activation, release of
endothelium-derived vasoconstrictors or a direct effect on venous smooth muscle
cells. Neither norepinephrine nor tirofiban co-infusion appeared to affect this potent
venoconstrictor effect. In combination with the apparent absence of in situ
thrombosis, this suggests that PAR-1 induced venoconstriction was not mediated by
platelet aggregation although we cannot preclude an effect of platelet activation.
Arterial effects ofPAR activating peptides
In contrast to the venous effects, both PAR-1 and PAR-2 activation caused dose-
dependent vasodilatation of forearm resistance vessels. We have not assessed the
mechanism of this vasodilatation but vasomotor studies, and animal and clinical
models suggest that this is likely to be endothelium- and NO-dependent [Yang et al
1994; Cheung et al, 1998; Robin et al, 2003]. However, data from animal studies
have limited relevance in man because of the wide species variability in PAR-1
receptor expression and function. The mechanism of PAR-1 induced vasodilatation
needs to be addressed in future clinical studies.
Protease-activated receptor expression varies between endothelial cell cultures
originating from different human blood vessels [Fujiwara et al, 2004] and this may
partly explain the contrasting responses between PAR-1 and PAR-2 in the arterial
*
and venous circulations. Our findings that PAR-2 activation causes venous and
arterial dilatation are consistent with previous findings [Robin et al, 2003], and
supports the vascular role ofPAR-2 receptors in inflammatory conditions.
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4.5.2 Effects of par activating peptides on endothelium-derived factors
Intra-arterial PAR-1, but not PAR-2, agonism caused an acute dose-dependent
increase in local endothelial t-PA release. In contrast to in vitro human endothelial
culture studies [Cleator et al, 2005], this occurred in the absence of the release of
other endothelium-derived factors, such as PAI-1 and vWF. However, there was an
apparent rise in plasma PAI-1 antigen (P=0.08) with high dose PAR-1 agonism, but
given the absence of an effect on PAI-1 activity and vWF, this may reflect the
associated platelet activation and release of platelet-derived PAI-1. Plasminogen
activator inhibitor type 1 is stored in platelet a-granules where its activity is ~5% of
plasma due to the absence of the stabilising effect of vitronectin. Thus, PAR-1
agonism appears to have a selective pro-fibrinolytic effect on the arterial
endothelium.
4.5.3 Effects of par activating peptides on platelet activation
Inhibition of platelet activation has been of major benefit in the prevention and
treatment of cardiovascular diseases. Thrombin is one of the most potent
physiological stimulants of platelet activation that appears to be mediated largely
through the PAR-1 receptor although major contributions are also provided by PAR-
4 and GPIb receptors. To date, strategies to reduce the action of thrombin have
focused on direct inhibition of its enzymatic activity. Recently, PAR-1 antagonists
have been developed as potential antiplatelet agents [Chackalamannil et al, 2005]
that do not affect the coagulation cascade. It is therefore important to define the
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in vitro and in vivo effects of PAR-1 agonism in man. As anticipated, we have
demonstrated that PAR-1, but not PAR-2, agonism caused concentration-dependent
platelet activation and aggregation. Moreover, in the presence of complete inhibition
of platelet aggregation with the GPIIb/IIIa receptor antagonist tirofiban, PAR-1
agonism continued to induce platelet activation as measured by platelet-monocyte
binding both in vitro and in vivo. This is consistent with our previous findings that
whilst GPIIb/IIIa receptor antagonism inhibits platelet aggregation, it does not affect
platelet activation or platelet-monocyte binding [Sarma et al, 2002], The stimulatory
effects of PAR-1 activation have previously been studies in vitro but here we
demonstrate that PAR-1 activation in vivo causes marked platelet activation as
measured by levels of platelet-monocyte binding. To enable us to carry out this
study, tirofiban was infused throughout to inhibit the formation of platelet aggregates
and prevent intra-arterial thrombosis, and doses based on previous in vitro studies.
4.5.4 Physiological significance of vascular par-i activation
We have, for the first time, described the unexpected and contrasting vascular effects
of PAR-1 agonism in vivo in man. How do we interpret these effects? In an intact
normal vessel, homeostatic mechanisms attempt to maintain vessel patency and
minimise intravascular thrombus formation. Dorsal hand veins do not have resting
tone and the induction of venodilatation will not affect venous blood flow. Therefore
in the presence of developing venous thrombosis, venodilatation would not be
beneficial whereas venoconstriction will potentially limit thrombus propagation and
embolisation. In contrast, in the arterial circulation, it would be anticipated that
increasing blood flow and endogenous fibrinolysis would limit arterial thrombosis by
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ensuring rapid clearance and dissolution of a developing thrombus. We therefore
propose that the vascular effects of PAR-1 agonism in vivo in man can be understood
in terms of limiting intravascular thrombosis and maintaining vessel patency. We
speculate that these physiological effects may be disturbed in patients with
cardiovascular disease or prothrombotic disorders.
We conclude that PAR-1 agonism causes platelet activation, venoconstriction,
vasodilatation and t-PA release in vivo in man. This has important implications in
understanding the physiological vascular effects of thrombin as well as the
pathogenesis of thromboembolic and atherothrombotic disorders.
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CHAPTER 5
ROLE OF THE ENDOTHELIUM IN THE VASCULAR EFFECTS
OF THE PROTEASE-ACTIVATED RECEPTOR-1 IN HUMANS
Gudmundsdottir IL, Lang NN, Boon NA,
Ludlam CA, Webb DJ, Fox KA, Newby DE.
Role of the endothelium in the vascular effects of the thrombin receptor
(protease-activated receptor type 1) in humans.
JAm Coll Cardiol 2008;51:1749-1756.
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5.1 SUMMARY
Thrombin is central to the pathophysiology of atherothrombosis. Its cellular actions
are mediated via PAR-1. Protease-activated receptor-1 activation causes arterial
vasodilatation, venoconstriction, platelet activation and t-PA release in man. The aim
of this study was to determine the role of the endothelium in the vascular actions of
PAR-1 activation in vivo in man. Dorsal hand vein diameter was measured during
infusion of the PAR-1 activating peptide SFLLRN in six healthy volunteers before
and after endothelial denudation. Forearm arterial blood flow, plasma fibrinolytic
factors and platelet activation were measured in twenty-four healthy volunteers
during venous occlusion plethysmography. The effects of inhibition of prostacyclin,
NO and EDHF on PAR-1 responses were assessed during co-administration of
aspirin, the 'nitric oxide clamp' L-NMMA and sodium nitroprusside, and TEA
respectively. Endothelial denudation did not affect PAR-1 evoked venoconstriction
(SFLLRN; 0.05-15 nmol/min). Although aspirin had no effect, SFLLRN-induced
vasodilatation (5-50 nmol/min) was attenuated by the 'nitric oxide clamp'
(P<0.0001) and TEA (P<0.05), and abolished by their combination (PO.Ol). The
'nitric oxide clamp' augmented SFLLRN-induced t-PA and PAI-1 antigen
(P<0.0001) release whilst TEA and aspirin had no effect. SFLLRN-induced platelet
activation was unaffected by NO or prostacyclin inhibition. We conclude that acting
via PAR-1, thrombin causes contrasting effects in the human vasculature and has a
major interaction with the endothelium. This highlights the critical importance of
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endothelial function during acute arterial injury and intravascular thrombosis, as
occurs in cardiovascular events including myocardial infarction and stroke.
5.2 INTRODUCTION
Thrombin plays a central role in the coagulation cascade and thrombosis [Patterson
et al, 2001]. It is one of the most powerful physiological agonists in the
cardiovascular system and its actions are fundamental to the processes of
atherosclerosis and its thrombotic consequences.
In addition to the enzymatic generation of fibrin, thrombin stimulates a range of cell
types including platelets, endothelium and vascular smooth muscle cells. An
extensive search for thrombin receptors ultimately culminated in the identification of
a group of G-protein coupled receptors termed protease-activated receptors. These
receptors are characterised by a unique mechanism of activation whereby the
receptor undergoes proteolytic cleavage, unmasking a short peptide sequence that
remains tethered and auto-activates the receptor [Vu et al, 1991; Swift et al, 2006],
To date, four different types of PARs have been identified: PAR-1, -3 and -4 are all
activated by thrombin. PAR-2 is mainly activated by trypsin but transactivation of
PAR-2 by cleaved PAR-1 has been recognised [O'Brien et al, 2000; Hollenberg and
*
Compton, 2002],
Protease-activated receptors-1 are the principal thrombin receptors in man and have
been extensively studied in small animals and cell cultures suggesting a diverse and
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important role in various organs. Their activation stimulates a network of G-protein
coupled signalling pathways that involve phospholipase CP, protein kinase C,
calcium release, MAP kinases and potassium channels [Osssovskaya and Bunnett,
2004; Coughlin, 2006]. However, there is significant species heterogeneity with pre¬
clinical studies of limited relevance to man [Kinlough-Rathbone et al, 1993].
Exploring the role of PAR-1 receptors in the human vasculature, and the mechanisms
involved, would deepen our understanding of the physiological role of thrombin and
be important in the clinical development of new therapeutic strategies.
To understand the physiological actions of thrombin in the human vasculature is
challenging because direct thrombin instillation has the potential to cause acute
thrombosis in situ and hence vascular occlusion. The use of a PAR-1 activating
peptide, however, permits the direct assessment of cellular responses to thrombin
without the enzymatic activation of the coagulation cascade and fibrin formation.
Using the short peptide mimetic SFLLRN, we have recently described the in vivo
effects of PAR-1 activation in platelets, endothelium and vascular smooth muscle in
man. For the first time, we were able to show that PAR-1 activation has unique and
contrasting effects in the human vasculature including arterial dilatation, venous
constriction, platelet activation and t-PA release [GuQmundsdottir et al, 2006], Given
the central role of thrombin in the pathophysiology of cardiovascular disease, it is
important to establish the mechanisms of these PAR-1 mediated effects and, in
particular, the role of the endothelium. We therefore set out to explore the role of the




Thirty healthy non-smokers (mean age 22 years; range 19-37 years) were recruited
into the study. The study was approved by the Lothian Research Ethics Committee
and conducted in accordance with the Declaration of Helsinki and with the written
informed consent of all volunteers. Participants were screened and excluded for
clinically significant conditions including hypertension, hyperlipidaemia, diabetes
mellitus, asthma and coagulopathy. No participant had suffered a recent infective or
inflammatory condition or had taken any medications in the 7 days prior to the
study.
All studies were carried out in a quiet, temperature controlled room (22-24°C).
Participants were semi-recumbent (venous studies) or supine (arterial studies) and
had abstained from alcohol for 24 hours, and from food and caffeine-containing
drinks for at least 4 hours prior to the study.
5.3.2 Drugs
Custom synthesised clinical grade SFLLRN, bradykinin and L-NMMA and TEA
were purchased from Clinalfa, Laufelfmgen, Switzerland. Acetylcholine was from
Novartis Pharmaceuticals UK Ltd, Frimley, UK, sodium nitroprusside from David
Bull Laboratories, Faulding, UK, norepinephrine from Abbott Laboratories,
Maidenhead, UK, and tirofiban from Merck, Sharp and Dohme, Hoddesdon, UK.
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Infused drugs were all administered following dissolution in 0.9% saline. All
solutions were freshly prepared on the day of the study.
5.3.3 Venous studies
A 23-gauge needle was sited in a dorsal hand vein and total infusion rate kept
constant at 0.25 mL/min in all studies. The hand was supported above the level of the
heart and an upper arm cuff inflated to 40 mmHg to obstruct venous return. The
internal diameter of the dorsal hand vein was measured by the Aellig technique
[Aellig, 1981] in six healthy volunteers. In brief, a magnetised lightweight rod rested
on the summit of the infused vein approximately 1 cm downstream from the tip of
the infusion needle. The rod passes through the core of a LVDT, supported above the
hand by a small tripod. Changes in diameter of the vein cause vertical displacement
of the rod, leading to a linear change in the voltage generated by the transformer.
This enables calculation of absolute changes in vein size.
Protocol 1: Venous effects ofPAR-1 activation
First we established the presence of functional endothelium. As dorsal hand veins do
not have resting tone, norepinephrine (1-128 ng/min) was used to induce 70%
reduction in vein diameter. Once stable venoconstriction was obtained, acetylcholine
(1 nmol/min; Novartis Pharmaceuticals UK Ltd, Frimley, UK) was co-infused with
norepinephrine for 8 minutes to demonstrate endothelium-dependent venodilatation
and an intact, functional endothelium. Following a 20-minute saline infusion, the
PAR-1 activating peptide, SFLLRN (0.05-15 nmol/min; Clinalfa, Switzerland), was
administered intravenously before a final 20-minute saline washout infusion.
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Protocol 2: Venous effects ofPAR-1 activation following endothelial denudation
At the end of Protocol 1, the endothelium of the venous segment was denuded as
previously described [Sogo et al, 2000b], In brief, a second 23-gauge butterfly needle
was sited in the opposite direction, 3-4 cm downstream from the tip of the infusion
needle, and this segment of the vein isolated by the use of occlusion wedges.
Distilled water was infused through the venous segment at a rate of 5 mL/min for
15 minutes, thereby causing endothelial denudation that persists for at least 2 days
[Sogo et al, 2000b], Aspirin (300 mg orally), was given 30 minutes prior to start of
the first study, and on each of the two subsequent days to prevent venous thrombosis.
On the second day following denudation, subjects re-attended and Protocol 1 was
repeated.
5.3.4 Arterial studies
All subjects underwent cannulation of the brachial artery with a 27-gauge standard
wire steel needle under controlled conditions. The intra-arterial infusion rate was
kept constant at 1 mL/min throughout all studies. Forearm blood flow was measured
in the infused and non-infused arms by venous occlusion plethysmography using
mercury-in-silastic strain gauges as described previously [Newby et al, 1997a;
Newby et al, 1999], Supine heart rate and blood pressure were monitored at intervals
throughout each study using a semi-automated non-invasive oscillometric
sphygmomanometer. Tirofiban (1.25 pg/min) was co-infused during the studies to
inhibit potential PAR-1 activation induced platelet aggregation in vivo
[GuSmundsdottir et al, 2006]. This dose of tirofiban does not affect
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platelet-monocyte binding, forearm blood flow or baseline concentration of t-PA
[GuSmundsdottir et al, 2006].
Protocol 3: Role ofnitric oxide andprostacyclin in PAR-1 induced vasodilatation
Forearm blood flow was measured by venous occlusion plethysmography in
response to brachial artery infusion of SFLLRN (PAR-1 agonist; 5-50 nmol/min)
with tirofiban (1.25 pg/min) in eight healthy volunteers on four visits using a
randomised controlled cross-over study employing a two-by-two factorial design:
with and without aspirin (600 mg orally; to inhibit prostacyclin synthesis) and the
'nitric oxide clamp'. Assuming total forearm blood flow of 25 mL/min, this will
achieve end-organ concentrations of 0.2-2.0 pM SFLLRN.
The 'nitric oxide clamp' was used to determine the contribution of NO in PAR-1
mediated vascular effects. Following baseline intra-arterial tirofiban infusion, the
NO synthase inhibitor, L-NMMA (8 pmol/min), was co-infused. To compensate for
L-NMMA induced basal vasoconstriction, forearm blood flow was returned to
baseline using a titrated dose of exogenous NO in the form of intra-brachial sodium
nitroprusside (90-900 ng/min). This dose of sodium nitroprusside was co-infused
with L-NMMA and continued throughout the study. This arrangement allows a
constant 'clamped' delivery of exogenous NO whilst endogenous NO synthase
activity is inhibited.
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Protocol 4: Role of calcium-activated potassium channels/EDHF in PAR-1
induced vasodilatation
Forearm blood flow was measured in a further eight healthy volunteers in whom
intrabrachial SFLLRN (5-50 nmol/min), bradykinin (30-300 pmol/min) and sodium
nitroprusside (2-8 pg/min) were co-infused with either saline placebo or TEA
(1 mg/min) on either of two visits using a randomised double blind cross-over
design. Again, agonists were co-infused with intra-arterial tirofxban (1.25 pg/min),
which was continued throughout the study. At the dose used, TEA is a non-selective
potassium channel antagonist [Champion et al, 1997; Honing et al, 2000; Inokuchi et
al, 2004],
Protocol 5: Role of endothelium-dependent vasodilators in PAR-1 induced
vasodilatation
In the final series of studies, TEA or saline placebo was co-infused with ascending
doses of bradykinin and SFLLRN in eight volunteers using a randomised double
blind cross-over design. In this series, EDHF activity was isolated by inhibiting NO
and prostacyclin production on both visits. The 'nitric oxide clamp' was employed as
described above {Protocol 3), and cyclooxygenase activity was inhibited with a
single 600 mg dose of oral aspirin 1 hour prior to each study.
*
Blood sampling
Seventeen-gauge venous cannulae were inserted into left and right antecubital
fossae. Blood samples were drawn simultaneously from each arm at baseline. Blood
samples were also drawn before SFLLRN or bradykinin infusion and after each dose
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of SFLLRN or bradykinin. Blood was collected into acidified buffered citrate
(Stabilyte, Biopool International, UK; for t-PA assays) and into citrate (Becton
Dickinson Vacutainer, BD UK Ltd, UK; for PAI-1, p-thromboglobulin and vWF
assays). Samples were kept on ice before centrifugation at 2000 g for 30 minutes at
4°C. Platelet-free plasma was decanted and stored at -80°C before assay. Plasma
t-PA antigen and activity (t-PA Combi Actibind Elisa Kit; Technoclone, Austria),
PAI-1 antigen and activity (Elitest-PAI-1 Antigen and Zymutest PAI-1 Activity;
Hyphen Biomed, France), P-thromboglobulin (Asserachrom Btg, Diagnostica Stago,
France) and vWF (Dako, Glostrup, Denmark) concentrations were determined by
enzyme-linked immunosorbant assays. Full blood count was measured at baseline
and at the end of the study.
Platelet-monocyte binding
In Protocols 3 and 4, blood was collected from each arm for determination of
platelet-monocyte binding at baseline and after the highest dose of SFLLRN. Five
millilitres of venous blood were collected and transferred into a tube
containing the direct thrombin inhibitor, PPACK. Five minutes after sampling, blood
was incubated with appropriate monoclonal antibodies labelled with fluorochromes
for 20 minutes and platelet-monocyte aggregates measured as described previously
[Harding et al, 2004],
5.3.5 Data analysis and statistics
Dorsal hand venous [Haynes et al, 1995] and forearm plethysmographic [Newby et
al, 1997a] data were analysed as described previously. Variables are reported as
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means±SEM and analysed using repeated measures ANOVA with post-hoc
Bonferroni corrections and two-tailed Students t-test as appropriate. Statistical
analysis was performed with GraphPad Prism (Graph Pad Software) and statistical
significance taken at the 5% level.
5.4 RESULTS
5.4.1 Endothelium and par-1 induced venoconstriction
The role of the endothelium in PAR-1 induced vasomotor effects was assessed by
comparing venous responses before and after local endothelial denudation. This was
achieved through brief instillation of distilled water in an isolated dorsal hand vein
segment. The dorsal hand vein was pre-constricted with norepinephrine to achieve
approximately 70% constriction (35±4% before denudation, 33±7% on the second
visit), the dose of norepinephrine required to achieve this constriction appeared
slightly higher on the second visit although not statistically significant (6±2 versus
13±6 ng/min, P=0.2), which is in keeping with previous publications [Sogo et al,
2000b], After pre-constriction with norepinephrine, the presence or absence of
functional endothelium was confirmed by the co-infusion of acetylcholine
(1 nmol/min). Acetylcholine caused venodilatation in the presence of endothelium
and venoconstriction in its absence (Figure 5.1; from 35±4% to 55±7% in the
presence of endothelium versus 33±7% to 18±6% in the absence of endothelium;
P<0.01 for both; ANOVA). After endothelial denudation, there appeared to be a
trend toward enhanced venoconstriction induced by the PAR-1 activating peptide,
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Figure 5.1 Dorsal hand vein responses to acetylcholine and SFLLRN (after pre-constriction with
norepinephrine). Before (solid triangles) and after (open triangles) endothelial denudation. *P<0.05
and NS=non-significant (P=0.09); presence versus absence of the endothelium (ANOVA).
ANOVA - analysis of variance.
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5.4.2 Endothelium-derived vasodilators and par-1 induced
vasodilatation
SFLLRN caused an increase in forearm blood flow that was unaffected by
prostacyclin inhibition with oral aspirin (600 mg; Figure 5.2A). The NO synthase
inhibitor, L-NMMA, caused -50% decrease in basal forearm blood flow (from
3.04+0.37 to 1.49±0.19 mL/100mL tissue/min; P0.001). Intra-brachial sodium
nitroprusside (90-900 ng/min), an exogenous NO donor, was titrated to restore
forearm blood flow back to baseline levels (2.77±0.24 mL/100mL tissue/min; P=0.46
clamp dose sodium nitroprusside versus baseline; paired Student's /-test). The
inhibition of endogenous NO synthesis by the 'nitric oxide clamp' attenuated
SFLLRN-induced vasodilatation (Figure 5.2B).
Potassium channel antagonism with TEA (1 mg/min) did not affect baseline blood
flow (P=0.76; data not shown). It attenuated vasodilatation to SFLLRN (Figure 5.2C)
whilst the combination of prostacyclin, NO synthase and potassium channel
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Figure 5.2 SFLLRN-induced forearm arterial vasodilatation. In the presence (closed symbols) and
absence (open symbols) of A) aspirin (squares); NS=non-significant (P=0.53) in the presence versus the
absence of aspirin; analysis of variance (ANOVA), B) the 'nitric oxide (NO) clamp' (circles); *P<0.0001
in the presence versus the absence of the 'NO clamp' (ANOVA), C) tetraethylammonium (TEA)
(triangles); tP<0.05 in the presence versus the absence ofTEA (ANOVA), and D) aspirin, the 'NO clamp'
and TEA (diamonds).
#P<0.01 in the presence versus the absence of aspirin, the 'NO clamp' and TEA (ANOVA).
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Both with and without concurrent NO synthase and prostacyclin synthase inhibition,
TEA attenuated, but did not abolish arterial vasodilatation to the control
endothelium-dependent vasodilator, bradykinin. (Figure 5.3A and 5.3B).
Tetraethylammonium did not affect endothelium-independent forearm arterial
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Figure 5.3 Bradykinin- and sodium nitroprusside-induced forearm arterial vasodilatation. Forearm
arterial vasodilatation induced by (A) bradykinin (squares), (B) bradykinin in the presence of the
'nitric oxide clamp' and aspirin (circles) and (C) sodium nitroprusside (diamonds), in the presence
(solid symbols) and absence (open symbols) of tetraethylammonium (TEA). *P<0.05, tP=0.0001,
NS=non-significant (P=0.41) in the presence versus the absence ofTEA (ANOVA).
ANOVA - analysis of variance.
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5.4.3 Endothelium-derived vasodilators and par-1 induced release of
fibrinolytic and coagulant factors
SFLLRN increased net t-PA antigen and activity and PAI-1 antigen release but did
not affect net PAI-1 activity (Figure 5.4). This increase was augmented by the 'nitric
oxide clamp' (Figure 5.4) but not affected by aspirin or TEA (data not shown; P=NS;
ANOVA). Bradykinin caused a dose-dependent increase in net t-PA antigen (P<0.05;
ANOVA) and activity (PO.OOOl; ANOVA) release but did not affect PAI-1 antigen
and activity release (P=NS for both; ANOVA). Tetraethylammonium did not alter
bradykinin-induced PAI-1 or t-PA release. Neither bradykinin nor SFLLRN affected
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Figure 5.4 SFLLRN-induced tissue plasminogen activator and plasminogen activator inhibitor
release. Net tissue plasminogen activator (t-PA; squares) and plasminogen activator inhibitor type 1
(PAI-1; circles) antigen (solid lines) and activity (dashed lines) in response to intra-brachial SFLLRN
in the presence (solid symbols) and absence (open symbols) of the 'nitric oxide (NO) clamp'.
*P<0.0001, NS=non-significant (P=0.075) in the presence versus the absence of the 'NO clamp'
(ANOVA).
ANOVA - analysis of variance.
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5.4.4 Endothelium-derived vasodilators and par-1 induced platelet
activation
SFLLRN increased platelet-monocyte binding but this was unaffected by inhibition
of NO or prostacyclin (Table 5.1). In contrast, SFLLRN increased
P-thromboglobulin (PO.OOl; ANOVA) that was augmented during the 'nitric oxide
clamp' (PO.Ol; ANOVA; Figure 5.5) but unaffected by aspirin (P=NS; ANOVA).
TABLE 5.1 Per cent platelet-monocyte binding at baseline and after intrabrachial
SFLLRN (50 nmol/min) in the infused and non-infused forearm in the presence and
absence of aspirin and the 'nitric oxide clamp'. *P<0.001 versus baseline (ANOVA)
Per cent platelet-monocyte binding
Baseline Post SFLLRN
InfusedArm Non-Infused arm InfusedArm Non-InfusedArm
Placebo 16.62+4.38 12.48+1.61 75.89+5.09* 41.36+6.86*
Aspirin only 14.43+1.95 14.87+3.61 72.07+5.41* 49.67+7.82*
NO clamp
only
11.84+1.52 16.95+3.23 81.21+5.68* 46.42+7.42*
Aspirin +
NO clamp
12.19+1.66 14.15+2.02 82.85+5.57* 46.63+6.48*




























Figure 5.5 SFLLRN-induced 13-thromboglobulin release. In the presence (closed circles) and absence
(open circles) of the 'nitric oxide (NO) clamp'. *P<0.01 net ^-thromboglobulin release induced by




Thrombin is one of the most powerful physiological agonists in the cardiovascular
system and its actions are fundamental to the processes of atherothrombosis. In a
series of studies, we have described here the contrasting role of the endothelium in
the PAR-1 mediated vascular actions of thrombin in vivo in man. Whilst not
providing a major contribution to venoconstriction or PAI-1 release, the endothelium
mediates PAR-1 induced arterial vasodilatation and t-PA release. Our findings
provide clear evidence of a major interaction between the vascular endothelium and
thrombin in vivo in man. Furthermore, it highlights the critical importance of
endothelial function at the time of acute arterial injury and intravascular thrombosis,
such as during acute coronary syndromes.
5.5.1 Role of the endothelium in par-i induced vasomotion
We have previously described the unexpected finding of PAR-1 induced
venoconstriction in man [GuQmundsdottir et al, 2006], Whilst not caused by platelet
aggregation [GuQmundsdottir et al, 2006], this effect could be mediated by either a
direct action on vascular smooth muscle or via the release of endothelium-derived
vasoconstrictors, such as endothelin or angiotensin II. To address this question, we
assessed PAR-1 venoconstriction before and after endothelial denudation by
*
instillation of distilled water. There was a modest trend towards enhanced
venoconstriction after endothelial denudation and we cannot exclude a small
contribution from the endothelium that may also include the release of venodilatory
mediators such as nitric oxide. However, PAR-1 continued to induce a marked
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dose-dependent venoconstriction even in the absence of the endothelium suggesting
a dominant and direct effect ofPAR-1 on the vascular smooth muscle cells.
In contrast to effects on the venous circulation, PAR-1 agonism causes potent arterial
vasodilatation. This suggests a different effect on the arterial vasculature that is likely
to be mediated by the endothelium. It would be difficult and ethically challenging to
conduct comparable in vivo endothelial denudation studies in the arterial circulation
of man. We chose, therefore, to use a pharmacological approach to the inhibition of
the three main known mediators of endothelium-dependent vasodilatation:
prostacyclin, NO and EDHF. Although prostacyclin inhibition appeared to have no
effect, inhibition ofNO and potassium channels both attenuated the PAR-1 induced
vasodilatation. Consistent with some cross-talk and compensatory up-regulation,
combined inhibition of all vasodilator mechanisms appeared to produce greater
inhibition, if not abolition, of the vasodilator actions of PAR-1 agonism. This
suggests that, unlike the venous circulation, PAR-1 mediated arterial actions are
dominated by, and dependent upon, the vascular endothelium.
5.5.2 PAR-1 INDUCED RELEASE OF ENDOTHELIUM-DERIVED FACTORS
In addition to vasomotion, PAR-1 has important effects on the release of
endothelium-derived coagulant and fibrinolytic factors. In keeping with a wide range
of other endothelial G-protein coupled receptor dilator agonists [Oliver et al, 2005],
we confirmed our earlier findings that PAR-1 agonism causes endothelial t-PA
release without affecting vWF. Flowever, we also report here that SFLLRN-induced
t-PA release appeared to be augmented by the inhibition of endogenous NO
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production. Smith et al [2003] have reported similar findings when they examined
bradykinin evoked t-PA release in the presence and absence of L-NMMA. Because
t-PA release is independent of NO and cyclooxygenase activity, it has been
suggested that EDHF is responsible for its release [Brown et al, 2000], One could
speculate that, by inhibiting NO activity, EDHF is up-regulated and accounts for the
augmented t-PA release induced by SFLLRN in our study and by bradykinin in
Smith's study [Smith et al, 2003]. However, in contrast to TEAs inhibitory effects on
SFLLRN-induced arterial vasodilatation, it had no effect on SFLLRN evoked t-PA
release. Similar findings have recently been reported by Muldowney and colleagues
[2007] who examined the role of EDHF in an in vitro model of thrombin-induced
endothelial t-PA release in their study. A variety of potassium channel antagonists,
including TEA, had no effect on thrombin-induced t-PA release whilst antagonists of
specific EETs appeared to inhibit thrombin-induced release of t-PA.
One further novel finding in our study was the increase in PAI-1 release, especially
during NO synthase inhibition. To date, there have been no reports of acute increases
in plasma PAI-1 concentrations following the administration of endothelial agonists,
especially using the forearm model [Oliver et al 2005], Whilst the endothelium is an
important source of PAI-1, we believe our findings are consistent with acute platelet
release of PAI-1. There are several reasons to support our contention. First, although
PAI-1 antigen concentrations increased, there was no corresponding rise in PAI-1
activity. Indeed, PAI-1 activity fell during marked release of t-PA. Plasminogen
activator inhibitor type 1 is stored in platelet a-granules where its activity is very low
(<5% of the activity seen in plasma) due to the absence of the stabilising effect of
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vitronectin. In contrast, endothelial-derived PAI-1 would be anticipated to remain
active. Second, there was no concurrent rise in vWF confirming a selective effect on
the endothelium with isolated t-PA release. Third, we also demonstrated concomitant
platelet activation with marked increases in platelet-monocyte binding and release of
[3 thromboglobulin; the latter is also stored in the a-granules of platelet. Finally,
PAR-1 induced PAI-1 release was augmented during the 'nitric oxide clamp'. Nitric
oxide has important antiplatelet effects and, in the presence of its inhibition,
increased platelet activation may have led to greater PAI-1 release.
5.5.3 Clinical relevance
Until recently, it has not been possible to undertake a safe clinical assessment of the
vasomotor effects of thrombin due to its potent stimulatory effects upon the
coagulation cascade. However, the synthetic activating peptide, SFLLRN, allows the
examination of activation of the human PAR-1 thrombin receptor without activation
of the coagulation cascade. This also permits the assessment of PAR-1 actions
independent of the potential confounding effects that the activated coagulation
pathway may have upon vascular responses.
We have demonstrated that many of the arterial effects of PAR-1 agonism are
dependent upon, and mediated through, the endothelium and can therefore be used to
assess endothelial function. To date, many endothelial G-protein coupled receptor
agonists have been used to assess endothelial function, such as acetylcholine and
substance P. However, such agents are unlikely to have a major role in vascular
physiology or pathophysiology and, as pharmacological tools, their relevance to the
125
assessment of endothelial vasomotor function has limitations. As a more
physiologically relevant tool, PAR-1 agonism may be a more appropriate method of
assessing endothelial function in the context of atherothrombosis. These novel
insights into the vascular actions of PAR-1 agonism will not only contribute to our
understanding of human physiology and pathophysiology but also promises to
inform the clinical development of novel antithrombotic PAR-1 receptor antagonists.
5.5.4 Study limitations
We chose to use SFLLRN as a PAR-1 agonism for several reasons. First, the vast
majority of published work has employed SFLLRN as a PAR-1 activating peptide
and its actions have been widely characterised. Second, we have previous clinical
experience of the in vivo actions of SFLLRN and this has facilitated the
comparability of our current findings with our previous 'first-into-man' clinical
studies. Finally, SFLLRN is identical to the active cleaved sequence of the human
PAR-1 receptor and represents a more physiologically relevant agonist of the
receptor.
Whilst SFLLRN is selective for the PAR-1 receptor, it does have agonist activity at
the PAR-2 receptor: 4-fold greater selectivity for the PAR-1 versus PAR-2 receptor
[Kawabata et al, 1999]. Therefore, there remains a possibility that a contribution of
the observed actions of SFLLRN may represent PAR-2 agonism. However, we do
not believe this is likely for several reasons. First, we have previously shown that
SLIGKV, a highly selective PAR-2 activating peptide, causes only modest arterial
vasodilatation at high doses and, in contrast to PAR-1 activation, causes marked
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venodilatation and does not cause arterial t-PA release in vivo [GuQmundsdottir et al,
2004], Moreover, the predicted end-organ concentration of the highest dose of
SFLLRN used in our current and previous studies is 4-fold lower than the EC50 for
the PAR-2 receptor [Kawabata et al, 1999]. However, we do accept that, in future
studies, consideration should be given to the use of the more selective PAR-1
activating peptide, TFLLRN [Kawabata et al, 1999; Osssovskaya and Bunnett,
2004],
5.5.5 Conclusions
Activation of PAR-1 causes contrasting effects in the human vasculature. It causes
endothelium-dependent arterial vasodilatation and t-PA release as well as
endothelium-independent venoconstriction and PAI-1 release. There appears to be a
major interaction between the vascular endothelium and thrombin's PAR-1 mediated
effects in vivo in man. This highlights the critical importance of endothelial function
particularly at the time of acute arterial injury and intravascular thrombosis, such as




THE EFFECTS OF PROTEASE-ACTIVATED RECEPTOR-1
ACTIVATION ON VASCULAR RESPONSES
AND FIBRINOLYSIS IN SMOKERS
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6.1 SUMMARY
Cigarette smoking is associated with increased risk of atherothrombosis and impaired
endogenous fibrinolysis. Activation of the thrombin receptor PAR-1 causes
endothelium-dependent arterial vasodilatation and release of endogenous fibrinolytic
factors. The aims of this study were to test the hypothesis that cigarette smoking
adversely alters PAR-1 mediated vascular effects in vivo in man. Forearm blood flow
was measured by venous occlusion plethysmography in twelve cigarette smokers and
twelve age- and sex-matched non-smokers during intrabrachial infusions of PAR-1
activating peptide (SFLLRN; 5-50 nmol/min), bradykinin (100-1000 pmol/min) and
sodium nitroprusside (2-8 pg/min). Plasma tissue plasminogen activator and PAI-1
antigen and activity concentrations were measured at regular intervals throughout. All
agonists caused dose-dependent increases in forearm blood flow (P0.0001 for all).
Whilst bradykinin and sodium nitroprusside caused similar vasodilatation, SFLLRN-
induced vasodilatation was attenuated in smokers (P=0.04). Smokers had modest
reductions in bradykinin-induced active t-PA release (reduced by 37%, P=0.03) and had
a marked impairment of SFLLRN-induced t-PA antigen (P=0.02) and activity
(P=0.006) release, with a 96% reduction in overall net t-PA antigen release. SFLLRN
also caused similar (P=NS) increases in inactive PAI-1 in both cigarette smokers and
non-smokers (P<0.002 for both). We conclude that cigarette smoking causes marked
impairment of PAR-1 mediated endothelial vasomotor and fibrinolytic function.
Relative arterial stasis and near abolition of t-PA release will strongly promote clot
propagation and vessel occlusion. The impairment of these protective homeostatic
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responses suggests a major contribution of impaired endothelial PAR-1 action to the
increased incidence ofmyocardial infarction and stroke in cigarette smokers.
6.2 INTRODUCTION
Smoking tobacco remains one of the most important and consistent modifiable risk
factors for myocardial infarction and fatal coronary artery disease [Ambrose and Barua,
2004], The INTERHEART study revealed that smoking tobacco increases the risk of
non-fatal myocardial infarction by up to 7-fold [Teo et al, 2006]. The
pathophysiological mechanisms underlying this association are likely to be a
combination of accelerated atherosclerosis [Zieske et al, 2005] and a propensity to acute
coronary thrombosis [Burke et al, 1997; Ambrose and Barua, 2004].
The endogenous fibrinolytic system is responsible for the dissolution of arterial thrombi
that are frequently found on the surface of atherosclerotic plaques at areas of endothelial
denudation [Davies et al, 1988; Oliver et al, 2006], It is regulated by the pro-fibrinolytic
factor, t-PA, and its endogenous inhibitor, PAI-1 [Jansson et al, 1993; Meade et al,
1993; Nordenhem et al, 2005], The rapid mobilisation of t-PA from the endothelium is
crucial, with thrombus dissolution being much more effective if t-PA is incorporated
during, rather than after, thrombus formation [Fox et al, 1985]. Indeed, acute stimulated
t-PA release predicts the future risk of cardiovascular events [Robinson et al, 2007],
Thrombin plays a central role in the coagulation cascade and thrombosis. It is one of the
most powerful physiological agonists in the cardiovascular system and its actions are
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fundamental to the processes of atherothrombosis. Distinct from its enzymatic role in
the coagulation cascade, thrombin causes direct cellular activation through stimulation
of a novel family of G-protein coupled receptors, protease-activated receptors
[Coughlin, 2000]. These receptors have a unique mechanism of activation whereby
agonist-induced proteolytic cleavage of the extracellular domain reveals a short peptide
sequence that remains tethered and causes auto-activation of the receptor. To date, four
different types of PARs have been identified: PAR-1, -3 and -4 are all activated by
thrombin whilst PAR-2 is mainly activated by trypsin [Hollenberg and Compton, 2002].
Protease-activated receptor-1 is the principal receptor that mediates the cardiovascular
actions of thrombin. The hexapeptide, SFLLRN, represents the short peptide sequence
revealed during PAR-1 activation and can be used as a selective agonist of the human
PAR-1 thrombin receptor without activation of the coagulation cascade. Using
SFLLRN, we have previously described the in vivo effects of PAR-1 activation in
platelets, endothelium and vascular smooth muscle in man. For the first time, it was
demonstrated that thrombin has unique and contrasting effects in the human vasculature
including arterial dilatation, venous constriction, platelet activation and t-PA release
[GuSmundsdottir et al, 2006].
We, and others, have previously reported that pharmacological stimulation of acute
t-PA release in the peripheral [Newby et al, 1999; Pretorius et al, 2002] and coronary
[Newby et al, 2001; Takashima et al, 2007] arterial circulations is markedly attenuated
in smokers. In this study the hypothesis is that smokers have impaired PAR-1 mediated
vascular responses. We have therefore, examined PAR-1 mediated t-PA release and
131




Twelve healthy cigarette smokers (5-20 cigarettes/day) and twelve age- and sex-
matched non-smokers between 20 and 46 years old participated in the study, which was
undertaken with the approval of the Lothian Research Ethics Committee and in
accordance with the Declaration of Helsinki. The written informed consent of each
subject was obtained before entry into the study. Exclusion criteria included a history of
asthma, hypertension, diabetes mellitus, coagulopathy, hyperlipidaemia or vascular
disease. Control subjects were lifelong non-smokers and were not exposed to regular
environmental tobacco smoke. Smokers had a history of regular daily cigarette smoking
of at least 5 years and maintained their normal smoking habits in the week before
attendance.
None of the subjects received vasoactive or nonsteroidal anti-inflammatory drugs in the
week before the study, and all abstained from alcohol for 24 hours before and from
food, tobacco, and caffeine-containing drinks on the day of the study. All studies were
performed in a quiet, temperature controlled room maintained at 22-24°C.
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6.3.2 Drugs
Custom synthesised clinical grade SFLLRN and bradykinin were purchased from
Clinalfa, Laufelfingen, Switzerland. Sodium nitroprusside from David Bull
Laboratories, Faulding, UK, and tirofiban from Merck, Sharp and Dohme, Ffoddesdon,
UK. Infused drugs were all administered following dissolution in 0.9% saline. All
solutions were freshly prepared on the day of the study.
6.3.3 Study design
All subjects underwent brachial artery cannulation with a 27 standard-wire-gauge steel
needle. The intra-arterial infusion rate was kept constant at 1 mL/min throughout all
studies. Forearm blood flow was measured in the infused and non-infused arms by
venous occlusion plethysmography using mercury-in-silastic strain gauges as described
previously [Newby et al, 1997a; Newby et al, 1999], Supine heart rate and blood
pressure were monitored at intervals throughout each study using a semi-automated
non-invasive oscillometric sphygmomanometer.
After a 20-minute intra-arterial infusion of 0.9% saline, the GPIIb/IIIa antagonist,
tirofiban (1.25 pg/min), was infused and continued throughout the study to inhibit
potential PAR-1 induced platelet aggregation. This dose of tirofiban does not affect
forearm blood flow [GuSmundsdottir et al, 2006].
During tirofiban administration, subjects received intra-arterial infusions of the PAR-1
activating peptide, SFLLRN (5, 15 and 50 nmol/min), bradykinin (an endothelium-
dependent vasodilator that causes the release of t-PA; 100, 300 and 1000 pmol/min) and
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sodium nitroprusside (an endothelium-independent vasodilator that does not
release t-PA; 2, 4 and 8 pg/min). Study drugs were infused in random order for
10 minutes at each dose and were separated by a 20-minute infusion of 0.9% saline.
Blood sampling
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the
antecubital fossae of both arms. Blood samples were drawn simultaneously from each
arm at the beginning of the study and during infusion of each dose of PAR-1 activating
peptide (SFLLRN), bradykinin and sodium nitroprusside. Venous blood was collected
into acidified buffered citrate (Stabilyte, Trinity Biotech Pic, Co. Wicklow, Ireland; for
t-PA assays) and into citrate (Becton and Dickinson Vacutainer, BD UK Ltd, Oxford,
UK; for PAI-1 and vWF assays). Samples were kept on ice before centrifugation at
2000 g for 30 minutes at 4°C. Platelet-free plasma was decanted and stored at 80°C
before assay. Plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit;
Technoclone, Vienna, Austria), PAI-1 antigen and activity (Elitest PAI-1 antigen and
Zymutest PAI-1 Activity; Hyphen Biomed, Neuville-Sur-Oise, France) and vWF
antigen (Dako A/S, Glostrup, Denmark) concentrations were determined by enzyme-
linked immunosorbant assays. Full blood count and haematocrit were measured at
baseline and the end of the study.
6.3.4 Data analysis and statistics
Forearm plethysmographic data were analysed as described previously [Newby el al,
1997a], Estimated net release of plasma t-PA, PA-1 and vWF has been defined
previously as the product of the infused forearm plasma flow (based on the mean
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haematocrit and the infused forearm blood flow) and the concentration difference
between the infused and non-infused arms [Newby et al, 1997b], Variables are reported
as mean±SEM and analysed using repeated measures ANOVA with post-hoc
Bonferroni corrections and two-tailed Students t-test as appropriate. Statistical analysis
was performed with GraphPad Prism (Graph Pad Software) and statistical significance
taken at the 5% level.
6.4 RESULTS
There were no differences in baseline characteristics between cigarette smokers and
non-smokers (Table 6.1). There were no changes in blood pressure, heart rate or
haematocrit (data not shown) during the study. Smokers had a mean cigarette
consumption of 15±1 cigarettes per day over a mean period of 9±2 years (7±2 pack
years).
6.4.1 Forearm blood flow
Tirofiban did not affect forearm blood flow (data not shown). Intra-arterial sodium
nitroprusside, bradykinin and the PAR-1 activating peptide, SFLLRN, all caused dose-
dependent vasodilatation in the infused arm of smokers and non-smokers (PO.OOOl for
all; ANOVA). There were no changes in blood flow in the non-infused arm (data not
shown).
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TABLE 6.1 Baseline subject characteristics
Non-smokers Smokers
Age (y) 26±2 29±2
Sex (M/F) 12/0 12/0
Body mass index (kg/m2) 24±1 27±1
Mean arterial pressure (mm Hg) 97+2 99±2
Heart rate (bpm) 66±2 64+7
Baseline haematocrit 0.42±0.01 0.42±0.01
Although there was no difference with bradykinin (P=0.64; ANOVA smokers versus
non-smokers), vasodilatation to SFLLRN was attenuated in smokers (P=0.044;
ANOVA smokers versus non-smokers). Endothelium-independent vasodilatation
evoked by sodium nitroprusside was similar in both groups (P=0.74; ANOVA smokers
versus non-smokers; Figure 6.1).
6.4.2 Plasma fibrinolytic and haemostatic factors
Baseline plasma t-PA antigen and activity (Table 6.2) and vWF antigen (Table 6.3)
concentrations were similar in smokers and non-smokers. There appeared to be a trend
towards higher absolute plasma PAI-1 antigen and activity concentrations in smokers
but this difference did not reach statistical significance (smokers versus non-smokers:
PAI-1 antigen, P=0.07 and P=0.10, and PAI-1 activity, P=0.18 and P=0.24; infused and
non-infused arms respectively; Table 6.4).
SFLLRN caused a dose-dependent net release of t-PA antigen in non-smokers
(P<0.0005; ANOVA) but not smokers (P=0.18; ANOVA; Figure 6.2). In comparison to
non-smokers, the release of t-PA antigen and activity by SFLLRN was markedly
attenuated in smokers (P=0.02 and P=0.006, respectively; ANOVA). However,
SFLLRN induced a dose-dependent net release of PAI-1 antigen release in both non-
smokers (P=0.0002; ANOVA) and smokers (P=0.001; ANOVA). The response was
similar in both groups (P=0.36; ANOVA) and was associated with no change in net
PAI-1 activity (P=NS for all; ANOVA [data not shown]) or vWF antigen release
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Figure 6.1 Forearm arterial vasodilatation in smokers and non-smokers. Forearm arterial
vasodilatation induced by SFLLRN (squares), bradykinin (circles) sodium nitroprusside (triangles) in
smokers (closed symbols) and non-smokers (open symbols). *P<0.05, NS=non-significant; analysis of
variance (ANOVA), smokers versus non-smokers.
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One-way analysis of variance (ANOVA) for dose response, P=NS for all; two-way ANOVA, P=NS
for all, smokers versus non-smokers.
Bradykinin - BK; Non-significiant - NS.
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Figure 6.2 Net release of tissue plasminogen activator (t-PA) in smokers and non-smokers. Net
t-PA antigen (circles) and activity (squares) release induced by SFLLRN (top panels) and bradykinin
(bottom panels) in smokers (closed symbols) and non-smokers (open symbols). *P<0.05, tP=0.005,
NS=non-significant; analysis of variance (ANOVA), smokers versus non-smokers.
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Bradykinin caused a dose-dependent net release of t-PA antigen and activity in both
smokers and non-smokers (PO.Ol for all; ANOVA). Bradykinin also evoked a dose-
dependent increase in absolute t-PA activity in the non-infused arm of both non-
smokers (PO.OOOl; ANOVA) and smokers (P=0.008; ANOVA). Net release of t-PA
activity induced by bradykinin was less in smokers than non-smokers (P=0.032,
smokers versus non-smokers; ANOVA; Figure 6.2). Bradykinin caused no change in
net PAI-1 antigen or activity and did not affect vWF antigen in either group (P=0.91,
non-smokers; P=0.98, non-smokers; ANOVA). As expected [Brown et al, 1999]
sodium nitroprusside caused no change in absolute or net release of t-PA, PAI-1 or vWf
(data not shown).
6.5 DISCUSSION
Here it has been demonstrated that thrombin mediated vascular responses are markedly
impaired in cigarette smokers with a substantial reduction in PAR-1 mediated
endothelial t-PA release and forearm arterial vasodilatation. This impaired vasomotor
and fibrinolytic response may represent an important shift in the fine balance between
intravascular thrombosis and fibrinolysis that could account for the increased incidence
of atherothrombosis in cigarette smokers.
6.5.1 Smoking and par-i induced arterial vasomotion
As reported by others [Pretorius et al, 2002], no effect of smoking status on
endothelium-dependent vasodilatation to bradykinin or endothelium-independent
vasodilatation to sodium nitroprusside was observed. One of the important novel
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observations from this study is that vasodilatation evoked via PAR-1 is impaired in
smokers, especially at the higher doses of SFLLRN. Because homeostatic mechanisms
attempt to maintain vessel patency and minimise intravascular thrombus formation in
healthy arteries, we have previously hypothesised that the arterial vasodilatation to
PAR-1 activation represents a protective feedback mechanism. In the presence of a
developing thrombus, PAR-1 mediated vasodilatation will increase blood flow to limit
arterial thrombosis by facilitating its rapid clearance and dissolution [GuQmundsdottir et
al, 2006]. Thus, this specific impairment of PAR-1 induced vasodilatation may have
major pathophysiological consequences during acute thrombotic events such as
myocardial infarction.
6.5.2 Smoking and par i induced release of endothelium-derived factors
Over and above diminished vasomotion, the major finding of this study was the almost
complete abolition of PAR-1 mediated t-PA antigen release in cigarette smokers.
Furthermore, PAR-1 activation caused only a very modest rise in t-PA activity despite
causing substantial t-PA antigen and activity release in non-smokers.
The current findings confirm previous studies from our own and other groups reporting
reduced t-PA release in cigarette smokers [Newby et al, 1999; Pretorius el al, 2002;
Takashima et al, 2007], Although not seen with t-PA antigen, the present finding of
reduced bradykinin-induced active t-PA release is consistent with similar observations
previously reported by Pretorius et al [2002]. Flowever, the magnitude of the reduction
in t-PA release is substantially greater for PAR-1 evoked responses than it is for
bradykinin or substance P (96% versus 40-50%) [Newby et al, 1999;
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Pretorius et al, 2002], It is therefore possible that SFLLRN evoked t-PA release may be
a more sensitive and pathophysiological^ relevant assessment of endothelial vasomotor
and fibrinolytic function.
Of note, PAR-1 activation also caused the release of PAI-1 antigen but did not cause an
appreciable rise in PAI-1 activity and neither indices were altered by smoking status.
This rise in PAI-1 antigen without a change in activity suggests that SFLLRN is
releasing PAI-1 from platelets rather than the endothelium since platelet-derived PAI-1
is relatively inactive due to the absence of the stabilising effects of vitronectin [Seiffert
et al, 1994; Pretorius et al, 2002]. Furthermore, our recent work has demonstrated a
concomitant rise in p-thromboglobulin suggesting degranulation of platelet alpha
granules [GuQmundsdottir et al, 2008], Therefore, the contribution of the endogenous
fibrinolytic system to the prothrombotic state found in cigarette smokers is likely to be
driven by impaired endothelial t-PA release and not by alterations in PAI-1 release or
activity.
6.5.3 Par-i activation as a pathophysiologically relevant marker of
endothelial function
Previous studies to assess the endothelial release of endogenous fibrinolytic factors have
employed diverse methods. Historical means of stimulating t-PA release have included
systemic intravenous infusion of desmopressin and bradykinin but this causes
significant confounding effects by altering systemic haemodynamics, activation of the
sympathetic nervous system and concomitant release of other mediators [Oliver et al,
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2005]. By assessing the regional release of t-PA and PAI-1 in response to locally acting
agonists, such confounding effects are avoided.
Our group has previously demonstrated that substance P-induced t-PA release in the
peripheral [Newby et al, 1999] and coronary [Newby et al, 2001] circulations is
impaired in cigarette smokers, and predicts future adverse cardiovascular events in
patients with coronary heart disease [Robinson et al, 2007], However, whilst substance
P has been a useful pharmacologic tool, it is unclear whether substance P is likely to act
as a major pathophysiological mediator in atherothrombosis. In contrast, bradykinin
may have a more direct role since it is released during the contact phase of coagulation
and there is enhanced activation of the kallikrein system and bradykinin release in
patients with acute coronary syndromes [Hoffmeister et al, 1995], However, it can be
argued that, given its central role in thrombosis and inflammation, thrombin is the most
powerful and pathophysiologically relevant mediator in this setting. These present
findings not only reinforce previous findings but give the clearest indication yet that
impaired endothelial function is of critical and dynamic importance in the setting of
coronary heart disease and acute coronary syndromes.
6.5.4 Smoking and endothelium-dependent mechanisms
Protease-activated receptor-1 appears to mediate arterial vasodilatation via two
endothelium-dependent mechanisms, NO and EDHF [GuSmundsdottir et al, 2008]. The
pathways via which PAR-1 activation causes the endothelial release of t-PA are less
clear and, in fact, inhibition ofNO synthesis causes augmented SFLLRN-induced t-PA
release [GuSmundsdottir et al, 2008]. This has raised the question as to whether EDHF
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is responsible for t-PA release and, in the absence of NO, EDHF responses undergo a
compensatory up-regulation. Whilst the bulk of evidence suggests that smoking
predominantly affects endothelial function by increasing oxidative stress with
consequent disruption ofNO production [Kiowski et al, 1994; Puranik and Celermajer,
2003], studies specifically examining the effect of smoking upon EDHF mediated
responses are lacking.
6.5.5 Study limitations
The forearm circulation has been an extremely reliable model for the assessment of
vascular physiology and pathophysiology. We do accept that the findings in the forearm
may not be accurately representative of the coronary circulation. However, we and
others have previously demonstrated consistent findings of impaired endothelial t-PA
release in both the forearm [Newby et al, 1999; Pretorius et al, 2002] and coronary
[Newby et al, 2001; Takashima et al, 2007] circulations of cigarette smokers. Although
the forearm vascular bed is relatively protected from the development of atheroma, it
therefore seems likely that changes in its fibrinolytic capacity are indicative of the
coronary circulation.
It could be argued that the safety requirement for the co-administration of tirofiban with
SFLLRN detracts from its advantage as a pathophysiologically relevant agent for the
assessment of endothelial function. However, this locally active dose of GPIIb/IIIa
inhibitor abolishes SFLLRN mediated platelet aggregation without affecting platelet-
monocyte aggregation, a sensitive marker of platelet activation. Furthermore, it has no
effect upon forearm blood flow or fibrinolytic responses to SFLLRN
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[GuQmundsdottir et al, 2006]. We therefore believe that SFLLRN remains an important
and relevant tool. However, we accept that hitherto unrecognised and subtle vascular
effects of tirofiban may introduce a degree of confounding to the interpretation of
SFLLRN-induced responses.
We have demonstrated an important impairment of fibrinolytic capacity in smokers but
it remains unclear whether this reflects an impairment of synthesis, storage and release
of t-PA, or indeed acceleration of its degradation. Addressing these questions will be
challenging and is likely to require specifically designed in vitro studies.
6.5.6 Conclusions
In healthy vessels, thrombin's powerful procoagulant and prothrombotic effects are
offset by its ability to evoke the release of t-PA and induce arterial vasodilatation. We
have shown here that cigarette smoking causes a marked impairment in PAR-1
mediated endothelial vasomotor and fibrinolytic function. Relative arterial stasis and
abolition of t-PA release will strongly enhance clot expansion and vessel occlusion.
Taken together, these findings suggest a major contribution of impaired endothelial
PAR-1 action to the increased atherothrombotic risk of smokers. These important and
novel findings are of direct relevance to our understanding of the pathophysiology by
which cigarette smoking causes an increased propensity to atherothrombotic disorders
including acute myocardial infarction and stroke.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
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7.1 PAR ACTIVATION OF HUMAN PLATELETS
7.1.1 In vitro effects of par activation in human platelets
Thrombin is one of the most important physiological stimulants of platelet activation
that in human platelets, appears to be mediated largely through the PAR-1 receptor,
as well as by PAR-4 and GPIb receptors [Kahn et al, 1999; Lova et al, 2004],
whereas PAR-2 and PAR-3 are not expressed on human platelets. Prior to studies in
the vasculature, the effects of PAR-1 activation on human platelet aggregation and
activation in vitro were explored. The PAR-1 activating peptide SFLLRN, with and
without a PAR-1 antagonist, was compared with other platelet agonists such as
thrombin and the thromboxane A2 agonist U46619. Although PAR-1 activation has
been addressed extensively in human and animal platelet studies in the past, it was
important to obtain concentration-response curves for both our research and clinical
grade PAR activating peptides prior to assessing the effects ofPAR activation in vivo
and we have confirmed that SFLLRN, thrombin and U46619 all caused
concentration-dependent platelet aggregation.
Selective PAR-1 antagonists (thrombin receptor antagonists) have recently been
developed as antiplatelet agents. Protease-activated receptor-1 antagonists block
thrombin receptors without affecting the enzymatic cleavage of thrombin in the
coagulation cascade, and therefore inhibit direct cellular effects of thrombin but not
fibrin production. There are currently ongoing large phase III clinical trials assessing
the thrombin receptor antagonist SCH530348 [Angiolillo and Guzman, 2008;
Chintala et al, 2008], but this drug has not been readily available for academic
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research. We have assessed the in vitro effects of the PAR-1 antagonist RWJ-58259
and confirmed that it fully inhibits SFLLRN-induced platelet aggregation but did not
affect aggregation induced by U46619.
Thrombin-induced platelet aggregation was only partially inhibited by the PAR-1
antagonist RWJ-58259 and this was not augmented with increasing concentrations of
the antagonist nor reduced by increasing concentrations of thrombin. Thrombin-
induced platelet aggregation was however, as expected, fully blocked by the direct
thrombin inhibitor lepirudin. The findings with lepirudin and RWJ-58259 suggest the
presence of an alternative platelet receptor for thrombin when PAR-1 receptors are
blocked. PAR-2 and PAR-3 receptors are not present on human platelets. In our
studies the PAR-4 activating peptide GYPGKV did not induce human platelet
aggregation at concentrations up to 3 mM. PAR-4 is a very low affinity receptor and
PAR-4 activation is unlikely to solely account for the PAR-1 independent platelet
aggregation induced by thrombin. The GPIb receptor is also known to be stimulated
by thrombin and may be a more likely candidate [Soslau et al, 2001].
Activation of platelets by thrombin induces calcium-dependent expression of
P-selectin on the platelet surface and subsequent binding to monocytes through the
counter-receptor P-selectin glycoprotein ligand-1 [Jungi et al, 1986; Sako et al,
1993]. Platelet activation was assessed by measuring levels of platelet-monocyte
binding in whole blood with flowcytometry. Concentration-response curves were
obtained for PAR-1 agonism with and without GPIIb/IIIa inhibition with tirofiban
and compared with platelet aggregometry findings. Protease-activated receptor-1
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agonism continued to induce platelet activation as measured by levels of platelet-
monocyte binding in the presence of tirofiban, whereas tirofiban completely inhibited
PAR-1 induced platelet aggregation measured by platelet aggregometry. This is
consistent with previous findings that although GPIIb/IIIa receptor antagonism
inhibits the final steps leading to platelet aggregation, it does not prevent platelet
activation and platelet-monocyte aggregate formation [Sarma et al, 2002].
7.1.2 Par-i stimulation and platelet activation in vivo
We have demonstrated for the first time that PAR-1 agonism with intra-arterial
SFLLRN caused very marked platelet activation in vivo as measured by platelet-
monocyte binding (from baseline of 16±5% to peak of 74±5%), but declined towards
baseline with time. The half-life of the platelet-monocyte aggregates appeared to be
around 1 hour and this would be in keeping with the aggregation being irreversible
and the half-life being determined by clearance from the circulation (see section 7.2).
By infusing tirofiban before and during SFLLRN it was possible to measure
increased levels of platelet activation during PAR-1 stimulation in vivo, whilst
preventing platelet aggregation and potential thrombosis. Tirofiban infusion on its
own did not affect baseline platelet activation.
7.2 THE VASCULAR EFFECTS OF PAR ACTIVATION
Establishing the receptor mediated effects of thrombin in the vasculature is ofmajor
physiological and therapeutic relevance and the direct vascular effects of thrombin
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receptor agonism have not been previously reported in man. The aim of these studies
was to assess the role of PAR-1 receptors in the human vasculature. Investigation of
the in vivo vascular effects of thrombin is challenging as direct activation of the
coagulation cascade and platelets could result in intravascular thrombosis and tissue
damage. The PAR-1 activating peptide SFLLRN was therefore used to achieve direct
cellular stimulation through thrombin receptors without enzymatic activation of the
coagulation cascade.
Thrombin and PAR-1 activating peptides have previously been shown by others to
cause diverse vasomotor effects in myography studies on ex-vivo vascular segments.
In canine and porcine ring segments, thrombin and PAR-1 activating peptide cause
endothelium- and NO-dependent venous and arterial dilatation [Ku and Zaleski, 1993
Tesfamariam et al, 1993]. In human tissue thrombin causes endothelium-dependent
vasodilatation in internal mammary and coronary artery ring segments [Yang et al,
1994], whereas in human umbilical and placental arteries thrombin and PAR-1
agonism have different effects causing an endothelium-independent contractile
response, and no endothelium mediated relaxing response [Tay-Uyboco et al, 1995].
Whilst to some extent myography studies can be difficult to interpret, this is also
likely to reflect differences in PAR expression and translation of PAR signalling in
different vascular beds [Fujiwara et al, 2004].
Activation of PAR-1 and PAR-2 in vivo in mice causes vasodilatation, where the
hypotensive effect of PAR-1 but not PAR-2 is reversed by inhibition of NO leading
to vasoconstriction [Cheung et al, 1998], In rabbits, femoral artery balloon injury has
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been shown to cause up-regulation of PAR-1 expression and to induce a
vasoconstrictive response to PAR-1 activation [Fukunaga et al, 2006].
The marked species variability in PAR expression necessitates the direct exploration
of PAR function in man since animal models are likely to be unrepresentative of the
clinical setting. This project was further challenged by the absence of specific non-
human primate data on the effects of PAR-1 agonism. The clinical studies were
therefore planned in a cautious incremental fashion. The first step was to carry out
preliminary in vitro studies to assess the effects on platelets and to obtain
concentration-response curves, followed by pilot studies in vivo using very low
concentrations of the agonists. Initially the effects of PAR-1 agonism were assessed
in the dorsal hand vein, where very low doses of drugs can be used to measure
localised venomotor responses. We then moved on to the arterial circulation using
the forearm model, first in healthy volunteers looking at both effects and mechanism
and subsequently comparing smokers with non-smokers. In the arterial studies
tirofiban was co-infused throughout to prevent platelet aggregation.
7.2.1 Venous effects of par activating peptides
Having confirmed previous observations of PAR-2 mediated venodilatation [Robin
et al, 2003], the discovery that PAR-1 caused dose-dependent venoconstriction was
unexpected. Initial studies were carried out after inducing venous tone with
norepinephrine, to be able to detect either constriction or dilatation as veins do not
have a resting tone. Further studies were carried out to look at this effect in more
detail, and PAR-1 activation caused consistent marked venoconstriction both with
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and without norepinephrine or tirofiban co-infusion, as well as after endothelial
denudation where absence of functional endothelium had been confirmed. In
combination with the apparent absence of in situ thrombosis, this suggests that
PAR-1 induced venoconstriction was not mediated by platelet aggregation although
an effect of platelet activation can not be precluded. We therefore believe that this
potent venoconstriction is most likely due to direct effect on vascular smooth muscle.
7.2.2 Arterial effects of par activating peptides
In contrast to the venous effects, both PAR-1 and PAR-2 activation caused dose-
dependent vasodilatation of forearm resistance vessels, with PAR-2 having a much
smaller effect and requiring much higher doses.
Protease-activated receptor expression varies between endothelial cell cultures
originating from different human blood vessels [Fujiwara et al, 2004] and this may
partly explain the different responses between PAR-1 and PAR-2 in the arterial and
venous circulations. Our findings that PAR-2 activation causes venous and arterial
dilatation are in keeping with previous findings [Robin et al, 2003] and consistent
with the vascular role of PAR-2 receptors in inflammatory conditions.
The vasomotor effects of PAR-1 activation were short-acting, with forearm blood
flow returning to baseline during a 6-minute washout infusion. The effect on levels
of platelet-monocyte binding was longer lasting, with a half-life of approximately
1 hour. This is in keeping with in vitro studies in various cell lines that have
demonstrated that PAR-1 receptors are rapidly internalised by endocytosis after
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activation, terminating the effect. A sustained signal therefore requires mobilisation
of intact receptors from intracellular stores or the synthesis of new receptors [Trejo et
al, 2000]. Platelets on the other hand only need to respond once. Platelets do not
internalise their receptors, and neither have the ability to synthesise new receptors,
nor have large intracellular stores and thrombin causes irreversible platelet
aggregation. The half-life of platelet-monocyte aggregates therefore appears to be
determined by their clearance from the circulation.
The study protocol was vigilant to minimise any potential prothrombotic effects
associated with PAR-1 induced platelet aggregation. Having defined the in vitro
concentration of tiroflban that would permit direct in vivo intravascular infusion of
PAR-1 activating peptide, without inducing platelet aggregation and potential
thrombosis, tiroflban was infused throughout arterial studies. No significant adverse
clinical side-effects or thrombosis were observed, although the generation of
subclinical microthrombi can not be fully excluded. It could be argued that, in these
studies, the safety requirement for the co-administration of tirofiban with SFLLRN in
the arterial studies detracts from our findings. However, locally active doses of
tiroflban were used, that abolish SFLLRN mediated platelet aggregation without
affecting platelet-monocyte binding, a sensitive marker of platelet activation. The
total dose of tiroflban administered (approximately 200 pg over 150 min) is much
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lower than that required to achieve systemic antiplatelet effects in clinical practice
(28 pg/min loading dose for 30 minutes followed by 7 pg/min maintenance dose).
Furthermore, at this dose, tiroflban had no effect upon basal forearm blood flow or
fibrinolytic or platelet responses to SFLLRN. We therefore believe that SFLLRN is
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an important and relevant tool to assess these fundamental pathophysiological
aspects of endothelial function.
7.3 THE ROLE OF ENDOTHELIUM IN VASCULAR EFFECTS OF PARs
Animal models indicated that PAR induced vasodilatation was likely to be
endothelium- and NO-dependent [Cheung et al, 1998)]. However, as previously
discussed, data from animal studies have limited relevance in man because of the
wide species variability in PAR-1 receptor expression and function. We have
described the contrasting role of the endothelium in the vascular actions ofPAR-1 in
vivo in man. Whilst not providing a major contribution to venoconstriction or PAI-1
release, the endothelium mediates PAR-1 induced arterial vasodilatation and t-PA
release. Our findings provide clear evidence of a major interaction between the
vascular endothelium and thrombin in vivo in man. Furthermore, they highlight the
critical importance of endothelial function at the time of acute arterial injury and
intravascular thrombosis, such as during acute coronary syndromes.
7.3.1 Role of the endothelium in par-i induced vasomotion
Having described the unexpected finding of PAR-1 induced venoconstriction in man
we wanted to address whether this effect could be mediated by either a direct action
on vascular smooth muscle or via the release of endothelium-derived
vasoconstrictors, such as endothelin or angiotensin II. We therefore assessed PAR-1
induced venoconstriction before and after endothelial denudation by instillation of
distilled water where the absence of functional endothelium was confirmed by a lack
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of venodilatation to acetylcholine. Activation of PAR-1 continued to induce a
marked dose-dependent venoconstriction even in the absence of the endothelium,
suggesting a dominant and direct effect of PAR-1 on the vascular smooth muscle
cells.
In contrast to effects on the venous circulation, PAR-1 agonism causes potent arterial
vasodilatation. This suggests a different effect on the arterial vasculature that is likely
to be mediated by the endothelium. It would be difficult and not safe to conduct
comparable in vivo endothelial denudation studies in the arterial circulation. A
pharmacological approach to the inhibition of the three main known mediators of
endothelium-dependent vasodilatation, prostacyclin NO and EDHF was therefore
used. Although prostacyclin inhibition appeared to have no effect, inhibition of NO
and potassium channels both attenuated the PAR-1 induced vasodilatation.
Combined inhibition of all three almost abolished the vasodilator actions of PAR-1
agonism. This suggests that, unlike the venous circulation, PAR-1 mediated arterial
actions are dominated by, and dependent upon, the vascular endothelium and are
mediated by NO and EDHF.
These results are in keeping with previous ex vivo myography studies on the
vasomotor effects of thrombin and PAR-1 activating peptides on human coronary
and internal mammary artery ring segments that suggested that thrombin causes
endothelium-dependent vasodilatation [Yang et al, 1994], Our group has also
previously shown concordance between the coronary and forearm circulations
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[Newby et al, 1999; Newby et al, 2001] and our findings are likely to reflect the
vasomotor response to thrombin receptor activation in the coronary circulation.
7.3.2 Par-i induced release of endothelium-derived factors
We have demonstrated that as well as having vasomotor effects, PAR-1 has
important effects on the release of endothelium-derived coagulant and fibrinolytic
factors causing endothelial t-PA release without affecting vWF, which is in keeping
with studies of other G-protein coupled receptor vasodilators [Oliver et al, 2005].
Looking into the mechanism of t-PA release, SFLLRN-induced t-PA release
appeared to be augmented by the inhibition of endogenous NO production.
Bradykinin-induced t-PA release has previously been found to be independent of
nitric oxide and cyclooxygenase activity, and it has been suggested that EDHF is
responsible for its release [Brown et al, 2000], It is possible that when NO synthesis
is inhibited, EDHF is up-regulated and accounts for the augmented t-PA release
induced by SFLLRN. However, in contrast to tetraethylammonium's inhibitory
effects on SFLLRN-induced arterial vasodilatation, it had no effect on SFLLRN
evoked t-PA release, suggesting that t-PA release is independent of potassium
channels.
A further novel finding in the arterial studies was the increase in PAI-1 release,
especially during NO synthase inhibition. There have been no previous reports of
acute increases in plasma PAI-1 concentrations following the administration of
endothelial agonists, especially using the forearm model [Oliver et al, 2005], Whilst
the endothelium is an important source of PAI-1, we believe these findings are
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consistent with acute platelet release of PAI-1. There are several reasons to support
this. First, although PAI-1 antigen concentrations increased, there was no
corresponding rise in PAI-1 activity. Indeed, PAI-1 activity fell during marked
release of t-PA. Plasminogen activator inhibitor type 1 is stored in platelet a-
granules where its activity is very low (<5% of the activity seen in plasma) due to the
absence of the stabilising effect of vitronectin. In contrast, endothelium-derived
PAI-1 would be anticipated to remain active. Second, there was no concurrent rise in
vWF confirming a selective effect on the endothelium with isolated t-PA release.
Third, we have also demonstrated concomitant platelet activation with marked
increases in platelet-monocyte aggregate formation and release of
P-thromboglobulin; the latter is also stored in the a-granules of platelets. Finally,
PAR-1 induced PAI-1 release was augmented during the 'nitric oxide clamp'. Nitric
oxide has important antiplatelet effects and, in the presence of its inhibition,
increased platelet activation may have led to greater PAI-1 release.
7.4 COMPARISION OF EFFECTS OF PAR ACTIVATION BETWEEN
SMOKERS AND NON-SMOKERS
Cigarette smoking is strongly associated with atherothrombotic events such as
myocardial infarction and stroke. This is caused by multiple pathogenetic pathways
including accelerated atherosclerosis, increased platelet activation and impaired
endogenous fibrinolysis. Burke et al have previously demonstrated that among men
who died of sudden coronary death, smokers have a significantly higher incidence of
acute thrombosis, whereas those with hyperlipidaemia are more likely to develop
160
plaque rupture [Burke et al, 1997], Thrombin is central to this process, probably
through its receptor mediated effects via PAR-1, but a direct causative link has not
been previously established in vivo. We have described a marked impairment of
PAR-1 mediated vasodilatation and endogenous fibrinolysis in otherwise healthy,
young cigarette smokers in vivo. Forearm arterial flow was compared in response to
PAR-1 activation, bradykinin and sodium nitroprusside. Whilst all agonists caused
similar increase in forearm blood flow, it was only the response to PAR-1 activation
that was significantly impaired in smokers. The most striking finding was that
endogenous net t-PA release to PAR-1 activation was almost abolished in smokers
compared with non-smokers. The impairment of these protective responses may shift
the balance between intravascular thrombosis and endogenous fibrinolysis towards
thrombotic events and suggests a major contribution of impaired endothelial PAR-1
action to the increased incidence of myocardial infarction and stroke in cigarette
smokers.
7.5 SELECTION OF PAR ACTIVATING PEPTIDES
The PAR-1 activating peptide SFLLRN was chosen as PAR-1 agonist for several
reasons. The PAR activating peptides have been extensively investigated in vitro,
both by ligand binding and functional assays and by peptide binding studies.
The hexapeptide SFLLRN is as selective and has the same effect as the fourteen
amino acid active cleaved tail of the human PAR-1 receptor [Scarborough et al,
1992], Another hexapeptide, TFLLRN is a synthetic modification of this. We accept
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that current data suggest that TFLLRN has greater PAR-1 selectivity than SFLLRN,
with PAR-l/PAR-2 selectivity for SFLLRN being approximately 4:1 versus 220:1
for TFLLRN [Kawabata et al, 1999]. We do however believe that by using SFLLRN,
the in vivo molecular mechanisms and results of PAR-1 cleavage are more closely
represented,
The effects of the PAR-1 activating peptide SFLLRN were compared with the PAR-
2 activating peptide SLIGKV, the endothelium-dependent vasodilator bradykinin and
the endothelium-independent vasodilator sodium nitroprusside, and not with a
scrambled peptide. SLIGKV has previously been compared with a scrambled peptide
in vivo [Robin et al, 2003] using similar vascular methods, and the scrambled peptide
had no effect at concentrations about 30-fold of those that we used. Our group has
also tested the effects of similarly sized peptides in the past demonstrating no effect.
It is recognised that there can be functional interaction and cross-activation between
different PAR receptors. Thrombin activates PAR-1, PAR-3 and PAR-4 at different
potencies but not PAR-2 which is mainly activated by trypsin and some coagulation
factors. The PAR-1 activating peptide SFLLRN can also activate the PAR-2 receptor
but not vice versa [Blackhart et al, 1996]. We believe that the vascular effects seen in
our studies are a reflection of PAR-1 activation and do not reflect PAR-2 activity.
*
We have assessed the in vivo effects of intra-arterial SFLLRN and SLIGKV, the
selective PAR-2 agonist. Whilst SFLLRN caused potent arterial vasodilatation,
SLIGKV caused only minor arterial vasodilatation at doses approximately 160-fold
greater than those of SFLLRN (Figure 4.3). Furthermore, SFLLRN caused marked
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t-PA antigen and activity release, whilst PAR-2 agonism had no effect on t-PA
levels. They also had opposing effects in the venous circulation, PAR-1 activation
with SFLLRN causing venoconstriction whilst PAR-2 activation caused
venodilatation. Whilst expression of the PAR-2 receptor may be up-regulated by
inflammation, the vascular effects of PAR-2 are likely to be modest in the healthy
human in vivo. Finally, although the PAR-2 receptor can in vitro be activated by
SFLLRN at high concentrations [A1 Ani et al, 1999], this is of limited physiological
relevance as it is not activated by thrombin, the principal PAR-1 agonist in vivo.
7.6 FUTURE DIRECTIONS
In this series of studies, the role of thrombin receptor activation in vivo in the human
vasculature has been explored and established for the first time, including the role of
the endothelium and comparison of the effect in smokers and non-smokers. Protease-
activated receptors appear to be central to a diverse array of physiological and
pathophysiological processes including atherothrombotic diseases, cancer metastasis,
neuropathic pain and sepsis, with the number of publications on the subjects
reflecting this. We will discuss here some of the main areas of research into protease-
activated receptors that are of ongoing interest to our group.
7.6.1 Relevance of pars to pathophysiology and cardiovascular
diseases
There is a marked difference in the response to PAR-1 activation in smokers and
non-smokers that is likely to be relevant to smokers' increased risk of acute
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thrombosis. Studies of PAR expression in patients with inflammatory and
atherothrombotic conditions will provide useful information as PAR expression is
up-regulated by disease processes such as inflammation [Schouten et al, 2008] and
atherosclerosis [Nelken et al, 1992] and this in turn could cause different responses.
It is of great interest to assess the vasomotor and fibrinolytic response to PAR-1 and
possibly PAR-2 activation in subjects with other cardiovascular risk factors, such as
hyperlipidaemia, diabetes mellitus and in patients with coronary artery disease.
Studies in patient groups such as diabetics and patients with coronary artery disease
will however be challenging. These groups may have increased baseline levels of
platelet activation and impaired vasodilatory and endogenous fibrinolytic responses
to PAR-1 activation. Whilst stimulating PAR-1 receptors in healthy volunteers is
unlikely to have clinical consequences, the concern would be that in patients with
marked atherosclerosis this could potentially have prothrombotic effects.
The role of PAR-3 and PAR-4 in the vasculature has not been established. The lack
of a functional PAR-3 agonist and the high concentrations of agonist required to
stimulate PAR-4 activation have prevented the in vivo study of these receptors, and
although their role in man appears fairly limited, further understanding of this would
be of interest, in particular clarifying the role ofPAR-4.
7.6.2 Relevance of pars to treatment
The emerging new PAR-1 antagonists/thrombin receptor antagonists will be of great
interest, not only to assess antiplatelet effects but also their effects on vasomotor and
endogenous fibrinolytic function, both in the presence and absence of PAR-1
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stimulation, both in healthy volunteers and patients. Although large phase III clinical
trials are conducted to assess antiplatelet effects of thrombin receptor antagonists,
and safety and clinical endpoints (see section 7.7), there remains a role for studies
looking specifically into vasomotor and fibrinolytic function and the mechanism of
these effects.
Direct thrombin receptors are new oral anticoagulant agents that are currently being
compared with warfarin, the mainstay of oral anticoagulation for over 60 years.
These drugs, unlike thrombin receptor antagonists, inhibit the enzymatic activity of
thrombin in the coagulation cascade. Development of the direct thrombin inhibitor
ximelagatran was terminated and the drug withdrawn after large clinical trials,
mainly due to concerns regarding adverse affects on liver function [Agnelli et al,
2009], More recently the RE-LY trial compared another direct thrombin inhibitor,
dabigatran, with warfarin treatment in patients with atrial fibrillation with promising
results [Connolly et al, 2009]. Both drugs do, however, appear to have in common a
very small rise in myocardial infarction. This could be explained by up-regulation of
PAR-1 or impaired t-PA release and we are interested in assessing whether platelet
and endothelial PAR-1 expression is up-regulated during treatment with direct




The findings described in this thesis have potential implications for the application of
novel PAR-1 receptor antagonists that are currently under clinical development as
potential antiplatelet therapies. Following successful phase II clinical trials,
recruitment is currently taking place for two large phase III clinical trials assessing
the effects of the thrombin receptor antagonist (PAR-1 antagonist) TRA-SCH
530348, which has been granted fast track status by the American Food and Drug
Administration. Both are large multicentre randomised placebo controlled trials
(clinicaltrials.gov). The TRA 2°P-TIMI 50 study will assess approximately 19 500
patients with prior myocardial infarction, stroke or existing peripheral arterial
disease. Patients are followed up for at least one year and the endpoints are
cardiovascular death, myocardial infarction, urgent coronary revascularisation or
stroke. This trial is due to be completed in 2010. The Thrombin Receptor Antagonist
Clinical Event Reduction in acute coronary syndrome (TRACER) trial will follow
10,000 patients with non ST-segment elevation acute coronary syndrome taking
standard antiplatelet treatment, with or without SCH 530348, over a year and assess
the impact on cardiovascular mortality, myocardial infarction, re-hospitalisation for
acute coronary syndrome, urgent coronary revascularisation and stroke. This trial is
due to be completed in 2011. The findings of these two trials will be very interesting,
in particular due to the long follow up period [Angiolillo and Guzman, 2008].
The role of PARs in angiogenesis is an exciting field and remains to be explored
further. Protease-activated receptor-1 expression is up-regulated and appears to
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correlate directly to the metastatic potential of various cancers including ovarian
[Agarwal et al, 2008] and breast cancer [Yang et al, 2009] and malignant melanoma
[Melnikova et al, 2009]. This is thought to be related to inflammatory pathways,
platelet activation and breakdown of cell-cell barriers, and PAR-1 inhibition may in
particular be advantageous in advanced metastatic cancer. Related to its role in
angiogenesis PAR-1 inhibition could, however, adversely affect wound healing and
tissue ischaemia.
7.8 CONCLUSIONS
In this series of pre-clinical and clinical studies the in vivo vascular effects of PAR-1
activation in man have been established for the first time. Activation of PAR-1 has
been demonstrated to cause venous constriction, arterial dilatation, platelet activation
and release of endogenous t-PA. These intriguing and contrasting effects of PAR-1
agonism reveal the diverse nature of the vascular consequences of thrombin
activation in man. The vascular effects of PAR-1 agonism in vivo can be understood
in terms of limiting intravascular thrombosis and maintaining vessel patency and
haemostatic balance: in the presence of a developing intravascular thrombosis, in
veins constriction would limit thrombus propagation and embolisation, whereas in
the arteries, increased blood flow and endogenous fibrinolysis would limit arterial
thrombosis by ensuring thrombus clearance and dissolution. This delicate balance is
affected in smokers who have a reduced vasodilatory response to PAR-1 activation
and an all but abolished fibrinolytic response, which would enhance clot expansion
and vessel occlusion. This could in part explain the increased risk in smokers of
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acute thrombotic events. These findings are likely to be directly relevant to the
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Introduction
Blood coagulation prevents blood loss and has been crucial to survival throughout
evolution. It is initiated by 'intrinsic' factors in the blood coming into contact with a
foreign surface, such as collagen or subendothelial matrix, or in response to 'extrin¬
sic' factors released by injured tissues, such as tissue factor (Fig. 7.1). These intrinsic
and extrinsic pathways converge and lead to thrombin activation. Thrombin is the
central enzyme catalysing the conversion of fibrinogen to fibrin, and generates the
characteristic fibrin mesh of thrombus.
Although blood coagulation prevents inappropriate haemorrhage and exsanguin-



























of factors II, VII, IX and X
Fig. 7.1 Schematic view of the coagulation cascade.
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morbidity and mortality. Arterial thrombosis causes tissue ischaemia including
myocardial and cerebral infarction, and is the leading cause of death in Western
societies. Venous thrombosis can cause localized tissue oedema but is most serious
when it embolises to the lung where it may cause life-threatening pulmonary
thromboembolism.
Anticoagulant therapy
Anticoagulant therapy is used in the treatment and prevention of arterial and venous
thrombosis in patients with a range of conditions including atrial fibrillation,
mechanical prosthetic heart valves, deep venous thrombosis, acute coronary syn¬
dromes and pulmonary embolism. Current parenteral and oral anticoagulant thera¬
pies tend to act at multiple sites in the coagulation cascade (Table 7.1; Fig. 7.1) and
have significant drawbacks that limit their use. Warfarin and heparin are the most
commonly used anticoagulant agents but have unpredictable pharmacokinetic and
pharmacodynamic actions, potentially serious side effects, and important drug and
food interactions. They require regular repeated monitoring and dose adjustments.
There is therefore a need for more convenient, predictable and reliable anticoagulant
therapies.
This chapter will describe recent data regarding a new class of anticoagulant
therapy that acts solely through direct enzymatic inhibition of thrombin: the direct
thrombin inhibitors. Although other agents exist (Table 7.1), wewill principally con¬
sider two new agents: ximelagatran and bivalirudin. Ximelagatran, the pro-drug of
melagatran, is the first orally available anticoagulant since the introduction of
warfarin over 60 years ago |1|. Bivalirudin is a parenteral peptidic agent that is show¬
ing particular promise in use during percutaneous coronary intervention (PCI).
Drugs that act earlier in the coagulation cascade, such as the pentasaccharide
fondaparinux, are also under development and are now entering clinical use |2|.
These drugs act indirectly to decrease thrombin generation by factor Xa inhibition
and will not be discussed further here.
Intravascular thrombosis and anticoagulation
Anticoagulation is widely used for the treatment and prophylaxis of thrombosis
and thromboembolism. Vessel occlusion can occur either in the arterial or venous
circulation and the clinical consequences differ depending on the location.
Venous thrombosis
Venous blood flow is slow and under low pressure. Thrombus formation is most
common in the calf veins and mainly consists of red blood cells in a mesh of fibrin;
so-called 'red thrombus'. Venous thrombosis is therefore readily prevented and
treated by inhibiting thrombin-induced fibrin formation.
Consistent with Virchow's triad, any condition that causes venous congestion
(reduced flow), trauma (vessel wall damage) or activation of the coagulation system
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(hypercoagulability) will predispose to venous thrombosis. There are several well
recognized risk factors including major surgery, malignancy (especially adeno¬
carcinoma), immobility, genetic traits and oral contraceptive or hormone replace¬
ment therapy |3|.
Most venous thrombi of the calves go unnoticed and small emboli are frequently
filtered from the circulation in the lungs without causing symptoms. The risk of
complications increases steeply if the thrombus extends more proximally and
detachment may lead to symptomatic pulmonary embolism.
Venous thromboembolism (VTE) prophylaxis, normally with low doses of
heparin, is indicated in immobilized and post-operative patients. Longer treatment is
indicated in those with confirmed proximal (above-knee) deep vein thrombosis and
pulmonary embolism but the length of treatment varies between 3 months and
indefinitely |4,5|.
Arterial thrombosis
Thrombus formation in the arterial circulation is often more rapid and even a small
thrombus can have devastating effects. Arterial thrombus tends to be caused by
mechanical injury or plaque rupture of atherosclerotic arteries. The thrombus is rich
in platelets connected by fibrin strands; so-called 'white thrombus'. Agents that
minimize either platelet activation or fibrin deposition are very important in the pre¬
vention and treatment of arterial thrombus.
Arterial occlusion can be caused by thrombosis in situ, as occurs with an acute
coronary syndrome, or as a result of thromboembolism, such as a stroke from aortic
or cardiac thrombus. In atrial fibrillation, cardiac thrombus forms because of atrial
blood stagnation and is not as platelet rich |6|. This may, in part, explain why aspirin is
less effective in preventing stroke than warfarin in patients with atrial fibrillation |7|.
Current treatment
Warfarin
Warfarin blocks the hepatic y-carboxylation of the vitamin K-dependent clotting
factors II, VII, IX and X. The onset of anticoagulant activity is delayed in accordance
with the half-life of these factors, 2-3 days. Long-term anticoagulation with warfarin
is considered in patients with atrial fibrillation, prosthetic heart valves, rheumatic
heart disease, deep vein thrombosis or pulmonary embolism. Patients with atrial
fibrillation should be considered for anticoagulation if they have one or more of
the following risk factors: previous history of stroke; transient ischaemic attack
or systemic embolism; hypertension; diabetes mellitus; impaired left ventricular
function; and age over 65 years |5,8|. In such patients, warfarin reduces the risk of
thromboembolism by 60-70% |9,10|.
Treatment with warfarin is complicated by the need to assess liver function at
onset and the continuous monitoring ofanticoagulant control using the international
Table7.1Anticoagulantsndheirmo efaction ModefactionH lf-life UnfractionatedBindste hancesI.v.inj.:1/2-1h heparin(UFH)thein ib toryactionofS.c.inj:10-12 antithrombinIII(AT1II) againstFXand thrombin(Flla) Inhibitsfreebutnotcl boundthrombin Lowmolecularw ightDerivedfr mUFHbutiffersb t en heparin(LMWH)smallerentas ccharidescompoundsbut andstrongerctivitygainstsuffici nforo ce FXathanll .In ibitsfreeortwiced ilys.c. butnocl to ndthrombinadmi istration WarfarinVitamKant go ist20-60hour (4-hydroxy-coumarin)whichinhibitst e -y-carboxylationoffactors II,VII,Xanditheliver
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normalized ratio (INR) of the prothrombin time. Achieving the appropriate level of
anticoagulation is hindered by numerous and important drug-drug and drug-food
interactions. Warfarin has a narrow therapeutic window and the risk of bleeding
increases steeplywith a small rise in INR. The risk ofmajor haemorrhage resulting in
death, hospitalization, intracranial haemorrhage or the need for blood transfusion
with warfarin is about 1-4% per year |11|. Warfarin also inhibits production of the
anticoagulant factors C and S. If their concentration falls dramatically, such as with
excessive loading doses or in people with hereditary Protein C or S deficiency, there is
a temporary procoagulant state with the risk of small vessel thrombosis and skin
necrosis.Warfarin can also be teratogenic and should be avoided in pregnancy.
Heparin
Heparin inhibits factors Xa and Ila (thrombin) by enhancing the activity of
antithrombin III. Unfractionated heparin has largely been replaced by low molecular
weight heparin (LMWH) for some indications, such as unstable angina and deep
vein thrombosis, but remains themost common anticoagulant in other settings, such
as during PCI |12|.
There are a number of limitations to the use of heparin. Plasma proteins can bind
to heparin and reduce its activity. Anticoagulation with unfractionated heparin is
often unpredictable and requires frequent monitoring and dose titration.
Antithrombin III only works against free factor Xa and there is little activity against
clot-bound factor Xa. Heparin also has a number of important side effects, especially
following longer term use, for example osteoporosis and heparin resistance. Heparin
can cause platelet activation and one of the most serious non-haemorrhagic side
effects is heparin-induced thrombocytopenia (HIT). The diagnosis ofHIT should be
suspected if there is a >50% unexplained fall in platelet count, if skin lesions form at
injection sites, or if the patient develops thrombosis while on heparin. In the com¬
mon non-immune (type I) form of HIT, the platelet count rarely falls below
100 X 109/1 and the patient normally recovers spontaneously. The more serious
autoimmune form (type II) of HIT occurs in about 3% of patients who receive
heparin for over 5 days |13|. In spite of the low platelet count, it is a very prothrom-
botic state and frequently leads to arterial or venous thrombosis, amputations or
death. HIT is much less common with LWMH |13| and very unlikely with the new
pentasaccharides |14|, such as fondaparinux.
Basic science underlying direct thrombin inhibitors
The role of thrombin in coagulation
Thrombin (factor Ila) is generated from prothrombin through activation ofboth the
intrinsic and extrinsic pathways of the coagulation cascade. Thrombin plays an
essential role in coagulation through its protease activity, leading to the formation of
fibrin from fibrinogen. This is further enhanced by positive feedback loops causing
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activation of factor V, VIII and X in the intrinsic pathway and factor VII in the
extrinsic pathway. Factor XIII is also activated by thrombin and stimulates cross-
linking and stabilization of fibrin (Fig. 7.1).
Thrombin is a direct mediator of platelet activation and vascular inflammation.
These effects are largely mediated via a novel group ofG-protein coupled receptors
called proteinase-activated receptors (PARs) |15|. Proteolytic cleavage of the receptor
leads to unmasking of a short peptide sequence that remains tethered and activates
the receptor leading to a cascade of intracellular signals. To date, four different types of
PAR have been identified. PAR-1, -3 and -4 are all activated by thrombin, whereas
PAR-2 ismainly activated by trypsin. PAR-1 mediatesmost of the effects of thrombin
in the cardiovascular system and is present on endothelial cells and platelets. In
healthy human arteries, PAR-1 appears to be expressed almost exclusively in the
endothelial layer, whereas in atheromatous arteries there is a more widespread
expression, raising the possibility that PAR-1 receptor activation may contribute to
atherogenesis and restenosis.
Direct thrombin inhibitors
The direct thrombin inhibitors bind to the substrate-recognition/and or catalytic site
of thrombin and, by virtue of their small size, can bind to and inactivate both free
and clot-bound thrombin. They are not inactivated by plasma proteins and are not
affected by other drugs or food. They therefore have a more predictable anticoagu¬
lant effect, which requires less monitoring. Direct thrombin inhibitors also have
antiplatelet effects |16| and may augment thrombolysis induced by fibrinolytic agents
|17|. Melagatran and related agents bind to thrombin in an extended conformation at
three different sites, whereas argatroban and related drugs bind to thrombin in a
more compact way (Fig. 7.2).
Several direct thrombin inhibitors are in development but only a few have been
studied in large trials. Ximelagatran, the oral prodrug of melagatran, has been
studied most extensively. Other oral agents, such as BIBR 1048 |18| and SSR182289A
1 |19|, are promising direct thrombin inhibitors that are in the very early stages of
clinical development.
Three parenteral direct thrombin inhibitors are currently available: hirudin/
lepirudin, bivalirudin and argatroban. Hirudin was originally isolated from salivary
glands of the medicinal leech in 1904, but is now available in a recombinant form
as lepirudin |20|. Further modifications have also been made to generate a hirudin
analogue, bivalirudin. Clinical studies in the 1990s assessing the use of hirudin in
patients with ischaemic heart disease |21-24| showed an increased risk of bleeding
when doses were sufficient to have therapeutic benefit. Argatroban is a small syn¬
thetic molecule |25| that binds reversibly to the catalytic site of thrombin. Caution is
required with use in patients with impaired liver function because of its biliary
excretion but it is safe to use in patients with renal impairment |26|. Hirudin and
argatroban are indicated in patients with heparin-induced thrombocytopenia and a
recent study suggests that argatroban is a safe anticoagulant in patients with acute
ischaemic stroke, although efficacy has not been established |27|.
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NEW FIG 7.2 TO COME
FULL PAGE
Fig. 7.2 (a) A schematic representation of the modes of inhibition of (a) heparin and
(b) direct thrombin inhibitors of fibrin-bound thrombin, (b) Chemical structure of argatroban
(to the left) and argatroban and active site region (right) of the complexes formed between
thrombin (yellow connections) and argatroban (orange connections). Source: (a) To be
modified from Weitz Jl, Thrombosis Research 2003; 109: S17-S22. (b) Hauptmann J and
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Melagatran/ximelagatran
Melagatran is a selective competitive inhibitor ofhuman thrombin and inhibits both
free and clot-bound thrombin. Protecting groups have been added to melagatran to
form ximelagatran (Fig. 7.3), making it an uncharged and more lipophilic molecule,
which has better bioavailability |28,29|. Ximelagatran can be crushed or dissolved in
water and given via nasogastric tube for patients with swallowing difficulties |30|. It is
rapidly absorbed and biotransformed to melagatran, reaching peak plasma concen¬
tration 1.5-2.0 h after intake. Unlike vitamin K antagonists, where introducing full
anticoagulation takes 4-5 days, anticoagulation is almost immediate. Melagatran is
not metabolised further and is renally excretedwith a half-life of4-5 h |31|. Excretion
is delayed in patients with impaired renal function. Melagatran prolongs blood coagu¬
lation as measured by various clotting tests such as the activated partial thrombo¬
plastin time (APTT) and prothrombin time. There is no interaction with the hepatic
cytochrome P450 (CYP) system |32| and therefore very few drug-drug interactions.
No specific antidote is available but anticoagulation is reversed within 1 day of stop¬
ping treatment because of its short half-life.
Fig. 7.3 Molecular structure of ximelagatran and melagatran. Source: Samama MM, et a/.
Pathophysiol Haemost Thromb 2002; 32: 218-24.
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About 6-7% of patients in clinical trials have developed derangements in liver
function tests (aminotransferase levels greater than threefold the upper limit of
normal) and this has been the most frequent side effect. Liver function tests typically
become abnormal 2-6 months into treatment and in most instances revert to normal
either spontaneously or after treatment cessation. However, there is evidence that
ximelagatran can induce severe liver injury and this is a major concern. A recent
review from the American Food and Drug Administration (FDA) concluded that the
potential risk of side effects, mainly deranged liver function, might outweigh the
benefits ofximelagatran and, on this basis, did not support the manufacturer's appli¬
cation for a licence |33|. Further work on the side effect profile of this drug will be
required. At present, the mechanism and the long-term effects of the hepatic injury
are unknown.
Bivalirudin
Bivalirudin is a recombinant polypeptide analogue of the carboxy-terminal of
hirudin |34|. It is a direct thrombin inhibitor given by intravenous infusion and forms
a bivalent complex with thrombin. The connection is slowly reversible as a result of
proteolytic cleavage by thrombin |35[. Bivalirudin is therefore partly broken down by
this catalytic mechanism and is, to a smaller extent, excreted through the kidneys and
liver. It has a short half-life of around 25 min |36|. Unlike hirudin, the binding of
bivalirudin to thrombin is reversible and potentially makes bivalirudin safer to use.
Recent studies assessing efficacy and safety of
ximelagatran
Stroke prevention with the oral direct thrombin inhibitor
ximelagatran compared with warfarin in patients with
non-valvular atrial fibrillation (SPORTIF III): randomised
controlled trial
SB and Executive Steering Committee on behalf of the SPORTIF III Investigators.
Lancet 2003; 362: 1691-8
Background. The aim of the study was to establish whether ximelagatran
represented a potential alternative and was non-inferior to warfarin, within a margin
of 2% per year for prevention of stroke and systemic embolisation. A total of
3410 patients from 23 countries, with non-valvular atrial fibrillation and one or more
risk factors for stroke were studied. Patients were treated in an open-label design
with either warfarin or ximelagatran (36 mg twice daily). Concomitant aspirin up to
100 mg daily was allowed but other anticoagulants prohibited. Primary end-points
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end-points were composites of: (1) major and minor bleeding; (2) treatment
discontinuation; (3) ischaemic stroke, transient ischaemic attack and systemic
embolism; (4) acute myocardial infarction (Ml), stroke, systemic embolism and death.
Interpretation. Systemic embolism occurred in 2.3%/year in the warfarin group and
1.6%/year in the ximelagatran group, absolute risk reduction of 0.7% (95% confidence
interval [CI] -0.1 to 1.4; P = 0.1000). Composite of mortality, stroke, systemic embolism
and Ml was 4.2% in the ximelagatran group and 4.9% in the warfarin group. The rate of major
or minor bleeding was 25.8% in the ximelagatran group and 29.8% in the warfarin group
(P = 0.0065; absolute risk reduction 4.0% with 95% CI -6.9 to -1.1). Fourteen per cent
of participants had to terminate treatment early in the warfarin group and 18% in the
ximelagatran group, mainly because of elevation of liver transaminases. Ximelagatran
was non-inferior to warfarin for the prevention of thromboembolic events in patients with
non-valvular atrial fibrillation.
Comments
Atrial fibrillation is the most common sustained cardiac arrhythmia, occurring
in about 6% of the population over 65 years of age |37|. Results of the AFFIRM
and RACE studies |38,39| have emphasized the importance of rate control and anti¬
coagulation in patients with recurrent atrial fibrillation rather than trying to obtain
or maintain sinus rhythm. Studies have consistently confirmed that anticoagulation
with warfarin is underutilized in spite of clear benefits in patients with atrial fibrilla¬
tion, and treatment that is easier to manage could improve this.
The major limitations of the SPORTIF III trial are its open-label design and the
wide non-inferiority margin (2% absolute difference) proposed by the investigators.
Open-label studies are likely to overestimate potential treatment benefits. The
SPORTIF V study is a double-blind, randomized, controlled trial that was carried
out on 3922 patients in the USA and Canada, and replicated SPORTIF III in a more
rigorous manner. The results of SPORTIF V have not yet been formally published.
An abstract |40| indicates that the results are similar to SPORTIF III, although the
stroke and embolic event rate in the warfarin group appeared to be slightly lower
than that with ximelagatran (absolute difference 0.45%; 95% CI -0.13 to 1.03). A
further ongoing study that is addressing the issue of anticoagulation in atrial fibrilla¬
tion is the ACTIVE trial, in which warfarin is compared with aspirin and clopidogrel.
Oral ximelagatran for secondary prophylaxis after
myocardial infarction: the ESTEEM randomised
controlled trial
Wallentin L, Wilcox RG, WeaverWD, eta/., for the ESTEEM Investigators. Lancet
2003; 362: 789-97
Background. The aim was to assess the effectiveness of ximelagatran combined
with aspirin against aspirin alone after Ml. This was a placebo-controlled,
dose-guiding, multicentre study of 1883 patients with ST-elevation or
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non-ST-elevation Ml within the previous 14 days. Study participants also had at least
one thromboembolic risk factor. Among exclusion criteria were PCI in the previous
4 months or planned PCI within 60 days, or if treatment with other antiplatelet or
anticoagulant drugs was indicated. Patients were randomized to receive either one of
four doses of ximelagatran (24, 36, 48 or 60 mg twice daily) or placebo for 6 months.
All patients received 75-160 mg aspirin daily.
Interpretation. Ximelagatran combined with aspirin was more effective than aspirin
alone in reducing the risk of the primary end-point of death, non-fatal Ml or severe recurrent
ischaemia (12.7% for ximelagatran vs 16.3% for placebo; P = 0.0357; Fig. 7.4). There was
no apparent difference in effect between the individual doses of ximelagatran. A post hoc
analysis found that ximelagatran reduced the cumulative risk of death, non-fatal Ml and
non-fatal stroke from 11.1% to 7.4% (hazard ratio [HR] 0.66; 95% CI 0.48-0.90). There was
no difference in the risk of major bleeding, 0.9% in placebo group versus 1.8 % in the
ximelagatran group. However, combined major and minor bleeding was more common in the
ximelagatran group (22% compared with 13% in placebo group; HR 1.76, 95% CI
1.38-2.25). Treatment was stopped in 7% of patients taking ximelagatran because of a rise
in liver enzymes, but this was less common in patients taking the lowest dose of 24 mg twice
daily than in patients taking higher doses.
Comments
This phase II study compared the combination of aspirin with either ximelagatran or
placebo rather than another antithrombotic agent such as warfarin. This limits the
value of the study as it has previously been shown that the combination ofwarfarin
20















Fig. 7.4 ESTEEM trial. Cumulative risk of death, myocardial infarction, and severe recurrent
ischaemia. All ximelagatran doses pooled. Analysis by intention to treat.
Source: Wallentin L, Wilcox RG, Weaver WD, et a/. Lancet 2003; 362: 789-97.
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with aspirin is superior to aspirin alone in preventing death and thromboembolic
events after acuteMI |41|. Furthermore, a considerable proportion ofpatients did not
qualify for the study as they were excluded if antithrombotic agents other than
aspirin or a PCI were indicated.
A recent report for the FDA |33| where adverse events were pooled and analysed
(post hoc), raised concern that the incidence of coronary events was higher in the
patients treated with ximelagatran. These data are mainly drawn from a group of
patients receiving prophylactic treatment for VTE after total knee replacement
(EXULT A and B studies) for a brief period and the numbers, although statistically
significant, are low. The underlying mechanism is also unclear, although one possi¬
bility is a rebound prothrombotic effect after drug withdrawal.
The direct thrombin inhibitor melagatran followed by oral
ximelagatran compared with enoxaparin for the
prevention of venous thromboembolism after total hip or
knee replacement: The EXPRESS study
Eriksson Bl, Agnelli G, Cohen AT, eta/., on behalf of the EXPRESS study group.
J Thromb Haemost 2003: 1: 2490-6
Background. A total of 2835 patients undergoing total hip or knee replacement
at 77 centres were randomized in a double-blind manner to receive VTE prophylaxis,
comparing melagatran followed by ximelagatran to enoxaparin. Melagatran, 2 mg,
was given subcutaneously immediately prior to surgery, 3 mg at least 8 h later and
then oral ximelagatran 24 mg twice daily. Patients receiving enoxaparin were given
the first dose of 40 mg subcutaneously 12 h before surgery and then once daily.
Prophylaxis was continued for 8-11 days when a venogram was performed. Other
anticoagulant or antiplatelet agents were prohibited apart from non-steroidal anti¬
inflammatory drugs including aspirin. The first-stage primary efficacy outcome (to
show non-inferiority within 2%) was major VTE during the treatment period: proximal
deep venous thrombosis, pulmonary embolism and/or death where pulmonary
embolism could not be ruled out. The second-stage primary efficacy outcome
(designed to show superiority of melagatran/ximelagatran) was: all deep venous
thrombosis (proximal or distal), pulmonary embolism and/or death from any cause.
Interpretation. About 80% of patients had venograms that could be appropriately
analysed. The rate of major deep venous thrombosis was lower in patients given
ximelagatran, 2.3% versus 6.3% in the enoxaparin group (absolute risk reduction 4.0%;
P = 0.0000018), although there was a smaller benefit in favour of ximelagatran in reducing
rate of total deep venous thrombosis (20.3% vs 26.6%; P <0.0004). The rate of
symptomatic deep venous thrombosis and pulmonary embolism was lower than 1% in both
groups during the study period. More patients in the ximelagatran (3.3%; 95% CI 2.4-4.4)
than enoxaparin group (1.4%; 95% CI 0.7-1.9) had severe bleeding. The investigators'
conclusion was that melagatran/ximelagatran was non-inferior and was indeed superior to
enoxaparin for VTE prophylaxis.
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Comments
Increased bleeding was seenmainly in patients undergoing total hip replacement and
not in patients having total knee replacement. This might be explained by the fact
that an arterial tourniquet is commonly applied during knee replacement surgery. This
additional bleeding risk did not cause increased mortality or wound complications.
Large orthopaedic operations such as total hip and knee replacements carry a high
risk of post-operative VTE. Current guidelines recommend at least 7-10 days of
prophylactic anticoagulation but there is evidence that VTE prophylaxis for
4-5 weeks after the operation is beneficial |42,43|. More convenient anticoagulants
might increase the use ofprolonged prophylactic treatment.
Direct thrombin inhibitor melagatran followed by oral
ximelagatran in comparison with enoxaparin for
prevention of venous thromboembolism after total hip or
knee replacement: The METHRO III study
Eriksson Bl, Agnelli G, Cohen AT, et a/. J Thromb Haemost 2003; 89: 288-96
Background. The study compared melagatran/ximelagatran with enoxaparin for
VTE prophylaxis after total hip or knee replacement. Two thousand seven hundred
and eighty-eight patients were randomized to receive for 8-11 days: either 3 mg
melagatran s.c. starting 4-12 h post-operatively, followed by oral ximelagatran
24 mg twice daily; or enoxaparin 40 mg s.c. once daily. The primary efficacy
end-point was VTE (composite of deep-vein thrombosis detected by mandatory
venography, pulmonary embolism or unexplained death).
Interpretation. Venous thromboembolism occurred in 31.0% in the ximelagatran
group compared with 27.3% in the enoxaparin group, an absolute risk reduction of 3.7% in
favour of enoxaparin (P = 0.053). The incidence of bleeding was similar.
Comments
It was on the basis of this study that a slightly different dosing regime was used in the
EXPRESS study. In the METHRO III study the melagatran was started 4—12 h post¬
operatively, but was started immediately prior to surgery in EXPRESS. This might
explain the observation that patients receiving ximelagatran in the EXPRESS study
had a slightly higher risk ofbleeding but lower risk ofVTE than in the METHRO III
study. Studies on new anticoagulant agents are often first carried out in patients
undergoing large orthopaedic operations, as the risk of venographically proven VTE
is high and fewer participants are thus required to reach a statistically significant
difference.
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A randomized, controlled, dose-guiding study of the oral
direct thrombin inhibitor ximelagatran compared with
standard therapy for the treatment of acute deep vein
thrombosis: THRIVE I
Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S.
J Thromb Haemost 2003; 1: 41-7
Background. This was a phase II dose-finding study of 350 individuals with acute
deep venous thrombosis comparing ximelagatran (24, 36, 48 or 60 mg twice daily)
with LWMH followed by warfarin. Treatment was started at diagnosis and continued
for 14 days, when a second venogram was performed.
Interpretation. Similar changes in thrombus size and clinical symptoms occurred in all
groups. No difference in bleeding was detected and major bleeding was rare.
Comments
THRIVE II and V are currendy ongoing double-blind phase III studies for treatment
of deep vein thrombosis and/or pulmonary embolism that may give further evidence
for the use ofximelagatran in this large group ofpatients. They are also likely to pro¬
vide valuable data regarding potential adverse effects includingMI.
Secondary prevention of venous thromboembolism with
the oral direct thrombin inhibitor ximelagatran. THRIVE
III
Schulman S, Wahlander K, Lundstrom T, Billing Clason S, Erikson H for the
THRIVE III Investigators. N Engl J Med 2003; 349:1713-21
Background. Ximelagatran was compared with placebo for secondary prophylaxis
of deep vein thrombosis. One thousand two hundred and thirty-three patients who
had already received conventional anticoagulation for 6 months after a confirmed
deep vein thrombosis or pulmonary embolus were randomized to receive either
ximelagatran 24 mg twice daily or placebo for 18 months. Objective tests were
undertaken if there was a clinical suspicion of new deep venous thrombosis or
pulmonary embolism. People with cancer were included in the study unless they had
a clear indication for continuing anticoagulation.
Interpretation. Ximelagatran significantly reduced the rate of recurrent
thromboembolic events compared with placebo (2.8% vs 12.6%; HR 0.16, 95% CI
0.09-0.30; P <0.001) and this risk reduction continued to increase overtime. Rate of
bleeding was low (<1%) and similar in both groups.
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Comments
There is an increased risk of recurrence after a first deep vein thrombosis but pro¬
longed treatment has traditionally not been given unless major risk factors are present.
Previous studies comparing placebo with long-term warfarin have also found reduced
incidence of recurrent thromboembolism |44-46|. Direct comparison is however
difficult as the duration of treatment differs. A trial designed to compare warfarin
and ximelagatran would be appropriate.
Comparison of ximelagatran with warfarin for the
prevention of venous thromboembolism after total knee
replacement
Francis CW, Berkowitz SD, Comp PC, et a/, for the EXULT A Study Group. N Engl
J Med 2003; 349: 1703-12
Background. This study followed an initial phase III trial which compared
ximelagatran 24 mg twice daily to warfarin after total knee replacement and found
ximelagatran to be at least as effective. The aim of this study was to determine
whether a higher dose of ximelagatran would be more effective than warfarin without
compromising safety. In this double-blind, multicentre study, 1851 patients were
randomized to receive either ximelagatran 24 mg twice daily, ximelagatran 36 mg
twice daily or warfarin for 7-12 days after total knee replacement.
Interpretation. Ximelagatran 36 mg twice daily was more effective than warfarin in
preventing the primary composite end-point of VTE and death from all causes
(20.3 % vs 27.6%; P = 0.003). There was no difference for the composite secondary
end-point of proximal deep vein thrombosis, pulmonary embolism and death or the rate of
major bleeding.
Comments
The primary end-point benefit was principally driven by a reduction in the rates of
distal deep vein thromboses, as diagnosed by venography. Such venous thromboses
are unlikely to cause pulmonary embolism or death. Ximelagatran was here com¬
pared with warfarin rather than LMWH for VTE prophylaxis after total knee replace¬
ment. This study is therefore mainly of relevance in the USA where warfarin is
commonly used as an anticoagulant after orthopaedic operations, whereas LMWH
is favoured in Europe. Furthermore, it takes warfarin 3-5 days to reach therapeutic
levels and INR levels were below the target range (1.8-3.0) in 35% of patients by day
three and 24% at the time of venography, highlighting how frequently patients
receiving warfarin are undertreated.
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Comparison of ximelagatran, an oral direct thrombin
inhibitor, with enoxaparin for the prevention of venous
thromboembolism following total hip replacement.
A randomized, double-blind study
Colwell CW, Berkowitz SD, Davidson BL, et al. J Thromb Haemost 2003; 1:
2119-30
Backqround. The aim of the study was to compare the efficacy and safety of
ximelagatran to enoxaparin following total hip replacement, with non-inferiority
pre-specified at 5%. This was a double-blind trial from 126 centres, mainly in the USA
and Canada. Starting from the morning after total hip replacement, 1838 patients
were randomized to either oral ximelagatran 24 mg twice daily or enoxaparin
30 mg s.c. twice daily for 7-12 days. Venography was performed on day 12. The
primary end-point was all venous thromboembolic events (deep vein thromboses that
were symptomatic or detected by routine venography and all pulmonary emboli).
Secondary end-points were proximal deep vein thromboses and/or pulmonary emboli
as well as bleeding events.
Interpretation. The incidence of VTE was higher in the ximelagatran group (7.9%
versus 4.6%; absolute difference 3.3% in favour of enoxaparin; 95% CI 0.9-5.7). Proximal
deep vein thromboses and/or pulmonary emboli occurred in 3.6% in the ximelagatran group
vs 1.2% in the enoxaparin group (absolute difference 2.4%; 95% CI 0.9-3.9). No significant
difference of bleeding was found. Elevated liver enzymes were more common in the group
that received enoxaparin.
Comments
The trial failed to show non-inferiority (within 5%) of ximelagatran at a dose of
24 mg twice daily versus enoxaparin in preventing VTE. The absolute difference was
3.3% in favour of enoxaparin with the upper limit of the 95% CI at 5.7%. Ximelaga¬
tran does not appear to be as effective as LMWH when administered post-operatively
but it should be emphasized that patients in this study did not receive peri-operative
melagatran, which is in contrast to the EXPRESS study. Oral factor Xa inhibitors
are also in development; comparison of these with LWMH will be of particular
interest.
Recent studies assessing efficacy and safety of
parenteral direct thrombin inhibitors (Table 7.3)
*
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Comparison of bivalirudin versus heparin during
percutaneous coronary intervention (the randomized
evaluation of PCI linking angiomax to reduced clinical
events [REPLACE] -1 trial)
Lincoff MA, Bittl JA, Kleiman NS, et a/. Am J Cardiol 2004; 93: 1092-6
Background. This was a pilot study carried out prior to REPLACE-2. One thousand
and fifty-six patients in the USA undergoing PCI were randomized to heparin or
bivalirudin during the procedure. All patients received aspirin. Clopidogrel was
encouraged and received by 56% before and 90% after the procedure. Glycoprotein
(GP) lla/lllb inhibitors were planned but at the physicians' discretion, and were given
in 72% of cases. Use of clopidogrel and GPIIa/Illb inhibitors was very similar between
the groups.
Interpretation. Composite end-point of death, Ml and repeat revascularization before
hospital discharge or within 48 h occurred in 5.6% of the bivalirudin versus 6.9% in the
heparin group (P = 0.40). Bleeding rate was similar but activated clotting times were higher
in the group that received bivalirudin (359 vs 293 sec; P <0.001), independent of GPIIa/lllb
inhibitor use.
Comments
This was a pilot study and treatment was not blinded. A statistically significant differ¬
ence was not established between the two groups. Subgroup analyses indicated that
bleeding rates were reduced with bivalirudin compared with heparin in those patients
who did not receive concomitant GPIIa/IIIb inhibitors, whereas there was a tendency
to reduce ischaemic events regardless ofGPIIa/IIIa inhibitor use. GPIIa/IIIb inhibit¬
ors were therefore used on a provisional rather than planned basis in REPLACE-II.
Bivalirudin and provisional glycoprotein llb/llla blockade
compared with heparin and planned glycoprotein llb/llla
blockade during percutaneous coronary intervention.
REPLACE-2 randomized trial
Lincoff MA, Bittl JA, Harrington RA, et al. JAMA 2003; 289: 853-63
Background. The aim of the study was to compare the direct thrombin inhibitor
bivalirudin and provisional GPIIb/llla inhibitor with heparin and planned GPIIb/llla
inhibitor during urgent or elective PCI. All patients received aspirin and clopidogrel
for at least 30 days after the procedure and a loading dose before PCI was also
encouraged. The primary composite end-point was 30-day incidence of death, Ml,
urgent repeat revascularization or in-hospital major bleeding. The secondary
composite end-point was death, Ml or urgent repeat revascularization within 30 days.
G-
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Interpretation. In a double-blind manner, 3008 patients were randomized to heparin
plus GPIIb/llla inhibitor and 2994 patients to bivalirudin. In the bivalirudin group, only
7.2% were given a GPIIb/llla inhibitor. Patients in the bivalirudin group had higher activated
clotting time values. Death, Ml, urgent repeat vascularization or in-hospital major bleeding
occurred in 10% in the heparin plus GPIIb/llla group and in 9.2% of the bivalirudin group
(P = NS). Secondary end-points were also similar, 7.1% for heparin plus GPIIb/llla compared
with 7.6% for bivalirudin. Thrombocytopenia (platelet count <100) was more common in the
heparin plus GPIIb/llla group (1.7 vs 0.7%; P <0.001).
Comments
The main strength and aim of this study was to compare bivalirudin to heparin using
aggressive antiplatelet strategywith aspirin, dopidogrel and GPIIa/IIIb inhibitors.
There was a small numerical (0.5%) but non-significant difference in ischaemic
events. Bleeding was less common in the bivalirudin group, mostly as a result of
reduced bleeding at the site of vascular access (2.5% vs 0.8%; P <0.001) as well
as minor bleeding (25.7% vs 13.4%; P <0.001). Patients with acute MI or unstable
ischaemia were excluded from the trial and these results should not be extrapolated
to this clinical setting. Only a small minority of patients in the bivalirudin group
(7.2%) received a GPIIb/IIIa inhibitor, and bivalirudin alone would be less expensive
than combined heparin plus GPIIb/IIIa inhibition. Bivalirudin, unlike heparin, is
likely to reduce thrombin-mediated platelet activation, which would be beneficial
during PCI.
It is of particular interest that 85% of patients received pre-treatment with a
thienopyridine, predominantly clopidogrel. The recent ISAR-REACT study |47| of
elective PCI showed that there was no additional benefit of giving a GPIIb/IIIa
inhibitor in patients pre-treated with clopidogrel. The ISAR-REACT trial therefore
raises the question ofwhether the results ofREPLACE-2 reflect the beneficial effects
of thienopyridine use rather than the equivalence of bivalirudin and a GPIIb/IIIa
inhibitor. However, a recent re-analysis of the REPLACE-2 data suggests that the
benefits of bivalirudin over heparin plus GPIIb/IIIa blockade are not influenced by
clopidogrel pre-treatment |48|.
Argatroban anticoagulation in patients with heparin-
induced thrombocytopenia
Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG for the Argatroban-915
Investigators. Arch Intern Med 2003; 163: 1849-56
Background. This was a prospective non-randomized study treating 418 patients
with HIT with argatroban for 5-7 days. This was compared with a historical control
cohort of 185 people. Patients were divided into two groups: those with isolated HIT
(n = 189) or HIT with thrombosis (HITTS; n = 229). Activated partial thromboplastin
time was used to monitor anticoagulation. The primary end-point was a composite of
death from all causes, amputation or new thrombosis in 37 days.
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Interpretation. There was a statistically significant difference in the occurrence of the
primary end-point in the isolated HIT study group who received argatroban compared with
control (28.0% vs 38.8%; P = 0.04) but not in the HITTS group where 41.5% of argatroban-
treated patients had a primary composite end-point versus 56.5% of controls (P = 0.07).
There was, however, a significant reduction of recurrent thrombosis in both the HIT
(P = 0.02) and HITTS groups (P = 0.008), as well as a reduction in death as a result of
thrombosis in the HITTS group. The rates of bleeding were similar.
Comments
There are inherent limitations in using a historical control group, in particular when
there is little information about how the control group was treated, mainly cessation
of heparin. Low molecular weight heparin and warfarin are contraindicated in HIT
because of the risk of cross-reaction with heparin antibodies or worsening throm¬
bosis |49|. Direct thrombin inhibitors are thus a promising treatment option for this
challenging condition and it would be interesting to see comparisons with other
direct thrombin inhibitors.
Argatroban anticoagulation in patients with acute
ischaemic stroke (ARGIS-1). A randomized, placebo
controlled safety study
LaMonte MP, Nash ML, Wang DZ, et a/, for the ARGIS-1 Investigators. Stroke
2004; 35: 1677-82
Background. The aim of the study was to assess the safety of argatroban
anticoagulation in acute ischaemic stroke. This was a multicentre, randomized,
double-blind study of 171 patients with acute stroke. Patients received intravenous
argatroban at either high or low dose or placebo for 5 days. The primary outcome was
symptomatic intracranial haemorrhage at 30 days. Activated partial thromboplastin
times were monitored during treatment.
Interpretation. The incidence of symptomatic intracranial haemorrhage was not
significantly different (high dose argatroban 5.1%, low dose argatroban 3.4%, placebo 0%;
P >0.18) and neither was the incidence of asymptomatic intracranial haemorrhage, major
systemic haemorrhage or 90 day mortality.
Comments
These results are in contrast with studies that have shown an increased risk of bleed¬
ing complications after heparin or LMWH in patients with ischaemic stroke. It is
also concerning that there was a trend of increased intracranial haemorrhage in the
argatroban groups, although this was not statistically significant. This was a safety
study and did not have the power to assess the efficacy of argatroban treatment, but
previous studies have suggested a possible treatment benefit |50,51|.
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Key safety issueswith direct thrombin inhibitors
The new thrombin inhibitors, in particular ximelagatran, have now been tested in at
least 17 000 people in large clinical trials. This experience does not, however, match
our knowledge of warfarin, which has been in clinical use for half a century. The
main concern regarding the oral direct thrombin inhibitor ximelagatran has been a
considerable (>3X upper limit of normal) elevation of plasma concentrations of
liver transaminases in approximately 6-7% of people taking the drug and the rather
unexpected increased rate ofMI in VTE prevention studies. The clinical significance
and mechanism behind ximelagatran-induced liver injury is unknown and needs to
be defined further before it can be considered for widespread use. For some patients,
the liver injury has been quite severe and potentially life-threatening.
The finding that short-term use of ximelagatran might carry an increased risk of
acute coronary events was unexpected and rather counterintuitive. Post hoc analyses
can bemisleading and the absolute number of events involved is small. However, this
potential adverse effect needs to be prospectively reassessed.
Warfarin has a large number of major limitations and serious adverse effects, and
is far from an ideal anticoagulant. Ultimately, as with the liver derangements and
rhabdomyolysis with statins, it remains to be established whether the benefits
outweigh the risks of therapy with ximelagatran. Advantages and disadvantages of
warfarin and ximelagatran are compared in Table 7.4.
Clinical studies of bivalirudin so far indicate that the drug has a very acceptable
safety profile with no reported specific adverse effects and no idiosyncratic reactions.
There is an inherent risk of bleeding associated with all anticoagulants, but
bivalirudin is at least as safe as heparin and it has a short plasma half-life. Because of
its partial renal excretion, the dose ofbivalirudin should be adjusted in patients with
renal impairment.
Table 7.4 Main advantages and disadvantages of warfarin and ximelagatran
Warfarin: advantages
Long half-life
Dose can be titrated to required INR





Slow onset of action
Regular and frequent monitoring required
Ximelagatran: advantages
Rapid onset of action
Monitoring of anticoagulation not required




Deranged liver function tests (—6%)
Fixed level of anti-coagulation
Short half-life requiring bid dosing
No antidote
Source: compiled by present authors.
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Conclusions
There are major limitations and problems with established anticoagulant therapies
such as warfarin and heparin. The advent of safe, effective and easier to use anticoag¬
ulant therapies is needed and welcome. Direct thrombin inhibition is an exciting,
potentially important and useful new option in the treatment and prophylaxis
of vascular thrombosis. However, many questions remain unanswered and direct
thrombin inhibitors have so far only been tested in selected patient groups under
clinical trial conditions. Questions of safety have been raised with the first orally
active agent, ximelagatran. Anticoagulation levels reached with ximelagatran are
fixed and thus might not be sufficient for conditions traditionally requiring higher
INR levels such as patients with prosthetic heart valves. The benefits ofnot having to
monitor anticoagulation levels are, at least partly, offset by the need to monitor liver
function and increased cost ofmedications.
The effects of prolonged direct thrombin inhibition are unknown. Thrombin not
only acts in the coagulation system but has a widespread physiological role in cell
signalling, largely through activation of proteinase-activated receptors. Studies, mainly
on small animals, have suggested that thrombin inhibition might reduce tumour inva¬
sion and metastases, and be beneficial in inflammatory conditions |52|. Whether these
potential benefits are likely to extend to adjuvant therapy in patients with cancer or as
secondary prevention in patientswith coronary heart disease remains to be established.
We are likely to see a major expansion in the indications for, and use of thrombin
inhibitors over the next few years and decades. Time will tell whether, and which,
new anticoagulants will supersede warfarin and heparin. However, the ease of use,
lack of the necessity for anticoagulant monitoring and the apparent low incidence of
interactions and side effects, make direct thrombin inhibitors very attractive thera¬
pies for patients and clinicians in the fight against vascular diseases.
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Vascular Medicine
Direct Vascular Effects of Protease-Activated Receptor
Type 1 Agonism In Vivo in Humans
Ingibjorg J. Gudmundsdottir, MD; Ian L. Megson, PhD; Jillian S. Kell, BSc;
Christopher A. Ludlam, MD; Keith A.A. Fox, MD; David J. Webb, MD; David E. Newby, MD, PhD
Background—Protease-activated receptor type 1 (PAR-1) has been proposed as the principal thrombin receptor in humans,
although its actions in vivo have not been defined. The aim of the present study was to determine the direct vascular
actions of PAR-1 agonism in humans.
Methods and Results—Dorsal hand vein diameter was measured by the Aellig technique in 14 healthy volunteers during
local intravenous SFLLRN (PAR-1 agonist; 0.05 to 15 nmol/min) and SLIGKV (PAR-2 agonist; 1.6 to 160 nmol/min)
infusions. The venous effects of SFLLRN were further assessed in the presence or absence of norepinephrine or the
glycoprotein Ilb/IIIa antagonist tirofiban. Forearm blood flow was measured by venous occlusion plethysmography in
16 volunteers during infusion of SFLLRN (1 to 50 nmol/min), SLIGKV (160 to 800 nmol/min), and the
endothelium-dependent vasodilator bradykinin (100 to 1000 pmol/min). Platelet-monocyte binding (a sensitive measure
of platelet activation) and plasma tissue plasminogen activator (tPA), plasminogen-activator inhibitor 1, and von
Willebrand factor concentrations were measured at intervals throughout the study. SFLLRN caused dose-dependent
venoconstriction (P<0.001) that was unaffected by norepinephrine or tirofiban co-infusion. In forearm resistance
vessels, SFLLRN increased forearm blood flow (P<0.001), tPA release (P<().0()1), and platelet-monocyte binding
(P<0.0001) without affecting plasma plasminogen-activator inhibitor 1 or von Willebrand factor concentrations.
SLIGKV caused venous (PC0.001) and arterial (P<0.01) dilatation without tPA release.
Conclusions—We have demonstrated that PAR-1 agonism causes platelet activation, venous constriction, arterial
dilatation, and tPA release in vivo in humans. These unique and contrasting effects provide important insights into the
physiological and pathophysiological role of thrombin in the human venous and arterial circulations. (Circulation. 2006;
114:1625-1632.)
Key Words: platelets ■ blood flow ■ veins ■ arteries ■ receptor, PAR-1 ■ receptor, PAR-2
Thrombin is a powerful physiological stimulant in thecardiovascul r system. Apart from its central enzymatic
role in the coagulation cascade, it directly activates platelets,
leukocytes, and vascular smooth muscle and endothelial
cells.' Thrombin is therefore a vital link between thrombosis,
cellular activation, and inflammation, key pathogenic factors
in atherothrombotic disorders.
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Given the apparent direct cellular effects of thrombin,
cloning methods2-3 were used to conduct an extensive search
for its receptor. This led to the identification of G-protein-
coupled protease-activated receptors (PARs) characterized by
a unique mechanism of activation whereby proteolytic cleav¬
age unmasks a short peptide sequence that remains tethered
and activates the receptor.2-4 Four different types of PARs
have been identified. PAR-1, -3, and -4 are all activated by
thrombin. The type 1 receptor has been proposed as the
principal thrombin receptor in humans.5-6 In contrast, the
PAR-2 receptor is activated by trypsin, by tryptase, and to a
lesser extent by coagulation factors upstream of thrombin.7 It
appears to be of importance in inflammatory conditions that
induce endothelial PAR-2 expression and vasodilatation.
PAR-1 receptor agonism has been extensively studied in
vitro and is associated with platelet activation and aggrega¬
tion,8 vasodilatation,9 and angiogenesis.10 Although studies in
small animals suggest that PAR-1 and PAR-2 agonism induces
vasodilatation,"-12 there is significant species heterogeneity, and
rodent models are of limited relevance to humans.13 Exploring
the role of PAR-1 receptors in the human vasculature would
deepen our understanding of the physiological role of thrombin
and would be of interest in the development of new therapeutic
strategies such as PAR-1 receptor antagonists14-15 and direct
thrombin inhibitors.16-17
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TABLE 1. Baseline Characteristics of Study Volunteers
Male, % 79 (41/52)
Age, y 24±0.5
Body mass index, kg/m2 O-HCOCM
Heart rate, bpm* 67±2




White cell count, X109/L* 4.98±0.37
Platelets, X109/L4 213±11
Values are mean±SEM.
*Data from vascular studies only.
Therefore, the aims of the present study were to determine
the direct in vivo vascular effects of PAR-1 agonism in the
human vasculature. Specifically, we wished to assess the
direct role of PAR-1 activation on platelet activation and
aggregation, venous and arterial tone, and the release of
endothelium-derived factors in vivo in humans.
Methods
Subjects
Fifty-two healthy male and female nonsmokers (age, 20 to 38 years)
were recruited into the study (Table 1). Participants had not been
taking any regular medications, over-the-counter medications, herbal
supplements, or vitamins. They did not have clinically significant
coexisting conditions, including hypertension, hyperlipidemia, dia¬
betes mellitus, asthma, and coagulopathy, and had not suffered a
recent infective or inflammatory condition. The study was approved
by the local research ethics committee and conducted in accordance
with the Declaration of Helsinki and with the written informed
consent of all volunteers.
Platelet Studies
Protocol 1: Platelet Aggregometry
Blood was sampled with a 19-gauge needle from the antecubital
fossa into a 50-mL syringe, transferred into tubes containing 3.8%
citrate, and centrifuged at 130g for 20 minutes at room temperature
to obtain platelet-rich plasma. Blood was centrifuged at 1200g for 10
minutes to obtain platelet-poor plasma for reference samples. Platelet
aggregation was measured at 37°C using standard optical platelet
aggregometry.18-19
Preliminary in vitro platelet studies were carried out to construct
concentration-response curves to define the concentration of the PAR-1
agonist SFLLRN-NH, that caused platelet activation and aggregation.
SFLLRN-NH, (Auspep, Parkville Victoria, Australia) was compared with
the thromboxane A, agonist U46619 (Sigma, Gillingham, UK) in both
platelet-rich plasma and washed platelets.18 To assess the specificity of the
PAR-1-activating peptide, both SFLLRN-NH2- and U46619-induced




4-difluorobenzenepropanamide; American Peptide Co, Sunnyvale, Calif) in
washed platelets. SFLLRN-NH,-induced platelet aggregation was also
assessed in the presence of the direct thrombin inhibitor lepimdin (0.1 and
1.0 mg/mL; Schering, Burgess Hill, UK).
We chose the concentration of SFLLRN-NH, that caused nearly
maximal platelet aggregation and assumed that the vascular and
platelet PAR-1 receptor sensitivities were equivalent. However,
before progressing to in vivo infusions, we defined the dose of
tirofiban that would completely inhibit platelet aggregation using the
clinical-grade preparation of SFLLRN-NH,. Platelet-rich plasma was
incubated for 5 minutes in the presence or absence of tirofiban
(Merck, Sharp and Dohme, Hoddesdon, UK) at 50 ng/mL.20 Platelet
aggregation was measured after administration of 0.06 to 12 pimol/L
of the PAR-l-activating peptide SFLLRN-NH2 (Clinalfa, Laufelfin-
gen, Switzerland) by a 4-channel platelet aggregometry profiler
(PAP-4D, Bio/Data Corp, Horsham, Pa) linked to PC interface
software (Platelet Aggregation Profiler, version 2.3, Bio/Data Corp).
Protocol 2: Platelet-Monocyte Binding
Venous blood (5 mL) was collected through a 19-gauge needle and
transferred into a tube containing the direct thrombin inhibitor
D-phenylalanyl-L-propyl-L-arginine chloromethylketone. For in
vitro studies, blood was collected into 2 D-phenylalanyl-L-propyl-L-
arginine chloromethylketone tubes containing either tirofiban (50
ng/mL) or SFLLRN-NH, (0.06 to 6 pmol/L). Five minutes after
sampling, blood was incubated with appropriate monoclonal and
bodies labeled with fluorochromcs for 20 minutes, and platelet
monocyte aggregates were measured as described previously.21
Vascular Studies
All studies were carried out in a quiet, temperature controlled room
(22°C to 24°C). Participants were semirecumbent (venous studies) or
supine (arterial studies) and had abstained from alcohol for 24 hours
and from food and caffeine-containing drinks for at least 4 hours
before the study.
Venous Studies
A 23-gauge needle was sited in a dorsal hand vein, and the total
infusion rate was kept constant at 0.25 mL/min in all studies. The
hand was supported above the level of the heart and an upper arm
cuff inflated to 40 mm Hg to obstruct venous return. The internal
diameter of the dorsal hand vein was measured by the Aellig
technique.22 In brief, a magnetized lightweight rod rested on the
summit of the infused vein ~ 1 cm downstream from the tip of the
infusion needle. The rod passed through a core of a linear variable
differential transformer, supported above the hand by a small tripod.
Changes in vein diameter caused vertical displacement of the rod,
leading to a linear change in the voltage generated by the linear
variable differential transformer. This enabled calculation of abso¬
lute changes in vein size.
Protocol 3: Effect on Venous Tone
Because dorsal hand veins do not have resting tone, norepinephrine
(1 to 128 ng/min) was used to induce and maintain a 50% to 70%
reduction in vein diameter throughout the study to allow detection of
either venodilatation or venoconstriction. This was followed by
co-infusion of the PAR-l-activating peptide SFLLRN-NH, (0.05 to
5 nmol/min) or the PAR-2-activating peptide SLIGKV-NH, (1.6 to
160 nmol/min; Clinalfa).
Protocol 4: Effect ofGlycoprotein Ilb/IIIa Receptor Antagonism
The effects of SFLLRN-NH, (0.05 to 15 nmol/min) in the presence
and absence of the glycoprotein Ilb/IIIa inhibitor tirofiban (250
ng/min) and norepinephrine (1 to 128 ng/min) were assessed to
determine the importance of platelet aggregation on PAR-l-medi-
ated alterations of venous tone. The doses of tirofiban and SFLLRN-
NH, were chosen to achieve end-organ concentrations equivalent to
those with efficacy in in vitro studies (protocol 1) and assumed a
dorsal hand vein flow of 5 mL/min.
Arterial Studies
All subjects underwent brachial artery cannulation with a 27-
standard-wire-gauge steel needle under controlled conditions. Intra¬
arterial infusion rate was kept constant at 1 mL/min throughout all
studies. Forearm blood flow was measured in the infused and
noninfused arms by venous occlusion plethysmography using
mercury-in-Silastic strain gauges as described previously.23-24 Su¬
pine heart rate and blood pressure were monitored at intervals
throughout each study using a semiautomated noninvasive oscillo¬
metry sphygmomanometer. Tirofiban (1.25 /xg/min) was co-infused
during PAR-1 activation to inhibit in vivo potential platelet aggre-
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Figure 1. Induction of platelet aggrega¬
tion by the PAR-1-activating peptide
SFLLRN-NH2 (A) and the thromboxane
A2 agonist U46619 (B; P<0.001 for both,
1 -way ANOVA). The PAR-1 antagonist
RWJ-58259 inhibited aggregation
induced by SFLLRN-NH2 (C; P<0.001,
1-way ANOVA) but not by U46619 (D;
P=NS). Values are mean±SEM.
gation. The doses of tirofiban and SFLLRN-NH. were chosen to
achieve end-organ concentrations equivalent to those with efficacy in
in vitro studies (protocol 1) and assumed a brachial artery blood flow
of 25 mL/min.
Blood Sampling
Venous cannulas (17 gauge) were inserted bilaterally into the
antecubital fossae. Blood samples were drawn simultaneously from
each arm during infusion of saline, tirofiban, and each dose of the
PAR-activating peptides and bradykinin. They were collected into
acidified buffered citrate (Stabilyte, Trinity Biotech Pic, Co Wicklow,
Ireland; for tissue plasminogen activator [tPA] assays) and into citrate
(BD Vacutainer, BD UK Ltd, Oxford, UK; for plasminogen activator
inhibitor type 1 [PAI-1] and von Willebrand factor [vWF] assays).
Samples were kept on ice before centrifugation at 2000g for 30 minutes
at 4°C. Platelet-free plasma was decanted and stored at — 80°C before
assay. Plasma tPA antigen and activity (tPA Combi Actibind Elisa Kit,
Technoclone, Vienna, Austria) and PAI-1 antigen and activity
(ElitestPAI-1 Antigen and Zymutest PAI-1 Activity, Hyphen Biomed,
Neuville-Sur-Oise, France) concentrations were determined by ELISAs.
Full blood count was measured at baseline and at the end of the study.
Blood was also collected from each arm to determine platelet-monocyte
binding (see protocol 2) at baseline, at the highest dose of SFLLRN-
NH2, during saline washout, and at the highest dose of bradykinin.
Protocol 5: PAR-1 Activation
After a 20-minute baseline saline infusion, tirofiban (1.25 pg/min)
was infused throughout the study. Thirty minutes after the tirofiban
infusion was started, the PAR-l-activating peptide SFLLRN-NH.
was co-infused at 5, 15, and 50 nmol/min for 8 minutes at each dose
separated by 6 minutes of saline washout infusions. This was
followed by a 30-minute washout period before co-infusion of
bradykinin (an endothelium-dependent vasodilator that releases tPA;
Clinalfa) at 100, 300, and 1000 pmol/min25 for 8 minutes at each
dose.
Protocol 6: PAR-2 Activation
After a 20-minute baseline saline infusion, the PAR-2-activating
peptide SLIGKV-NH, was infused at 160, 360, and 800 nmol/min
for 8 minutes at each dose separated by 6 minutes of saline washout
infusions. This was followed by a 30-minute saline infusion before
bradykinin was infused at 100, 300, and 1000 pmol/min25 for 8
minutes at each dose.
Data and Statistical Analyses
Dorsal hand venous26 and forearm plethysmography23 data were
analyzed as described previously. Variables are reported as
mean±SEM and analyzed using repeated-measures 1- or 2-way
ANOVA with post-hoc Bonferroni corrections and 2-tailed Student
t test as appropriate. Statistical analysis was performed with Graph-
Pad Prism (GraphPad Software, Inc, San Diego, Calif). Statistical
significance was taken at PC0.05.
The authors had full access to the data and take responsibility for their
integrity. All authors have read and agree to the manuscript as written.
Results
In Vitro Effects of PAR Agonism on Platelets
Both SFLLRN-NHj and U46619 caused dose-dependent
platelet aggregation (median effective concentration
[EC5o]=1.26 and 0.78 /xmol/L, respectively; Figure 1A and
IB; n=8). The PAR-1 antagonist RWJ-58259 selectively and
fully inhibited SFLLRN-NH2-induced (Figure 1C; n=8;
P<0.001, 1-way ANOVA) but not U46619-induced (Figure
ID; n=8; P=NS) platelet aggregation. In contrast, the direct
thrombin inhibitor lepirudin had no effect on SFLLRN-NH2-
induced platelet aggregation (n=6; P=NS; data not shown).
The clinical-grade SFLLRN-NH2 also caused a dose-
dependent increase in platelet aggregation (EC50=0.66 p.mol/L)
that was inhibited by tirofiban (Figure 2A; n=6; P<0.001,
2-way ANOVA). In contrast, PAR-1 activation caused a dose-
dependent increase in whole-blood platelet-monocyte binding
(EC5o=0.23 pimol/L) that was not affected by tirofiban (Figure
2B; n=6; P=NS, 2-way ANOVA). As anticipated, PAR-2

























Figure 2. PAR-1-activating peptide
(SFLLRN-NH2) induced platelet aggrega¬
tion (A) and platelet-monocyte binding
(B) in the presence (*) or absence (□) of
tirofiban (50 ng/mL). Values are
mean±SEM. A, P<0.0001 (2-way
ANOVA) vs tirofiban; B, P=NS (2-way
ANOVA) vs tirofiban.
activation with SLIGKV-NH, induced neither platelet aggrega¬
tion nor platelet-monocyte binding (n=?3; data not shown).
In Vivo Effects of PAR Agnnism on Dorsal
Hand Veins
After venoconstriction (50% to 70%) was induced and main¬
tained with norepinephrine, SFLLRN-NH2 and SL1KGV-NH2
caused dose-dependent venoconstriction (n=8; P<0.001, 1-way
ANOVA) and venodilatation (n=6; PC0.001, 1-way ANOVA),
respectively. In the absence of norepinephrine, SFLLRN-NH2
caused a dose-dependent venoconstriction (P<0.001, 1-way
ANOVA) that was able to induce complete constriction of the
venous segment. This was not mediated by platelet aggregation
because co-infusion of tirofiban had no effect on SFLLRN-
NH2-induced venoconstriction (Figure 3). SFLLRN-NH2 was
well tolerated by all subjects with no adverse effects. Vein
patency was maintained at all times with no clinically apparent
in situ thrombus formation.
In Vivo Effects of PAR Agonism on Forearm
Resistance Vessel Tone
There was no change in heart rate, blood pressure, or
noninfused forearm blood flow throughout either study.
Intra-arterial tirofiban had no effect on resting forearm blood
flow (P=NS). Both PAR-1 activation with SFLLRN-NH2






















0 30 40 50 60 70 80 90 100 m min




r 10 20 30 40 Al 00 7b miff










0 30 40 50 60 70 80 90 100 min









0 10 20 30 40 50 60 70 min
SFLLRN (nmot'min) 0.0510.15) 1,5 15
Tirofiban
Figure 3. The PAR-1-activating peptide
SFLLRN-NH2 causes concentration-
dependent venoconstriction (■; n=6 to 8;
P<0.001, 1-way ANOVA) that is unaf¬
fected by norepinephrine (A, B) or tirofi¬
ban (C, D) infusion, whereas the PAR-2-
activating peptide SLIGKV-NH2 (E)
induces venodilatation (□; n=6; P<0.001,
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Figure 4. Forearm vasodilatation induced
by the PAR-1-activating peptide
SFLLRN-NH2 (A; ■; n=8; P<0.001,
1-way ANOVA), the PAR-2-activating
peptide SLIGKV-NH2 (C; □; n=8; P<0.01,
1-way ANOVA), and bradykinin (B, •; D,
o; n=8; P<0.001, 1-way ANOVA). Values
are mean±SEM. *P<0.05, **P<0.01,
***P<0.001.
dependent vasodilatation (Figure 4A and 4C; n=8; P<0.001
and P<0.01, respectively, 1-way ANOVA) with a rapid onset
and offset of action. As anticipated, bradykinin increased
forearm blood flow (Figure 4B; P<0.001, 1-way ANOVA)
and was unaffected by tirofiban co-infusion (Figure 4D;
P=NS versus no tirofiban).
In Vivo Effects of PAR Agonism on
Endothelium-Derived Factors
Plasma tPA antigen and activity concentrations increased in a
dose-dependent manner during SFLLRN-NH2 and bradykinin
but not SLIGKV-NH2 infusion (Figure 5; P<0.001 for all).
Plasma PAI-1 antigen and activity and vWF concentrations
were unaffected by all infusions (P=NS for all; Table 2).
Although there was an apparent rise in plasma PAI-1 antigen
concentration at 50 nmol/min SFLLRN-NH2, it did not
achieve statistical significance (P=0.08, paired t test versus
baseline) and was not associated with increases in PAI-1
activity or vWF. There were no differences in peripheral
blood hematocrit (0.416±0.006 versus 0.426±0.008) or
platelet counts (213±16X109 versus 216±15X10'/L) at
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Figure 5. Plasma tPA antigen (solid lines)
and activity (dashed lines) during infusion
of the PAR-1-activating peptide
SFLLRN-NH2 (■) and bradykinin (•). Val¬
ues are mean±SEM.
Tirofiban
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TABLE 2. Plasma PAI-1 Antigen and Activity and vWF Antigen Concentrations in the Infused and
Noninfused Arms During Brachial Artery Infusion of SFLLRN-NH2 and Bradykinin
PAI-1 Antigen, ng/mL PAI-1 Activity, U/mL vWF Antigen, ng/mL
Infused Arm Noninfused Arm Infused Arm Noninfused Arm Infused Arm Noninfused Arm
Baseline 27.3±5.5 27.7±5.6 0.58±0.14 0.51 ±0.13 0.72±0.08 0.72±0.07
Tirofiban 25.6±5.5 24.5±4.4 0.40±0.09 0.43±0.12 0.69±0.04 0.62±0.08
SFLLRN-NH2, nmol/min
5 23.0 ±4.7 24.9±4.4 0.44±0.12 0.47 ±0.11 0.62±0.06 0.67±0.08
15 24.3±4.5 23.8±4.4 0.41 ±0.10 0.41 ±0.11 0.67±0.06 0.74±0.10
50 33.8±6.8 26.9±5.3 0.37±0.09 0.42±0.09 0.73±0.08 0.76±0.08
Washout 22.9±4.2 23.1 ±3.6 0.32±0.08 0.33±0.08 0.67±0.09 0.74±0.09
Bradykinin, pmol/min
100 19.6 ±3.7 21,3±3.9 0.27±0.07 0.35±0.09 0.80±0.08 0.64±0.09
300 19.5±4.4 19.5±4.9 0.25±0.06 0.26±0.07 0.73±0.08 0.70±0.07
1000 19.5±3.2 19.1 ±2.9 0.16±0.03 0.25±0.05 0.76 ±0.07 0.67±0.07
n=8 for all. Values are mean±SEM.
vivo platelet-monocyte binding (from 16±5% to peak of
74±5%; Figure 6; PCO.OOOl, 1-way ANOVA) that declined
toward baseline with time.
The PAR-2-activating peptide SLIGKV-NH2 had no effect
of plasma tPA concentrations (P=NS for all; data not
shown).
Discussion
In a series of clinical studies, we have, for the first time,
described the direct vascular effects of PAR-1 agonism and
established the induction of in vivo platelet activation, veno-
constriction, vasodilatation, and tPA release, as well as
confirming the vasodilatory effects of PAR-2 agonism. These
unique and contrasting effects of PAR-1 activation provide
important insights into the physiological and pathophysiolog¬
ical roles of thrombin in the venous and arterial circulations
of humans.
Platelet Effects of PAR-Activating Peptides
Inhibition of platelet activation has been of major benefit in
the prevention and treatment of cardiovascular diseases.
Thrombin is one of the most potent physiological stimulants
of platelet activation that appears to be mediated largely
through the PAR-1 receptor, although major contributions are
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Figure 6. Platelet-monocyte binding during the infusion of the
PAR-1 agonist SFLLRN-NH2 in the infused (open bars) and non¬
infused (gray bars) arms. Values are mean±SEM.
date, strategies to reduce the action of thrombin have focused
on direct inhibition of its enzymatic activity. Recently,
PAR-1 antagonists have been developed as potential anti¬
platelet agents15 that do not affect the coagulation cascade. It
is therefore important to define the in vitro and in vivo effects
of PAR-1 agonism in humans. As anticipated, we have
demonstrated that PAR-1 but not PAR-2 agonism caused
concentration-dependent platelet activation and aggregation.
Moreover, in the presence of complete inhibition of platelet
aggregation with the glycoprotein Ilb/IIIa receptor antagonist
tirofiban, PAR-1 agonism continued to induce platelet acti¬
vation as measured by platelet-monocyte binding both in
vitro and in vivo. This is consistent with our previous findings
that although glycoprotein Ilb/IIIa receptor antagonism inhib¬
its platelet aggregation, it does not affect platelet activation or
platelet-monocyte binding.27
Vascular Effects of PAR-Activating Peptides
PAR-1 appears to be the principal receptor responsible for the
vascular actions of thrombin and includes the regulation of
vasomotion, platelet aggregation, inflammation, and angio-
genesis. However, investigation of the in vivo vascular
effects of thrombin presents challenges because of the direct
activation of the coagulation cascade and platelets that may
result in intravascular thrombosis. Here, we have chosen to
use PAR-activating peptides that cause direct cellular stimu¬
lation without enzymatic activation of the coagulation
cascade.
The direct vascular effects of PAR-1 receptor agonism
have not been previously reported in humans. Our study
protocol was vigilant to minimize any potential prothrom-
botic effects associated with PAR-l-induced platelet aggre¬
gation. We defined the in vitro concentrations of glycoprotein
Ilb/IIIa receptor antagonism that would permit the direct in
vivo intravascular infusion of PAR-l-activating peptide
without inducing platelet aggregation and potential thrombo¬
sis. This appears to have been successfully achieved, given
the absence of significant adverse clinical side effects or
thrombosis.
Gudmundsdottir et al Vascular Effects of PAR-1 Agonism In Vivo 1631
Venous Effects of PAR-Activating Peptides
Thrombin and the PAR-1 agonist SFLLRN-NH, have previ¬
ously been shown to cause endothelium- and nitric oxide-
dependent venous and arterial dilatation in canine and porcine
ring segments.28'29 Although confirming previous observa¬
tions of PAR-2-mediated venodilatation,30 we have rather
unexpectedly described a dose-dependent venoconstriction
with PAR-1 activation. This may be mediated by platelet
activation, release of endothelium-derived vasoconstrictors,
or a direct effect on venous smooth muscle cells. Neither
norepinephrine nor tirofiban co-infusion appeared to affect
this potent venoconstrictor effect. In combination with the
apparent absence of in situ thrombosis, this suggests that
PAR-1-induced venoconstriction was not mediated by plate¬
let aggregation, although we cannot exclude an effect of
platelet activation.
Arterial Effects of PAR-Activating Peptides
In contrast to the venous effects, both PAR-1 and PAR-2
activation caused dose-dependent vasodilatation of forearm
resistance vessels. We have not assessed the mechanism of
this vasodilatation, but animal and clinical models suggest
that this is likely to be endothelium and nitric oxide depen¬
dent."-30 However, data from animal studies have limited
relevance in humans because of the wide species variability
in PAR-1 receptor expression and function. The mechanism
of PAR-l-induced vasodilatation needs to be addressed in
future clinical studies.
PAR receptor expression varies between endothelial cell
cultures originating from different human blood vessels,31
which may partly explain the contrasting responses between
PAR-1 and PAR-2 in the arterial and venous circulations. Our
findings that PAR-2 activation causes venous and arterial
dilatation are consistent with previous findings30 and support
the vascular role of PAR-2 receptors in inflammatory
conditions.
Effects of PAR-Activating Peptides on
Endothelium-Derived Factors
Intra-arterial PAR-1 but not PAR-2 agonism caused an acute
dose-dependent increase in local endothelial tPA release. In
contrast to in vitro human endothelial culture studies,32 this
occurred in the absence of the release of other endothelium-
derived factors such as PAI-1 and vWF. However, there was
an apparent rise in plasma PAI-1 antigen (P=0.08) with
high-dose PAR-1 agonism, but given the absence of an effect
on PAI-1 activity and vWF, this may reflect the associated
platelet activation and release of platelet-derived PAI-1.
PAI-1 is stored in platelet a-granules, where its activity is
<=5% of plasma because of the absence of the stabilizing
effect of vitronectin. Thus, PAR-1 agonism appears to have a
selective profibrinolytic effect on the arterial endothelium.
Physiological Significance of Vascular
PAR-1 Activation
We have, for the first time, described the unexpected and
contrasting vascular effects of PAR-1 agonism in vivo in
humans. How do we interpret these effects? In an intact
normal vessel, homeostatic mechanisms attempt to maintain
vessel patency and minimize intravascular thrombus forma¬
tion. Dorsal hand veins do not have resting tone, and the
induction of venodilatation will not affect venous blood flow.
Therefore, in the presence of developing venous thrombosis,
venodilatation would not be beneficial, whereas venocon¬
striction will potentially limit thrombus propagation and
embolization. In contrast, it would be anticipated that increas¬
ing blood flow and endogenous fibrinolysis would limit
arterial thrombosis by ensuring rapid clearance and dissolu¬
tion of a developing thrombus. We therefore propose that the
vascular effects of PAR-1 agonism in vivo in humans can be
understood in terms of limiting intravascular thrombosis and
maintaining vessel patency. We speculate that these physio¬
logical effects may be disturbed in patients with cardiovas¬
cular disease or prothrombotic disorders.
Conclusions
PAR-1 agonism causes platelet activation, venoconstriction,
vasodilatation, and tPA release in vivo in humans. This has
important implications in our understanding of the physio¬
logical vascular effects of thrombin and the pathogenesis of
thromboembolic and atherothrombotic disorders.
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CLINICAL PERSPECTIVE
In addition to its well-known central enzymatic role within the coagulation cascade, thrombin is a powerful direct cellular
activator of platelets, leukocytes, and vascular smooth muscle and endothelial cells. It is therefore a vital link between
thrombosis and inflammation, key pathogenic factors in atherothrombotic disease. It has recently been discovered that
thrombin causes direct cellular activation through a group of G-protein-coupled protease-activated receptors (PARs).
Although the PAR-1 receptor is believed to mediate most of the receptor-mediated effects of thrombin, the cellular actions
of PAR-1 activation have not been described in vivo in humans. In the present study, we establish for the First time the in
vivo vascular effects of PAR-1 activation and demonstrate that it causes venous constriction, arterial dilatation, platelet
activation, and release of endogenous tissue plasminogen activator. These intriguing and contrasting effects of PAR-1
agonism demonstrate the diverse nature of the vascular consequences of thrombin activation in humans. We suggest that,
in the presence of a developing intravascular thrombosis, venoconstriction would limit thrombus propagation and
embolization, whereas in the arterial circulation, increasing blood flow and endogenous fibrinolysis would limit arterial
thrombosis by ensuring thrombus clearance and dissolution. We therefore propose that the vascular effects of PAR-1
agonism in viVo in humans can be understood in terms of limiting intravascular thrombosis and maintaining vessel patency.
This has potential implications for applying novel PAR-1 receptor antagonists that are currently under clinical development
as potential antiplatelet therapies.
Role of the Endothelium in the
Vascular Effects of the Thrombin Receptor
(Protease-Activated Receptor Type 1) in Humans
Ingibjorg J. GuSmundsdottir, MRCP,* Ninian N. Lang, MRCP,* Nicholas A. Boon, MD, FRCP,f
Christopher A. Ludlam, PhD, FRCP,* David J. Webb, MD, FRCP,* Keith A. Fox, FRCP, FESC,*
David E. Newby, PhD, MRCP*
Edinburgh, United Kingdom
Objectives The purpose of this study was to determine the role of the endothelium in the vascular actions of protease-
activated receptor type 1 (PAR-1) activation in vivo in man.
Background Thrombin is central to the pathophysiology of atherothrombosis. Its cellular actions are mediated via PAR-1.
Protease-activated receptor type 1 activation causes arterial vasodilation, venoconstriction, platelet activation,
and tissue-type plasminogen activator release in man.
Methods Dorsal hand vein diameter was measured in 6 healthy volunteers before and after endothelial denudation.
Forearm arterial blood flow, plasma fibrinolytic factors, and platelet activation were measured in 24 healthy
volunteers during venous occlusion plethysmography. The effects of inhibition of prostacyclin, nitric oxide (NO),
and endothelium-derived hyperpolarizing factor on PAR-1 responses were assessed during coadministration of
aspirin, the "NO clamp" (L-NG-monomethyl arginine and sodium nitroprusside), and tetraethylammonium ion,
respectively.
Results Endothelial denudation did not affect PAR-l-evoked venoconstriction (SFLLRN; 0.05 to 15 nmol/min). Although
aspirin had no effect, SFLLRN-induced vasodilation (5 to 50 nmol/min) was attenuated by the NO clamp (p <
0.0001) and tetraethylammonium ion (p < 0.05) and abolished by their combination (p < 0.01). The NO clamp
augmented SFLLRN-induced tissue-type plasminogen activator and plasminogen activator inhibitor type 1 anti¬
gen (p < 0.0001) release, but tetraethylammonium ion and aspirin had no effect. SFLLRN-induced platelet acti¬
vation was unaffected by NO or prostacyclin inhibition.
Conclusions Acting via PAR-1, thrombin causes contrasting effects in the human vasculature and has a major interaction
with the endothelium. This highlights the critical importance of endothelial function during acute arterial injury
and intravascular thrombosis, as occurs in cardiovascular events including myocardial infarction and
stroke. (J Am Coll Cardiol 2008;51:1749-56) © 2008 by the American College of Cardiology Foundation
'hrombin plays a central role in the coagulation cascade and
irombosis (1). It is one of the most powerful physiological
ronists in the cardiovascular system, and its actions are
indamental to the processes of atherosclerosis and its
irombotic consequences.
In addition to the enzymatic generation of fibrin, throm-
in stimulates a range of cell types including platelets,
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endothelial cells, and vascular smooth muscle cells. An
extensive search for thrombin receptors ultimately culmi¬
nated in the identification of a group ofG-protein coupled
receptors termed protease-activated receptors (PARs).
See page 1757
These receptors are characterized by a unique mechanism of
activation whereby the receptor undergoes proteolytic cleav¬
age, unmasking a short peptide sequence that remains
tethered and auto-activates the receptor (2,3). To date, 4
different types of PARs have been identified: PAR-1, -3,
and -4 are all activated by thrombin; PAR-2 is mainly
activated by trypsin but transactivation ofPAR-2 by cleaved
PAR-1 has been recognized (4,5).
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Protease-activated receptor type
1 receptors are the principal
thrombin receptors in man and
extensive studies in small animals
and cell cultures suggest that they
have a diverse and important role
in various organs. Their activation
stimulates a network ofG-protein
coupled signaling pathways that
involve phospholipase C/3, protein
kinase C, calcium release, mitogen-
activated protein kinases, and po¬
tassium channels (6,7). However,
there is significant species hetero¬
geneity with pre-clinical studies of
limited relevance to man (8). Ex¬
ploring the role of PAR-1 recep¬
tors in the human vasculature
would deepen our understanding
of the physiological role of throm¬
bin and be important in the clini¬
cal development of new therapeu¬
tic strategies.
To understand the physiolog¬
ical actions of thrombin in the
uman vasculature is challenging because direct thrombin
istillation has the potential to cause acute thrombosis in
tu and hence vascular occlusion. The use of a PAR-1
:ceptor agonist, however, permits the direct assessment of
filular responses to thrombin without the enzymatic acti-
ation of the coagulation cascade and fibrin formation.
Fsing the short peptide mimetic SFLLRN, we have re¬
intly described the in vivo effects of PAR-1 activation in
latelets, endothelium and vascular smooth muscle in man.
'or the first time, we were able to show that PAR-1
ctivation has unique and contrasting effects in the human
asculature including arterial dilation, venous constriction,
latelet activation, and tissue-type plasminogen activator
:-PA) release (9). Given the central role of thrombin in the
athophysiology of cardiovascular disease, it is important to
stablish the mechanisms of these PAR-l-mediated effects
nd, in particular, the role of the endothelium. We therefore
:t out to explore the role of the endothelium in the vascular
ctions of PAR-1 activation in vivo in man.
lethods
ubjects. A total of 30 healthy nonsmokers (mean age 22
ears; range 19 to 37 years) were recruited into the study,
'he study was approved by the local research ethics com-
littee and conducted in accordance with the Declaration of
lelsinki and with the written informed consent of all
olunteers. Participants were screened and excluded for
linically significant conditions including hypertension, hy-
erlipidemia, diabetes mellitus, asthma, and coagulopathy,
lo participant had suffered a recent infective or inflamma¬
tory condition or had taken any medications in the 7 days
prior to the study.
Vascular assessments. All studies were carried out in a
quiet, temperature-controlled room (22°C to 24°C). Partic¬
ipants were semirecumbent (venous studies) or supine (ar¬
terial studies) and had abstained from alcohol for 24 h and
from food and caffeine-containing drinks for at least 4 h
prior to the study.
Venous studies. A 23-G needle was sited in a dorsal hand
vein and total infusion rate kept constant at 0.25 ml/min in
all studies. The hand was supported above the level of the
heart and an upper arm cuff inflated to 40 mm Hg to
obstruct venous return. The internal diameter of the dorsal
hand vein was measured by the Aellig technique (10) in 6
healthy volunteers. In brief, a magnetized lightweight rod
rested on the summit of the infused vein approximately 1
cm downstream from the tip of the infusion needle. The rod
passes through the core of a linear variable differential
transformer supported above the hand by a small tripod.
Changes in diameter of the vein caused vertical displace¬
ment of the rod, leading to a linear change in the voltage
generated by the transformer. This enabled calculation of
absolute changes in vein size.
PROTOCOL 1. VENOUS EFFECTS OF PAR-J ACTIVATION. First,
we established the presence of functional endothelium. As
dorsal hand veins do not have resting tone, norepinephrine
(1 to 128 ng/min) was used to induce 70% reduction in vein
diameter. Once stable venoconstriction was obtained, ace¬
tylcholine (1 nmol/min; Novartis Pharmaceuticals UK Ltd,
Frimley, United Kingdom) was coinfused with norepineph¬
rine for 8 min to demonstrate endothelium-dependent
venodilation and an intact, functional endothelium. Follow¬
ing a 20-min saline infusion, the PAR-1 activating peptide,
SFLLRN-NH2 (0.05 to 15 nmol/min; Clinalfa AG,
Laufelfingen, Switzerland), was administered intravenously
before a final 20-min saline washout infusion.
PROTOCOL 2. VENOUS EFFECTS OF PAR-1 ACTIVATION FOL¬
LOWING ENDOTHELIAL DENUDATION. At the end of proto¬
col 1, the endothelium of the venous segment was denuded
as previously described (11). In brief, a second 23-G
butterfly needle was sited 3 to 4 cm downstream from the
tip of the infusion-needle, and this segment of the vein was
isolated by the use of occlusion wedges. Distilled water was
infused through the venous segment at a rate of 5 ml/min
for 15 min, thereby causing endothelial denudation that
persists for at least 2 days (11). Aspirin (300 mg orally) was
given 30 min prior to start of the first study and on each of
the 2 subsequent days to prevent venous thrombosis. On the
second day following denudation, subjects reattended and
protocol 1 was repeated.
Arterial studies. All subjects underwent cannulation of the
brachial artery with a 27-G standard wire steel needle under
controlled conditions. The intra-arterial infusion rate was
kept constant at 1 ml/min throughout all studies. Forearm
blood flow was measured in the infused and noninfused arms
by venous occlusion plethysmography using mercury-in-
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■Silastic strain gauges as described previously (12,13). Supine
teart rate and blood pressure were monitored at intervals
hroughout each study using a semiautomated noninvasive
jscillometric sphygmomanometer. Tirofiban (1.25 /rg/min)
vas coinfused during the studies to inhibit potential PAR-1
ictivation-induced platelet aggregation in vivo (9). This
lose of tirofiban does not affect platelet-monocyte binding,
brearm blood flow, or baseline concentration of t-PA (9).
'rotocol 3: role of nitric oxide and prostacyclin in
jar-1—induced vasodilation. Forearm blood flow was
neasured by venous occlusion plethysmography in response
:o brachial artery infusion of SFLLRN (PAR-1 agonist; 5
:o 50 nmol/min) with tirofiban (1.25 /rg/min) in 8 healthy
volunteers on 4 visits using a randomized controlled cross-
)ver study employing a 2-by-2 factorial design: with and
vithout aspirin (600 mg orally; to inhibit prostacyclin
PGI2] synthesis) and the "nitric oxide (NO) clamp."
\ssuming total forearm blood flow of 25 ml/min, this will
ichieve end-organ concentrations of 0.2 to 2.0 ju.mol/1
IFLLRN.
The NO clamp was used to determine the contribution of
SfO in PAR-l-mediated vascular effects. Following base-
ine intra-arterial tirofiban infusion, the NO synthase in-
libitor, L-NG-monomethyl arginine citrate (L-NMMA; 8
xmol/min), was coinfused. To compensate for L-NMMA-
nduced basal vasoconstriction, forearm blood flow was
eturned to baseline using a titrated dose of exogenous NO
n the form of intrabrachial sodium nitroprusside (SNP; 90
o 900 ng/min). This dose of SNP was coinfused with
j-NMMA and continued throughout the study. This
Lrrangement allows a constant "clamped" delivery of exog-
:nous NO while endogenous NO synthase activity is
nhibited.
'rotocol 4: role of calcium-activated potassium
:hannels/endothelium-derived hyperpolarizing fac¬
tor in par-i-induced vasodilation. Forearm blood flow
vas measured in 8 other healthy volunteers in whom
ntrabrachial SFLLRN (5 to 50 nmol/min), bradykinin (30
o 300 pmol/min), and SNP (2 to 8 jug/min) were coinfused
vith either saline placebo or tetraethylammonium ion
TEA) (1 mg/min) on either of 2 visits using a randomized
louble-blind crossover design. Again, agonists were coin-
used with intra-artcrial tirofiban (1.25 p.g/min), which was
ontinued throughout the study. At the dose used, TEA is
. nonselective potassium channel antagonist (14-16).
'rotocol 5: role of endothelium-dependent vasodi-
.ators in par-1—induced vasodilation. In the final se-
ies of studies, TEA or saline placebo was coinfused with
.scending doses ofbradykinin and SFLLRN in 8 volunteers
ising a randomized double-blind crossover design. In this
eries, endothelium-derived hyperpolarizing factor (EDHF)
ctivity was isolated by inhibiting NO and PGI2 production
in both visits. The NO clamp was employed as described
ireviously (protocol 3), and cyclooxygenase activity was
nhibited with a single 600-mg dose of oral aspirin 1 h
lefore each study.
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blood sampling. Seventeen-gauge venous cannulac were
inserted into left and right antecubital fossae. Blood samples
were drawn simultaneously from each arm at baseline.
Blood samples were also drawn before SFLLRN or brady¬
kinin infusion and after each dose of SFLLRN or bradyki¬
nin. Blood was collected into acidified buffered citrate
(Stabilyte, Biopool International, Umea, Sweden; for t-PA
assays) and into citrate (BD Vacutainer, BD UK Ltd,
Oxford, United Kingdom; for plasminogen activator inhib¬
itor type 1 [PAI-1], beta thromboglobulin, and von Wille-
brand factor [vWF] assays). Samples were kept on ice before
centrifiigation at 2,000 g for 30 min at 4°C. Platelet-free
plasma was decanted and stored at — 80°C before assay. Plasma
t-PA antigen and activity (t-PA Combi Actibind Elisa Kit,
Technoclone, Vienna, Austria), PAI-1 antigen and activity
(Elitest-PAI-1 Antigen and Zymutest PAI-1 Activity,
HYPHEN BioMed, Neuville-sur-Oise, France), beta throm¬
boglobulin (Asserachrom Btg, Diagnostica Stago, Asnieres sur
Seine, France), and vWF (Dako, Glostrup, Denmark) concen¬
trations were determined by enzyme-linked immunosorbent
assays. Full blood count was measured at baseline and at the
end of the study.
platelet-monocyte binding. In protocols 3 and 4, blood
was collected from each arm for determination of platelet-
monocyte binding at baseline and after the highest dose of
SFLLRN. Samples of5 ml ofvenous blood were collected and
transferred into a tube containing the direct thrombin inhibi¬
tor, D-phenylalanyl-L-propyl-L-arginine chloromethylke-
tone. Five minutes after sampling, blood was incubated with
appropriate monoclonal antibodies labeled with fluorochromes
for 20 min and platelet-monocyte aggregates measured as
described previously (17).
Data analysis and statistics. Dorsal hand venous (18) and
forearm plethysmographic (12) data were analyzed as de¬
scribed previously. Variables are reported as means ± SEM
and analyzed using repeated measures analysis of variance
(ANOVA) with post hoc Bonferroni corrections and
2-tailed Student t test as appropriate. Statistical analysis was
performed with GraphPad Prism (Graph Pad Software, San
Diego, California) and statistical significance taken at the
5% level. The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agreed to the manuscript as written.
Results
Endothelium and PAR-l-induced venoconstriction.
The role of the endothelium in PAR-l-induced vasomotor
effects was assessed by comparing venous responses before
and after local endothelial denudation. This was achieved
through brief instillation of distilled water in an isolated
dorsal hand vein segment. After pre-constriction with
norepinephrine, the presence or absence of functional en¬
dothelium was confirmed by the coinfusion of acetylcholine
(1 nmol/min). Acetylcholine caused venodilation in the
presence ofendothelium and venoconstriction in its absence
752 Gudmundsdottir et al.
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Figure 1
Dorsal Hand Vein Responses to Acetylcholine and
SFLLRN (After Pre-Constriction With Norepinephrine)
Before (blue triangles) and after (red triangles) endothelial denudation.
*p < 0.05; NS = nonsignificant (p = 0.09); presence versus absence of the
endothelium (analysis of variance).
Fig. 1) (from 35 ± 4% to 55 ± 7% in the presence of
ndothelium versus 33 ± 7% to 18 ± 6% in the absence of
ndothelium; p < 0.01 for both; ANOVA). After endothe-
al denudation, there appeared to be a trend toward
nhanced venoconstriction induced by the PAR-1 activat-
ng peptide, SFLLRN (Fig. 1) (p = 0.09; ANOVA).
Endothelium-derived vasodilators and PAR-l-induced
asodilation. SFLLRN caused an increase in forearm
lood flow that was unaffected by PGI2 inhibition with oral
spirin (600 mg) (Fig. 2A). The NO synthase inhibitor,
,-NMMA, caused —50% decrease in basal forearm blood
ow (from 3.04 ± 0.37 ml/lOOml tissue/min to 1.49 ± 0.19
il/100ml tissue/min; p < 0.001). Intrabrachial SNP (90 to
00 ng/min), an exogenous NO donor, was titrated to
sstore forearm blood flow back to baseline levels (2.77 ±
.24 ml/lOOml tissue/min; p = 0.46 clamp dose SNP versus
aseline; paired Student t test). The inhibition of endoge-
ous NO synthesis by the NO clamp attenuated SFLLRN -
iduced vasodilation (Fig. 2B).
Potassium channel antagonism with TEA (1 mg/min)
id not affect baseline blood flow (p = 0.76; data not
hown). It attenuated vasodilation to SFLLRN (Fig. 2C),
ut the combination ofPGI2, NO synthase, and potassium
hannel inhibition appeared to abolish SFLLRN-induced
asodilation (Fig. 2D).
Both with and without concurrent NO synthase and PGI2
imthase inhibition, TEA attenuated, but did not abolish
rterial vasodilation to the control endothelium-dependent
asodilator, bradykinin (Figs. 3A and 3B). Tetraethylammo-
ium ion did not affect endothelium-independent forearm
rterial vasodilation to SNP (Fig. 3C).
Endothelium-derived vasodilators and PAR-l-induced re¬
lease of fibrinolytic and coagulant factors. The SFLLRN
increased net t-PA antigen and activity and PAI-1 antigen
release but did not affect net PAI-1 activity (Fig. 4). This
increase was augmented by the NO clamp (Fig. 4) but was
not affected by aspirin or TEA (data not shown; p = NS;
ANOVA). Bradykinin caused a dose-dependent increase in
net t-PA antigen (p < 0.05; ANOVA) and activity (p <
0.0001; ANOVA) release but did not affect PAI-1 antigen
and activity release (p = NS for both; ANOVA). Tetraeth-
ylammonium ion did not alter bradykinin-induced PAI-1 or
t-PA release (p = NS for both; ANOVA). Unpaired
analysis between the 2 subject groups (protocol 4 vs.
protocol 5) suggests that the NO clamp did not alter
bradykinin-induced t-PA or PAI-1 release (p = NS for all;
ANOVA). Neither bradykinin nor SFLLRN affected vWF
release (data not shown; p = NS; ANOVA).
Endothelium-derived vasodilators and PAR-l-induced
platelet activation. SFLLRN increased platelet-monocyte
binding but this was unaffected by inhibition of NO or
PGI2 (Table 1). In contrast, SFLLRN increased beta-
thromboglobulin (p < 0.001; ANOVA) that was aug¬
mented during the NO clamp (p < 0.01; ANOVA) (Fig. 5)
but unaffected by aspirin (p = NS; ANOVA).
Discussion
Thrombin is one of the most powerful physiological ago¬
nists in the cardiovascular system, and its actions are
fundamental to the processes of atherothrombosis. In a
series of studies, we have here described the contrasting role
of the endothelium in the PAR-l-mediated vascular actions
of thrombin in vivo in man. Although not providing a major
contribution to venoconstriction or PAI-1 release, the
endothelium mediates PAR-l-induced arterial vasodilation
and t-PA release. Our findings provide clear evidence of a
major interaction between the vascular endothelium and
thrombin in vivo in man. Furthermore, it highlights the
critical importance of endothelial function at the time of
acute arterial injury and intravascular thrombosis, such as
during acute coronary syndromes.
Role of the endothelium in PAR-l-induced vasomo-
tion. We have previously described the unexpected finding
of PAR-l-induced venoconstriction in man (9). Although
not caused by platelet aggregation (9), this effect could be
mediated by either a direct action on vascular smooth
muscle or via the release of endothelium-derived vasocon¬
strictors, such as endothelin or angiotensin II. To address
this question, we assessed PAR-1 venoconstriction before
and after endothelial denudation by instillation of distilled
water. There was a modest trend toward enhanced veno¬
constriction after endothelial denudation, and we cannot
exclude a small contribution from the endothelium that may
also include the release of venodilatory mediators such as
NO. However, PAR-1 continued to induce a marked
dose-dependent venoconstriction even in the absence of the
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Figure 2 SFLLRN-lnduced Forearm Arterial Vasodilation
In the presence (red symbols) and absence (blue symbols) of (A) aspirin (squares), NS - nonsignificant (p = 0.53) in the presence versus the absence of aspirin
(analysis of variance [ANOVA]); (B) the nitric oxide (NO) clamp (circles), «p < 0.0001 in the presence versus the absence of the NO clamp (ANOVA); (C) tetraethylam-
monium (TEA) (triangles), fp < 0.05 in the presence versus the absence of TEA (ANOVA); and (D) aspirin, the NO clamp, and TEA (diamonds), #p < 0.01 in the pres¬
ence versus the absence of aspirin, the NO clamp, and TEA (ANOVA).
ndothelium, which suggests a dominant and direct effect of
'AR-l on the vascular smooth muscle cells.
In contrast to effects on the venous circulation, the
'AR-l agonist causes potent arterial vasodilation. This
uggests a different effect on the arterial vasculature that is
kely to be mediated by the endothelium. It would be
ifficult and ethically challenging to conduct comparable in
ivo endothelial denudation studies in the arterial circula-
ion of man. We chose, therefore, to use a pharmacological
pproach to the inhibition of the 3 main known mediators of
ndothelium-dependent vasodilation: PGI2, NO, and EDHF.
dthough PGI2 inhibition appeared to have no effect, inhibi-
on of NO and potassium channels both attenuated the
'AR-l-induced vasodilation. Consistent with some cross talk
nd compensatory up-regulation, combined inhibition of all
asodilator mechanisms appeared to produce greater inhibi-
on, if not abolition, of the vasodilator actions of the PAR-1
gonist. This suggests that, unlike the venous circulation,
'AR-l-mediated arterial actions are dominated by, and de-
endent on, the vascular endothelium.
'AR-l-induced release of endothelium-derived factors,
n addition to vasomotion, PAR-1 has important effects on
ae release of endothelium-derived coagulant and fibrino-
rtic factors. In keeping with a wide range of other endo-
nelial G-protein coupled receptor dilator agonists (19), we
confirmed our earlier findings that the PAR-1 agonist
causes endothelial t-PA release without affecting vWF.
However, we also report here that SFLLRN-induced t-PA
release appeared to be augmented by the inhibition of
endogenous NO production. Smith et al. (20) have reported
similar findings when they examined bradykinin-evoked
t-PA release in the presence and absence of L-NMMA.
Because t-PA release is independent of NO and cyclooxy-
genase activity, it has been suggested that EDHF is respon¬
sible for its release (21). One could speculate that, by
inhibiting NO activity, EDHF is up-regulated, and this
accounts for the augmented t-PA release induced by
SFLLRN in our study and by bradykinin in Smith's study.
However, in contrast to TEA's inhibitory effects on
SFLLRN-induced arterial vasodilation, it had no effect on
SFLLRN-evoked t-PA release. Similar findings have re¬
cently been reported by Muldowney et al. (22) who exam¬
ined the role of EDHF in an in vitro model of thrombin-
induced endothelial t-PA release. A variety of potassium
channel antagonists, including TEA, had no effect on
thrombin-induced t-PA release, but antagonists of specific
epoxyeicosatrienoic acids appeared to inhibit thrombin-
induced release of t-PA.
Another novel finding in our study was the increase in
PAI-1 release, especially during NO synthase inhibition. To
754 Gudmundsdottir et al.
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Forearm arterial vasodilation induced by (A) bradykinin (squares), (B) bradykinin in
the presence of the NO clamp and aspirin (circles), and (C) sodium nitroprusside
(SNP) (diamonds) in the presence (red symbols) and absence (blue symbols) of
TEA. *p < 0.05; tP = O.OOOl; NS = nonsignificant (p = 0.41) in the presence
versus the absence of TEA (ANOVA). Abbreviations as in Rgure 2.
ate, there have been no reports of acute increases in plasma
'AI-l concentrations following the administration of en-
.othelial agonists, especially using the forearm model (19).
iven though the endothelium is an important source of
'AI-1, we believe our findings are consistent with acute
ilatelet release of PAI-1. There are several reasons to
upport our contention. First, although PAI-1 antigen
oncentrations increased, there was no corresponding rise in
'AI-l activity. Indeed, PAI-1 activity fell during marked
elease of fi-PA. Plasminogen activator inhibitor type 1 is
tored in platelet a-granules where its activity is very low
<5% of the activity seen in plasma) due to the absence of
he stabilizing effect of vitronectin. In contrast, we would
anticipate that endothelial-derived PAI-1 would remain
active. Second, there was no concurrent rise in vWF confirm¬
ing a selective effect on the endothelium with isolated t-PA
release. Third, we also demonstrated concomitant platelet
activation with marked increases in platelet-monocyte binding
and release ofbeta-thromboglobulin; the latter is also stored in
the a-granules of platelet. Finally, PAR-l-induced PAI-1
release was augmented during the NO clamp. Nitric oxide has
important antiplatelet effects and, in the presence of its inhi¬
bition, increased platelet activation may have led to greater
PAI-1 release.
Clinical relevance. Until recently, it has not been possible
to undertake a safe clinical assessment of the vasomotor
effects of thrombin due to its potent stimulatory effects upon
the coagulation cascade. However, the synthetic activating
peptide, SFLLRN, allows the examination of activation of
the human PAR-1 thrombin receptor without activation of
the coagulation cascade. This also permits the assessment
ofPAR-1 actions independent of the potential confounding
effects that the activated coagulation pathway may have
upon vascular responses.
We have demonstrated that many of the arterial effects of
the PAR-1 agonist are dependent on, and mediated through,
the endothelium and can therefore be used to assess endothelial
function. To date, many endothelial G-protein-coupled recep¬
tor agonists have been used to assess endothelial function, such
as acetylcholine and substance P. However, such agents are
unlikely to have a major role in vascular physiology or patho¬
physiology and, as pharmacological tools, their relevance to the
assessment of endothelial vasomotor function has limitations.
As a more physiologically relevant tool, the PAR-1 agonist
may be a more appropriate method of assessing endothelial
function in the context of atherothrombosis. These novel
insights into the vascular actions of the PAR-1 agonist will
not only contribute to our understanding of human physi¬
ology and pathophysiology but also promise to inform the
clinical development of novel antithrombotic PAR-1 recep¬
tor antagonists.
Study limitations. We chose to use SFLLRN as a PAR-1
agonist for several reasons. First, the vast majority of
published work has employed SFLLRN as a PAR-1 acti¬
vating peptide, and its actions have been widely character¬
ized. Second, we have previous clinical experience of the in
vivo actions of SFLLRN and this has facilitated the com¬
parability of our current findings with our previous "first-
into-man" clinical studies. Finally, SFLLRN is identical to
the active cleaved sequence of the human PAR-1 receptor
and represents a more physiologically relevant agonist of the
receptor.
Although SFLLRN is selective for the PAR-1 recep¬
tor, it does have agonist activity at the PAR-2 receptor:
4-fold greater selectivity for the PAR-1 versus PAR-2
receptor (23). Therefore, there remains a possibility that
a contribution of the observed actions of SFLLRN may
represent PAR-2 antagonism. However, we do not be¬
lieve this is likely for several reasons. First, we have
CC Vol. 51, No. 18, 2008
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Figure 4 SFLLRN-lnduced t-PA and PAI-1 Release
Net tissue-type plasminogen activator (t-PA) (squares) and plasminogen activator inhibitor type 1 (PAI-1) (circles) antigen (solid lines) and activity (dashed lines) in
response to intrabrachial SFLLRN in the presence (red symbols) and absence (blue symbols) of the NO clamp. *p < 0.0001; NS = nonsignificant (p = 0.075) in the
presence versus the absence of the NO clamp (ANOVA). Abbreviations as in Figure 2.
reviously shown that SLIGKV, a highly selective PAR-2
ctivating peptide, causes only modest arterial vasodilation
t high doses and, in contrast to PAR-1 activation, causes
larked venodilation and does not cause arterial t-PA
lease in vivo (24). Moreover, the predicted end-organ
oncentration of the highest dose of SFLLRN used in our
urrent and previous studies is 4-fold lower than the median
ffective dose for the PAR-2 receptor (23). However, we do
ccept that, in future studies, consideration should be given
3 the use of the more selective PAR-1 activating peptide,
TLLRN (23,25).
The role of NO in bradykinin-induced t-PA release
smains controversial (19) and the present study has not
efinitively addressed this issue. Although NO donors do
ot induce t-PA release (26,27), inhibition ofNO synthesis
as been reported either to have no effect (21), or to increase
20), bradykinin-induced t-PA release. Our own unpaired
nalysis of data from different subject populations is in
eeping with the findings of Brown et al. (21) and suggests
that bradykinin-induced t-PA release is unaffected by either
NO or prostaglandin inhibition. Further research into the
pathways involved in bradykinin-induced t-PA release is
needed to clarify the role of NO and other potential
mediators.
Conclusions
Protease-activated receptor type 1 activation causes contrasting
effects in the human vasculature. It causes endothelium-
dependent arterial vasodilation and t-PA release as well as
endothelium-independent venoconstriction and PAI-1 release.
There appears to be a major interaction between the vascular
endothelium and thrombin's PAR-l-mediated effects in vivo
in man. This highlights the critical importance of endothelial
function particularly at the time of acute arterial injury and
intravascular thrombosis, such as occurs during many acute




Infused Arm Nonlnfused Arm Infused Arm Noninfused Arm
Placebo 16.62 ± 4.38 12.48 ± 1.61 75.89 ± 5.09* 41.36 ± 6.86*
Aspirin only 14.43 ± 1.95 14.87 ± 3.61 72.07 ± 5.41* 49.67 ± 7.82*
NO clamp only 11.84 ± 1.52 16.95 ± 3.23 81.21 ± 5.68* 46.42 ± 7.42*
Aspirin + NO clamp 12.19 ± 1.66 14.15 ± 2.02 82.85 ± 5.57* 46.63 ± 6.48*
*p < 0.001 versus baseline (analysis of variance).
NO = nitric oxide.
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Figure 5 SFLLRN-lnduced Beta-Thromboglobulin Release
In the presence (red circles) and absence (blue circles) of the NO clamp.
*p < O.Ol net beta-thromboglobulin release induced by SFLLRN (50 nmol/min)
in the presence versus the absence of the NO clamp (ANOVA). Abbreviations
as in Figure 2.
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Marked Impairment of Protease-Activated
Receptor Type 1-Mediated Vasodilation
and Fibrinolysis in Cigarette Smokers
Smoking, Thrombin, and Vascular Responses In Vivo
Ninian N. Lang, MRCP,* Ingibjorg J. Gudmundsdottir, MRCP,* Nicholas A. Boon, MD, FRCP,f
Christopher A. Ludlam, PhD, FRCP,* Keith A. Fox, FRCP, FESC,* David E. Newby, PhD, FRCP*
Edinburgh, United Kingdom
Objectives We sought to test the hypothesis that cigarette smoking adversely alters protease-activated receptor type 1
(PAR-l)-mediated vascular effects in vivo in humans.
Background Distinct from its role in the coagulation cascade, thrombin exerts its major cellular and cardiovascular actions
via PAR-1. The activation of PAR-1 causes endothelium-dependent arterial vasodilation and the release of en¬
dogenous fibrinolytic factors.
Methods Forearm blood flow was measured with venous occlusion plethysmography in 12 cigarette smokers and 12 age-
and gender-matched nonsmokers during intrabrachial infusions of PAR-l-activating-peptide (SFLLRN; 5 to 50
nmol/min), bradykinin (100 to 1,000 pmol/min), and sodium nitroprusside (2 to 8 p.g/min). Plasma tissue plas¬
minogen activator (t-PA) and plasminogen-activator inhibitor 1 antigen and activity concentrations were mea¬
sured throughout the experiment.
Results All agonists caused dose-dependent increases in forearm blood flow (p < 0.0001 for all). Although bradykinin
and sodium nitroprusside caused similar vasodilation, SFLLRN-induced vasodilation was attenuated in smokers
(p = 0.04). Smokers had modest reductions in bradykinin-induced active t-PA release (reduced by 37%, p =
0.03) and had a marked impairment of SFLLRN-induced t-PA antigen (p = 0.02) and activity (p = 0.006) re¬
lease, with a 96% reduction in overall net t-PA antigen release. The use of SFLLRN also caused similar (p = NS)
increases in inactive plasminogen-activator inhibitor 1 in both smokers and nonsmokers (p < 0.002 for both).
Conclusions Cigarette smoking causes marked impairment of PAR-l-mediated endothelial vasomotor and fibrinolytic func¬
tion. Relative arterial stasis and near abolition of t-PA release will strongly promote clot propagation and vessel
occlusion. These findings suggest a major contribution of impaired endothelial PAR-1 action to the increased
atherothrombotic risk of cigarette smokers. (J Am Coll Cardiol 2008;52:33-9) © 2008 by the American
College of Cardiology Foundation
imoking tobacco remains one of the most important and
onsistent modifiable risk factors for myocardial infarc-
ion and fatal coronary artery disease (1). The recent
NTERHEART (A Study of Risk Factors for First
Myocardial Infarction in 52 Countries and Over 27,000
iubjects) study revealed that smoking tobacco increases
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the risk of nonfatal myocardial infarction by as much as
7-fold (2). The pathophysiological mechanisms underly¬
ing this association are likely to be a combination of
accelerated atherosclerosis (3) and a propensity to acute
coronary thrombosis (1,4).
The endogenous fibrinolytic system is responsible for the
dissolution of arterial thrombi that are frequently found on
the surface of atherosclerotic plaques at areas of endothelial
denudation (5,6). It is regulated by the profibrinolytic
factor, tissue plasminogen activator (t-PA), and its endog¬
enous inhibitor, plasminogen-activator inhibitor type 1
(PAI-1) (7-9). The rapid mobilization of t-PA from the
endothelium is crucial, with thrombus dissolution being
much more effective if t-PA is incorporated during, rather
than after, thrombus formation (10). Indeed, acute stimu-
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vWF = von Wiilebrand
factor
lated t-PA release predicts the
future risk of cardiovascular
events (11).
Thrombin plays a central role
in the coagulation cascade and
thrombosis. It is one of the most
powerful physiological agonists
in the cardiovascular system, and
its actions are fundamental to the
processes of atherothrombosis.
Distinct from its enzymatic role
in the coagulation cascade,
thrombin causes direct cellular
activation through stimulation of
a novel family of G-protein-
coupled receptors, protease-
activated receptors (PARs) (12).
fhese receptors have a unique mechanism of activation
vhereby agonist-induced proteolytic cleavage of the extra-
:ellular domain reveals a short peptide sequence that re-
nains tethered and causes autoactivation of the receptor. To
late, 4 different types of PARs have been identified:
?AR-1, -3, and -4 are all activated by thrombin whereas
5AR-2 is mainly activated by trypsin (13).
PAR-1 is the principal receptor that mediates the cardio-
'ascular actions of thrombin. The hexapeptide, SFLLRN,
epresents the short peptide sequence revealed during
TAR-l activation and can be used as a selective agonist of
he human PAR-1 thrombin receptor without activation of
he coagulation cascade. Using SFLLRN, we have recently
lescribed the in vivo effects ofPAR-1 activation in platelets,
ndothelium, and vascular smooth muscle in humans. For
he first time, we were able to show that thrombin has
mique and contrasting effects in the human vasculature,
ncluding arterial dilation, venous constriction, platelet ac-
ivation, and tissue-type plasminogen activator (t-PA) re-
ease (14).
We, and others, have previously reported that pharma-
ological stimulation of acute t-PA release in the peripheral
15,16) and coronary (17,18) arterial circulations is mark-
dly attenuated in smokers. In this study, we hypothesized
hat smokers have impaired PAR-l-mediated vascular re-
ponses. We, therefore, examined PAR-l-mediated t-PA
elease and vasomotor responses in the forearm circulation
if cigarette smokers and healthy nonsmoking control
ubjects.
Methods
iubjects. Twelve healthy cigarette smokers (5 to 20 ciga-
ettes/day) and 12 age- and gender-matched nonsmokers
etwcen ages 20 and 46 years participated in the study,
diich was undertaken with the approval of the local
esearch ethics committee and in accordance with the
leclaration of Helsinki. The written informed consent of
ach subject was obtained before entry into the study.
Exclusion criteria included a history of asthma, hyperten¬
sion, diabetes mellitus, coagulopathy, hyperlipidemia, or
vascular disease. Control subjects were lifelong nonsmokers
and were not exposed to regular environmental tobacco
smoke. Smokers had a history of regular daily cigarette
smoking of at least 5 years and maintained their normal
smoking habits in the week before attendance.
None of the subjects received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before the study, and
all abstained from alcohol for 24 h before and from food,
tobacco, and caffeine-containing drinks on the day of the
study. All studies were performed in a quiet, temperature-
controlled room maintained at 22°C to 24°C.
Intra-arterial drug administration. All subjects under¬
went brachial artery cannulation with a 27 standard-wire-
gauge steel needle. The intra-arterial infusion rate was kept
constant at 1 ml/min throughout all studies. Forearm blood
flow was measured in the infused and noninfused arms by
venous occlusion plethysmography with mercury-in-silastic
strain gauges as described previously (15,19). Supine heart
rate and blood pressure were monitored at intervals
throughout each study with the use of a semiautomated
noninvasive oscillometric sphygmomanometer.
After a 20-min intra-arterial infusion of 0.9% saline, the
glycoprotein Ilb/IIIa antagonist, tirofiban (1.25 /xg/min;
Merck, Sharp and Dohme, Hoddesdon, United Kingdom),
was infused and continued throughout the study to inhibit
potential PAR-l-induced platelet aggregation. This dose of
tirofiban does not affect forearm blood flow (14).
During tirofiban administration, subjects received intra¬
arterial infusions of the PAR-l-activating peptide,
SFLLRN (5, 15, and 50 nmol/min; Clinalfa, Laufelfingen,
Switzerland), bradykinin (an endothelium-dependent vaso¬
dilator that causes the release of t-PA; 100, 300, and 1,000
pmol/min; Clinalfa), and sodium nitroprusside (an
endothelium-independent vasodilator that does not release
t-PA; 2, 4, and 8 jug/min; David Bull Laboratories, War¬
wick, United Kingdom). Study drugs were infused in
random order for 10 min at each dose and were separated by
a 20-min infusion of 0.9% saline.
Blood sampling. Venous cannulae (17-gauge) were in¬
serted into large subcutaneous veins of the antecubital fossae
of both arms. Blood samples were drawn simultaneously
from each arm at the beginning of the study and during
infusion of each dose of PAR-l-activating peptide
(SFLLRN), bradykinin, and sodium nitroprusside. Venous
blood was collected into acidified buffered citrate (Stabilyte,
Trinity Biotech Pic, Co., Wicklow, Ireland; for t-PA assays)
and into citrate (BD Vacutainer, BD UK Ltd., Oxford,
United Kingdom; for PAI-1 and von Wiilebrand factor
[vWF] assays). Samples were kept on ice before centrifuga-
tion at 2,000 g for 30 min at 4°C. Platelet-free plasma was
decanted and stored at 80°C before assay. Plasma t-PA
antigen and activity (t-PA Combi Actibind Elisa Kit,
Technoclone, Vienna, Austria), PAI-1 antigen and activity
(Elitest PAI-1 antigen and Zymutest PAI-1 Activity, Hy-
JACC Vol. 52, No. 1, 2008
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phen Biomed, Neuville-Sur-Oise, France), and vWF anti¬
gen (Dako A/S, Glostrup, Denmark) concentrations were
determined with the use of enzyme-linked immunosorbent
assays. Full blood count and hematocrit were measured at
baseline and the end of the study.
Data analysis and statistics. Forearm plethysmographic
data were analyzed as described previously (19). Estimated
net release of plasma t-PA, PAI-1, and vWF has been
defined previously as the product of the infused forearm
plasma flow (based on the mean hematocrit and the infused
forearm blood flow) and the concentration difference be¬
tween the infused and noninfused arms (19). Variables are
reported as mean ± SEM and analyzed with repeated
measures analysis of variance (ANOVA) and a 2-tailed
Student t test as appropriate. Statistical analysis was per¬
formed with GraphPad Prism (GraphPad Software, San
Diego, California) and statistical significance taken at the
5% level. The authors had full access to the data and take
responsibility for its integrity. All authors have read and
igreed to the report as written.
Results
rhere were no differences in baseline characteristics be-
wccn cigarette smokers and nonsmokers (Table 1). There
vere no changes in blood pressure, heart rate, or hematocrit
[data not shown) during the study. Smokers had a mean
rigarettc consumption of 15 ± 1 cigarettes per day over a
mean period of 9 ± 2 years (7 ± 2 pack-years).
Forearm blood flow. The use of tirofiban did not affect
brearm blood flow (data not shown). Intra-arterial sodium
titroprusside, bradykinin, and the PAR-l-activating pep-
:ide, SFLLRN, all caused dose-dependent vasodilation in
he infused arm of smokers and nonsmokers (p < 0.0001 for
ill; ANOVA). There were no changes in blood flow in the
roninfused arm (data not shown).
Although there was no difference with bradykinin (p =
).64; ANOVA smokers vs. nonsmokers), vasodilatation to
SFLLRN was attenuated in smokers (p = 0.044; ANOVA
imokers vs. nonsmokers). Endothelium-independent vaso-
lilation evoked by the use of sodium nitroprusside was
iimilar in both groups (p = 0.74; ANOVA smokers vs.
tonsmokers) (Fig. 1).
flasma fibrinolytic and hemostatic factors. Baseline
tlasma t-PA antigen and activity (Table 2) and vWF
mtigen (Table 3) concentrations were similar in smokers
ind nonsmokers. There appeared to be a trend toward
Baseline Subject Characteristics
Nonsmokers Smokers
Age, yrs 26 ±2 29 ± 2
Gender, male/female 12/0 12/0
Body mass Index, kg/m2 24 ± 1 27 ± 1
Mean arterial pressure, mm Hg 97 ± 2 99 ± 2
Heart rate, beats/min 66 ± 2 64 ± 2
Baseline hematocrit 0.42 ± 0.01 0.42 ± 0.01
greater absolute plasma PAI-1 antigen and activity concen¬
trations in smokers, but this difference did not reach
statistical significance (smokers vs. nonsmokers: PAI-1
antigen, p = 0.07 and p = 0.10, and PAI-1 activity, p =
0.18 and p = 0.24; infused and noninfused arms, respec¬
tively) (Table 4).
The use ofSFLLRN caused a dose-dependent net release
of t-PA antigen in nonsmokers (p < 0.0005; ANOVA) but
not smokers (p = 0.18; ANOVA) (Fig. 2). In comparison
with nonsmokers, the release of t-PA antigen and activity by
SFLLRN was markedly attenuated in smokers (p = 0.02
16 Lang et al.
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Absolute Plasma t-PA Antigen and Activity Concentrations
t-PA Antigen (ng/ml) t-PA Activity (lU/ml)
Nonsmokers Smokers Nonsmokers Smokers
Arm Infused Noninfused Infused Nonlnfused Infused Nonlnfused Infused Nonlnfused
Baseline 8.15 2.18 8.33 ± 2.24 10.83 ± 1.94 10.93 2.23 0.48 ± 0.08 0.45 0.06 0.36 ± 0.07 0.35 ± 0.07
Pre-SFLLRN 8.08 2.07 8.41 1.92 11.35 ± 2.2 11.15 2.29 0.54 ± 0.08 0.44 ± 0.05 0.41 ± 0.07 0.40 0.07
SFLLRN 5 nmol/min 7.84 ± 2.23 7.68 ± 1.76 9.91 ± 2.08 11.51 ± 2.70 0.63 0.07 0.51 0.05 0.44 ± 0.08 0.44 0.08
SFLLRN 15 nmol/min 7.46 2.08 7.74 H- 2.00 10.56 ± 1.85 10.83 ± 2.52 0.84 ± 0.11 0.59 ± 0.06 0.56 ± 0.11 0.50 ± 0.08
SFLLRN 50 nmol/min 11.54 + 2.82* 6.93 + 1.87 12.08 2.58 11.17 ± 2.73 2.01 ± 0.38* 0.65 ± 0.09 0.78 ± 0.18ft 0.49 ± 0.10
Pre-BK 7.14 ± 1.68 8.17 ± 2.43 10.66 1.99 10.54 ± 2.12 0.55 0.06 0.53 ■+ 0.07 0.35 ± 0.08 0.40 ± 0.08
BK 100 pmol/min 9.39 1.76 7.55 ± 2.19 12.82 ± 2.76 10.44 -h 2.11 1.55 ± 0.21 0.54 0.07 0.84 ■+ 0.15 0.45 ± 0.07
BK 300 pmol/min 9.32 1.55 8.23 ± 2.42 13.66 2.66 12.42 ± 2.78 2.15 ± 0.31 0.74 ± 0.10 1.60 HK 0.29 0.57 ± 0.12
BK 1000 pmol/min 11.55 -+- 1.77* 8.44 ± 1.57 17.82 ± 3.49| 12.48 2.70 3.51 ± 0.40* 0.97 ± 0.12 2.25 ± 0.45*t 0.73 ± 0.13§
ine-way analysis of variance for dose response: *p < 0.005, fp < 0.01; 2-way analysis: f p < 0.001, §p < 0.05 smokers versus nonsmokers.
BK = bradyklnin; t-PA = tissue-type plasminogen activator.
ind p = 0.006, respectively; ANOVA). However,
5FLLRN induced a dose-dependent net release of PAI-1
intigen release in both nonsmokers (p = 0.0002; ANOVA)
md smokers (p = 0.001; ANOVA). The response was
imilar in both groups (p = 0.36; ANOVA) and was
issociated with no change in net PAI-1 activity (p = NS for
ill; ANOVA [data not shown]) or vWF antigen release (p =
IS; ANOVA) (Table 3).
Bradykinin caused a dose-dependent net release of t-PA
intigen and activity in both smokers and nonsmokers (p <
).01 for all; ANOVA). Bradykinin also evoked a dose-
lependent increase in absolute t-PA activity in the nonin-
iised arm of both nonsmokers (p < 0.0001; ANOVA) and
mokers (p = 0.008; ANOVA). Net release of t-PA activity
nduced by bradykinin was less in smokers than nonsmokers
p = 0.032, smokers versus nonsmokers; ANOVA) (Fig. 2).
Iradykinin caused no change in net PAI-1 antigen or
ctivity and did not affect vWF antigen in either group (p =
).91, nonsmokers; p = 0.98 nonsmokers; ANOVA). As
:xpected (20). sodium nitroprusside caused no change in
.bsolute or net release of t-PA, PAI-1 or vWf (data not
hown).
Discussion
To our knowledge, we have shown for the first time that
thrombin-mediated vascular responses are markedly im¬
paired in cigarette smokers, with a substantial reduction
observed in PAR-l-mediated endothelial t-PA release and
forearm arterial vasodilation. This impaired vasomotor and
fibrinolytic response may represent an important shift in the
fine balance between intravascular thrombosis and fibrino¬
lysis that could account for the increased incidence of
atherothrombosis in cigarette smokers.
Smoking and PAR-l-induced arterial vasomotion. As
reported by others (16), we observed no effect of smoking
status on endothelium-dependent vasodilation to bradyki¬
nin or endothelium-independent vasodilation to sodium
nitroprusside. One of the important novel observations from
our study is that vasodilation evoked via PAR-1 is impaired
in smokers, especially at the greater doses of SFLLRN.
Because homeostatic mechanisms attempt to maintain ves¬
sel patency and minimize intravascular thrombus formation
in healthy arteries, we have previously hypothesized the
arterial vasodilation to PAR-1 activation represents a pro-
Plasma von Wlllebrand Factor
Concentrations During SFLLRN and Bradykinin Infusions
von Wlllebrand Factor Antigen (ng/ml)
Nonsmokers Smokers
Arm Infused Nonlnfused Infused Nonlnfused
Baseline 0.72 ± 0.05 0.75 ± 0.19 0.77 ± 0.09 0.78 ± 0.13
Pre-SFLLRN 0.71 ± 0.06 0.80 ± 0.06 0.79 ± 0.07 0.71 ± 0.09
SFLLRN 5 nmol/min 0.70 ± 0.03 0.74 ± 0.05 0.72 ± 0.10 0.73 ± 0.06
SFLLRN 15 nmol/min 0.64 ± 0.03 0.73 ± 0.03 0.78 ± 0.06 0.63 ± 0.06
SFLLRN 50 nmol/min 0.70 ± 0.04 0.74 ± 0.04 0.78 ± 0.06 0.63 ± 0.06
Pre-BK 0.74 ± 0.06 0.74 ± 0.05 0.84 ± 0.10 0.74 ± 0.08
BK 100 pmol/min 0.76 ± 0.07 0.73 ± 0.05 0.78 ± 0.08 0.71 ± 0.05
BK 300 pmol/min 0.76 ± 0.06 0.74 ± 0.05 0.83 ± 0.08 0.68 ± 0.08
BK 1000 pmol/min 0.78 ± 0.06 0.76 ± 0.05 0.83 ± 0.08 0.76 ± 0.07
One-way analysis of variance for dose response, p = NS for all; 2-way analysis of variance, p = NS for all.
BK = bradykinin.
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Table 4 Absolute Plasma PAI-1 Antigen and Activity Concentrations
PAI-1 Antigen (ng/ml) PAI-1 Activity (AU/ml)
Nonsmokers Smokers Nonsmokers
Infused Nonlnfused Infused Infused Infused Noninfused
Baseline 23.58 ± 3.93 23.46 3.71 40.09 8.13 34.56 5.50 0.80 ± 0.15 0.86 0.15 00T-i 0.48 1.55 ± 0.60
Pre-SFLLRN 21.25 3.35 21.68 3.12 33.9 ± 7.19 33.08 ± 5.06 0.63 ± 0.12 0.73 + 0.13 1.52 0.56 1.57 ± 0.63
SFLLRN 5 nmol/min 21.03 ± 3.23 21.81 ± 3.36 38.52 ± 10.65 32.03 ± 6.04 0.62 ± 0.12 0.71 ± 0.14 1.52 ± 0.56 1.80 ± 0.61
SFLLRN 15 nmol/min 22.28 ± 3.55 21.13 ± 3.18 37.63 ± 9.06 32.92 ± 6.07 0.58 0.12 0.72 ± 0.13 1.65 ± 0.53 1.63 ± 0.63
SFLLRN 50 nmol/min 31.56 4.33* 20.52 ± 3.20 53.64 10.20t 34.97 ± 5.86 0.55 ± 0.13 0.72 0.14 1.59 ± 0.50 1.60 ± 0.67
Pre-BK 24.16 3.86 21.58 ± 3.27 38.44 9.67 37.41 ± 8.37 0.79 0.17 0.81 + 0.16 1.74 0.57 1.70 ± 0.69
BK 100 pmol/min 24.83 4.30 21.83 ± 3.13 38.13 9.93 37.44 ± 7.90 0.66 ± 0.18 0.77 ■± 0.17 1.54 0.53 1.78 ± 0.75
BK 300 pmol/mln 22.13 ± 3.24 23.68 ± 4.17 39.42 ± 0.39 37.10 ± 8.23 0.56 ± 0.16 0.76 + 0.19 1.58 ± 0.56 1.35 ± 0.47
BK 1,000 pmol/min 20.57 3.20 20.62 ± 2.91 34.53 ± 8.63 32.11 ± 6.57 0.45 ± 0.13 0.62 ± 0.16 1.33 ± 0.50 1.19 ± 0.40
Ine-way analysis of variance for dose response: *p < 0.05, tP < 0.0005; 2-way analysis of variance, p = NS for all, smokers versus nonsmokers.
BK = bradykinin; PAI-1 = plasminogen activator inhibitor type 1.
ective feedback mechanism. In the presence of a developing
hrombus, PAR-l-mediated vasodilation will increase
flood flow to limit arterial thrombosis by facilitating its
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Figure 2
Net Release of t-PA Activator
in Smokers and Nonsmokers
Net t-PA antigen (circles) and activity (squares) release induced by SFLLRN
(top panels) and bradykinin (bottom panels) in smokers (blue symbols) and
nonsmokers (red symbols). *p < 0.05, tP — 0.005. NS = nonsignificant
(analysis of variance, smokers vs. nonsmokers); t-PA = tissue-type plasmino¬
gen activator.
impairment of PAR-l-induced vasodilation may have ma¬
jor pathophysiological consequences during acute throm¬
botic events such as myocardial infarction.
Smoking and PAR-l-induced release of endothelium-
derived factors. Over and above diminished vasomotion,
the major finding of our study was the almost complete
abolition of PAR-l-mediated t-PA antigen release in
cigarette smokers. Furthermore, PAR-1 activation caused
only a very modest increase in t-PA activity despite causing
substantial t-PA antigen and activity release in nonsmokers.
The current findings confirm previous studies from our
own and other groups reporting reduced t-PA release in
cigarette smokers (15,16,18). Although not demonstrated
with t-PA antigen, the present finding of reduced bradyki¬
nin induced active t-PA release is consistent with similar
observations previously reported by Pretorius et al. (16)
However, the magnitude of the reduction in t-PA release is
substantially greater for PAR-l-evoked responses than it is
for bradykinin or substance P (96% vs. 40% to 50%) (15,16).
We would therefore argue that SFLLRN-evoked t-PA
release has the potential to be a more sensitive and patho-
physiologically relevant assessment of endothelial vasomotor
and fibrinolytic function.
Of note, PAR-1 activation also caused the release of
PAI-1 antigen but did not cause an appreciable increase in
PAI-1 activity, and neither indices were altered by smoking
status. This increase in PAI-1 antigen without a change in
activity suggests that SFLLRN is releasing PAI-1 from
platelets rather than the endothelium because platelet-
derived PAI-1 is relatively inactive as a result of the absence
of the stabilizing effects ofvitronectin (16,21). Furthermore,
our own recent work has demonstrated a concomitant
increase in beta-thromboglobulin, suggesting degranulation
of platelet alpha granules (22). Therefore, the contribution
of the endogenous fibrinolytic system to the prothrombotic
state found in cigarette smokers is likely to be driven by
impaired endothelial t-PA release and not by alterations in
PAI-1 release or activity.
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'AR-l activation as a pathophysiologically relevant
narker of endothelial function. The authors of previous
tudies to assess the endothelial release of endogenous
ibrinolytic factors have used diverse methods. Historical
neans of stimulating t-PA release have included the sys-
emic intravenous infusion of desmopressin and bradykinin,
>ut this method causes significant confounding effects by
.ltering systemic hemodynamics, activation of the sympa-
hetic nervous system, and concomitant release of other
nediators (6). By assessing the regional release of t-PA and
'ATI in response to locally acting agonists, we can avoid
uch confounding effects.
We have previously demonstrated that substance
'-induced t-PA release in the coronary (17) and peripheral
IS) arterial circulations is impaired in cigarette smokers,
nd allows one to predict future adverse cardiovascular
vents in patients with coronary heart disease (11). How-
:ver, although substance P has been a useful pharmacologic
ool, it is unclear whether substance P is likely to act as a
najor pathophysiological mediator in atherothrombosis. In
:ontrast, bradykinin may have a more direct role because it
s released during the contact phase of coagulation and there
s enhanced activation of the kallikrein system and brady-
dnin release in patients with acute coronary syndromes
23). However, we would argue that, given its central role in
hrombosis and inflammation, thrombin is the most pow-
:rful and pathophysiologically relevant mediator in this
etting. Our present findings not only reinforce previous
indings but give the clearest indication yet that impaired
:ndothelial function is ofcritical and dynamic importance in
he setting of coronary heart disease and acute coronary
yndromes.
imoking and endothelium-dependent mechanisms. We
lave previously demonstrated that PAR-1 mediates ar-
erial vasodilation via 2 endothelium-dependent mecha-
usms, namely nitric oxide (NO) and endothelium-
lerived hyperpolarizing factor (EDHF) (22). The
>athways via which PAR-1 activation causes the endo-
helial release of t-PA are less clear and, in fact, inhibi-
ion of NO synthesis causes augmented SFLLRN-
nduced t-PA release (22). This discrepancy has raised
he question as to whether EDHF is responsible for t-PA
elease and, in the absence of NO, whether EDHF
esponses undergo a compensatory up-regulation. Al-
hough the bulk of evidence suggests that smoking
)redominantly affects endothelial function by increasing
>xidative stress with consequent disruption of NO pro-
luction (24,25), studies specifically examining the effect
>f smoking upon EDHF-mediated responses are lacking.
Jtudy limitations. The forearm circulation has been an
xtremely reliable model for the assessment of vascular physi-
>logy and pathophysiology. We do accept that our findings in
he forearm may not be accurately representative of the
:oronaiy circulation. However, we and others have previously
lemonstrated consistent findings of impaired endothelial t-PA
elease in both the forearm (15,16) and coronary (17,18)
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circulations of cigarette smokers. Although the forearm vascu¬
lar bed is relatively protected from the development of ather¬
oma, it therefore seems likely that changes in its fibrinolytic
capacity are indicative of the coronary circulation.
Establishing the receptor-mediated effects of thrombin in
the vasculature is of major physiological and therapeutic
relevance. It could be argued that, in our studies, the safety
requirement for the coadministration of tirofiban with
SFLLRN detracts from these advantages. However, we
used locally active doses of glycoprotein Ilb/IIIa inhibitor
that abolish SFLLRN-mediated platelet aggregation with¬
out affecting platelet-monocyte binding, a sensitive marker
of platelet activation. Furthermore, it has no effect upon
basal forearm blood flow or fibrinolytic responses to
SFLLRN (14).We therefore believe that SFLLRN remains
an important and relevant tool to assess these fundamental
pathophysiological aspects of endothelial function.
We have demonstrated an important impairment of
fibrinolytic capacity in smokers, but it remains unclear
whether this reflects an impairment of synthesis, storage,
and release of t-PA, or indeed acceleration of its degrada¬
tion. Addressing these questions will be challenging and is
likely to require specifically designed in vitro studies.
Conclusions
In healthy vessels, thrombin's powerful procoagulant and
prothrombotic effects are offset by its ability to evoke the
release of t-PA and induce arterial vasodilation. We have
shown here that cigarette smoking causes a marked impair¬
ment in PAR-l-mediated endothelial vasomotor and fi¬
brinolytic function. Relative arterial stasis and abolition of
t-PA release will strongly enhance clot expansion and vessel
occlusion. Taken together, these findings suggest a major
contribution of impaired endothelial PAR-1 action to the
increased atherothrombotic risk of smokers. These impor¬
tant and novel findings are of direct relevance to our
understanding of the pathophysiology by which cigarette
smoking causes an increased propensity to atherothrombotic
disorders including acute myocardial infarction and stroke.
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stract
Nitric oxide (NO) inhibits platelet aggregation primarily via a cyclic 3'5'-guanosine monophosphate (cGMP)-dependent process,
lenafil is a phosphodiesterase type 5 (PDE5) inhibitor that potentiates NO action by reducing cGMP breakdown. We hypothesised
t sildenafil would augment the inhibitory effects of NO on in vitro platelet aggregation. After incubation with sildenafil or the soluble
tnylate cyclase inhibitor //-(l,2,4)oxadiazolo(4,3-a)quinoxallin-l-one (ODQ), collagen-mediated human platelet aggregation was
essed in the presence of two NO donors, the cGMP-dependent sodium nitroprusside (SNP) and the cGMP-independent diethylamine
zeniumdiolate (DEA/NO). SNP and DEA/NO caused a concentration-dependent inhibition of platelet aggregation. ODQ inhibited
1 sildenafil augmented the effect of SNP, and to a lesser extent the effect of DEA/NO. We conclude that sildenafil potentiates
)-mediated inhibition of platelet aggregation through blockade of cGMP metabolism and that PDE5 inhibitors may have important
iplatelet actions relevant to the prevention of cardiovascular disease.
2005 Elsevier Inc. All rights reserved.
'words: Nitric oxide; cGMP; Phosphodiesterase inhibitors; Platelet aggregation
Nitric oxide (NO) is a potent vasodilator and inhibitor
platelet aggregation. It is generated constitutively by ni-
; oxide synthase (NOS) in endothelial cells and platelets,
it can be derived from an exogenous source such as NO
nor drugs. The effects of NO are predominantly medi-
d via stimulation of soluble guanylate cyclase (sGC)
ich catalyses synthesis of the secondary messenger cyclic
'-guanosine monophosphate (cGMP) from guanosine
triphosphate (GTP) [1], cGMP reduces platelet adhesion
i aggregation via predominantly protein kinase C
<.C)-mediated pathways [2].
Phosphodiesterases are a group of enzymes responsible
the breakdown of cyclic nucleotides including cyclic
'-adenosine monophosphate (cAMP) and cGMP. Phos-
Corresponding author. Fax: +44 0131 242 6379.
E-mail address: Ingibjorg.Gudmunds@ed.ac.uk (I.J. Gudmundsdot-
phodiesterase type 5 (PDE5) is highly specific for cGMP
metabolism, with inhibition of PDE5 leading to accumula¬
tion of cGMP and augmentation of the effects of NO. Sil¬
denafil is a selective inhibitor of PDE5 and was originally
developed as a potential antianginal drug because it aug¬
ments the vasodilator effects of both endogenous NO, such
as from the endothelium or platelets, and exogenous NO,
such as from NO donor drugs. Although an ineffective
antianginal therapy, it is an efficacious treatment for erec¬
tile dysfunction by augmenting the physical response to
sexual stimulation and increasing penile blood flow by
relaxing smooth muscle in the corpus cavernosum [3,4],
Recently, there has been renewed interest in the therapeutic
potential of PDE5 inhibitors for other cardiovascular indi¬
cations and small trials have shown benefit in the treatment
of both primary [5-10] and secondary [11] pulmonary
hypertension.
Given the importance ofplatelet activation in thrombosis
associated with cardiovascular disease, it is important to
6-291X/S - see front matter © 2005 Elsevier Inc. All rights reserved.
10.1016/j.bbrc.2005.09.060
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determinewhether sildenafil also affects platelet aggregation.
Antiplatelet effects of sildenafil would have therapeutic
implications for patients with cardiovascular disease both
with respect to its potential use as a primary treatment and
because patients requiring sildenafil for impotence frequent¬
ly have other cardiovascular conditions. Previously pub¬
lished studies on the effects of sildenafil on platelet function
have been inconclusive and contradictory [3,12,13].
We hypothesised that sildenafil would augment the
inhibitory effects of NO donor drugs on collagen medi¬
ated human platelet aggregation in vitro and that the ef¬
fects of sildenafil would be affected by the relative cGMP
dependence of the NO donors. We therefore compared
the effects of sildenafil on two different NO donors, sodi¬
um nitroprusside (SNP) and diethylamine diazeniumdiao-
late (DEA/NO), that inhibit platelet aggregation through
:GMP-dependent and -independent mechanisms,
respectively.
Materials and methods
Materials. Sildenafil (Pfizer, Sandwich, UK) was diluted in saline and
cept at room temperature. ODQ (Tocris Cookson, Langford, UK) was
iissolved in dimethyl sulphoxide (DMSO) prior to dilution in saline; final
;oncentrations of DMSO did not exceed 0.5%. DEA/NO (Alexis, Not-
:ingham, UK) was dissolved in 0.01 M NaOH. SNP (Sigma chemicals,
JSA) was dissolved in saline and protected from light. Collagen was
tbtained from Chrono-Log, Havertown, USA. All other reagents were
tbtained from Sigma, Poole, Dorset, UK.
Samples. Peripheral venous blood was drawn from healthy human
ton-smokers (n = 25) who had not taken any medications including anti-
nflammatory drugs for at least 10 days. Blood was collected from the
inte-cubital fossa using a 19 gauge butterfly needle into a 50 mL syringe
ind transferred into tubes containing 3.8% sodium citrate. The blood was
:entrifuged at 130g for 20 min at room temperature to obtain platelet rich
tlasma (PRP) and the platelet count was adjusted to levels between 200
ind 250 x 109/L using autologous platelet poor plasma (PPP). Blood was
entrifuged at 1200g for 10 min to obtain PPP for this purpose and for
eference samples.
Platelet aggregation. Platelet aggregation was measured using standard
tptical platelet aggregometry [14], PRP samples were equilibrated at 37 °C
ind stirred continuously. Platelets were incubated with sildenafil, 1 pM
3,12], for 5 min, or the selective sGC inhibitor ODQ, 20 pM [15], for
5 min. PRP was then treated with the NO-donors SNP or DEA/NO
(0.1-10 pM; 1 min), before induction of platelet aggregation with a supra¬
maximal concentration of collagen (2.5 pg/mL). Aggregation was moni¬
tored for 5 min in a four channel aggregometer (Chronolog 470 VS,
Labmedics, Stockport, UK) linked to a MacLab 4s analogue-digital
converter (AD Instruments, Sussex, UK) and Chart software (AD
instruments, Sussex, UK). All results are expressed as a percentage of the
maximal collagen-induced aggregation.
Statistical analysis. Data were analysed using GraphPad Prism soft¬
ware and results are expressed as means ± SEM. Statistical significance
was taken at 5% level. Two-way analysis of variance (ANOVA) was used
to assess differences between the groups.
Results
Addition of both NO-donor drugs, SNP and DEA/NO,
at concentrations of 0.1-10 pM caused concentration-de¬
pendent inhibition of collagen (2.5 pg/mL) mediated plate¬
let aggregation (n = 25; ANOVA, p < 0.0001 for both SNP
and DEA/NO; Fig. 1).
cGMP-dependence of SNP and DEAINO
The inhibitory effects of SNP (0.1-10 pM) on collagen
mediated platelet aggregation were almost abolished by
15 min incubation with ODQ (20 pM) (n — 11; ANOVA,
p< 0.001; Fig. 1A). ODQ also reduced the inhibitory ef¬
fects of DEA/NO (n=12, IC50= 4.7xlO_9M versus
8.2 x 10~7 M, p < 0.001; Fig. IB) but to an apparently less¬
er degree than those of SNP.
Effects of sildenafil on NO mediated inhibition ofplatelet
aggregation
Pre-incubation with sildenafil (1 pM) for 5 min aug¬
mented the inhibitory effects of both SNP
(IC50 = 2.6 x 10~6 M versus 3.6xlO_7M; « = 14; ANO¬
VA, p < 0.0001; Fig. 2A) and to a lesser extent than those
of DEA/NO (IC50 = 1.6 x 10~7 M versus 1 x 10"7 M;
n= 13; ANOVA, p< 0.0001; Fig. 2B). Sildenafil (1 pM)
had no effects on its own (62 ± 3% versus 62 ± 4%;






■ig. 1. (A,B) Inhibition of collagen induced platelet aggregation by sodium nitroprusside (SNP; squares) and diethylamine diazeniumdiolate (DEA/NO;
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2. (A,B) Inhibition of collagen induced platelet aggregation by sodium nitroprusside (SNP; squares) and diethylamine diazeniumdiolate (DEA/NO;
les) in the presence (closed symbols) or absence (open symbols) of sildenafil, p < 0.001, p < 0.01, and p < 0.05.
A 100-1 B 100-,
cussion
We have shown that sildenafil alone does not inhibit
telet aggregation but has a powerful potentiating ef-
t on the antiplatelet effects of NO donor drugs. In
ping with the relative cGMP-dependence of the two
) donor drugs tested, SNP appeared to be more sensi-
; to sildenafil-mediated augmentation. We conclude
t sildenafil predominantly potentiates cGMP-depen-
it NO mediated inhibition of platelet aggregation,
is may have relevance to the potential cardiovascular
cts of sildenafil.
We selected two different NO donors for our studies,
P and DEA/NO. SNP is a cGMP-dependent NO
lor that acts by diffusing into the platelet where it
lergoes bioactivation to release NO and activate
2, leading to the production of cGMP. In contrast,
A/NO is hydrolysed spontaneously at physiological
iperature and pH, and releases NO primarily in the
racellular compartment, resulting in antiplatelet ef-
:s that are largely cGMP-independent [14,15], Sepa-
; experiments with similar diazeniumdiolates indicate
t these effects are mediated by increased sequestra-
i of Ca2+ into the sarcoplasmic reticulum through
ivation of the sarco-endoplasmic reticulum Ca2+
Pase (SERCA) [16]. In keeping with previous studies
], the sGC inhibitor ODQ nearly completely inhibited
effects of SNP, suggesting cGMP dependence, whilst
inly modestly affected DEA/NO. Furthermore, silde-
il was found to potentiate the effects of both SNP
I DEA/NO, but this effect was most marked with
P.
Previously published studies have been inconclusive
1 inconsistent. Some have suggested that sildenafil
;ht augment thrombin induced platelet aggregation
], whilst others describe an independent inhibitory ef-
; of sildenafil [17], Consistent with our own findings,
llis et al. [3] reported that sildenafil does not have di-
t effects, but does augment the inhibitory effects of an
l donor. The lack of effect of sildenafil alone on col¬
lagen-induced platelet aggregation is perhaps surprising,
given that platelets are known to contain constitutive ni¬
tric oxide synthase and to generate sufficient NO to mod¬
ulate aggregatory responses [18,19]. It is, however, worth
noting that activation of constitutive nitric oxide syn¬
thases is highly dependent on intracellular Ca2+ that, in
the case of platelets, is only elevated during activation.
Faced with a strong stimulus in the form of collagen,
it is likely that any increase in cGMP levels will be
"too little, too late" to have any impact on the aggrega¬
tion process. It does not, however, rule out an in vivo
effect of sildenafil on the activation process. Platelets
are continuously exposed to endothelium-derived NO as
well as that from platelets themselves, and at least some
of the activation stimuli are less intensive than the in vi¬
tro exposure to collagen.
We conclude that PDE 5 inhibitors may have important
antiplatelet effects that have potential in the treatment of
cardiovascular diseases.
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